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Abstract 
Generally, most of the in vitro tests used in neurotoxicology are limited to 
transformed cell lines which are derived from rodent or human. For an in vitro 
test to have high rate of predictability of neurotoxicity and teratogenicity it should 
undergo the important processes of embryological development, such as cell 
proliferation, cell migration, and differentiation. Human neural stem cells have 
been proposed for this purpose, which have the ability to divide, differentiate, and 
migrate. In this study, it was found that double coating of laminin with either poly 
D lysine or poly L lysine was most suitable for growing human neural stem cells 
rather than coating with a single extracellular molecule. Several chemicals and 
drugs were then chosen to assess the utility of neural stem cells as an assay for 
neurotoxicity: methyl mercury and lead acetate; four anti-epileptics drugs (sodium 
valproate, phenytoin, carbamazepine, and phenobarbitone); anti-oxidants (folic 
acid and melatonin). These anti-oxidants were tested alone and when added to 
sodium valproate and to phenytoin (which are well known in their teratogenicity), 
and other drugs (lithium, diazepam, and amitriptyline), which are weak 
teratogens. To assess the effects of these molecules on human neural stem cells 
cell survival, total cellular protein, neuronal process length, neurosphere sizes, 
migration distance, Glial Fibrillary Acidic Protein, and tubulin III protein 
expression were measured.  
The study shows that methyl mercury caused significant reduction in most of the 
end points from the dose of 1µM and it led to significant increase in Glial 
Fibrillary Acidic Protein expression (which is a sign of reactive gliosis). Lead 
acetate led to a significant reduction in cell migration 48hours after treatment with 
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10µM. In the case of the anti-epileptics, sodium valproate appeared to reduce 
neurosphere size significantly from the dose of 500µM and decrease migration 
distance significantly 48hours after treatment with 1000µM. Moreover, phenytoin 
treatment resulted in significant reduction in neurosphere sizes from the dose of 
25µM and reduced cell migration significantly from the dose of 50µM. However, 
the other anti-epileptics (carbamazepine and phenobarbitone) revealed their effect 
only at high doses which are above their therapeutic range. On the other hand, 
adding the anti-oxidants (Folic acid or Melatonin) to sodium valproate or 
phenytoin had to some extent beneficial effects, by making their toxic effect 
appear at doses which were higher than when used alone. Regarding the other 
drugs (lithium, diazepam, and amitriptyline), it seems that their toxic effect 
appeared only at doses which are higher than the therapeutic range. 
Therefore, it can be concluded that human neural stem cells are a sensitive model 
in detecting the neurotoxicity of methyl mercury and lead acetate at low doses and 
can predict the neurotoxicity of sodium valproate and phenytoin at their 
therapeutic doses. 
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1.1 Historical Background 
The history of neuroscience goes back over a century but started in a meaningful 
way with the advent of in vitro systems. One of the earliest theories had been 
proposed by Cajal in 1890, which was based on microscopic analysis of 
histological sections, who stated that immature neuronal cells can send out 
neurites which elongate freely, having a growth cone at the tip. Competing 
theories proposed that growth of neurites did not occur, but the neurites formed 
from elements produced from other cells, or formed by stretching of a 
protoplasmic bridge between the central and peripheral cell bodies of a 
multinucleated cells (y Cajal, 1989). These theories could not be tested at that 
time because the histological methods were primitive and the growth of neurites 
of living neurons could not be observed, since the old histological techniques 
were not applied to live cells. Harrison was the first who developed a culture 
system for living neural tube tissue for the long term examination of neuronal 
differentiation (Harrison et al., 1907) and he proved that Ramon Cajal theory in 
1890 concerning the development of nerve fibres was correct. His finding that the 
growth of neurites was from cell bodies has been considered as “ one of the most 
revolutionary results in experimental biology” (Shephard, 1994).  
50 years later, the discovery of nerve growth factor (NGF) by Levi-Montalcini, 
Hamberger, and Cohen provided a profound advance in tissue culture (Cohen et 
al., 1954). NGF became the basis for the discovery of other neuronal growth and 
differentiation factors. Those investigators used a chick ganglion bioassay 
technique to detect NGF in other sources. Neurons in the chick ganglion explants 
extended neurites toward NGF when they perceived its presence in extracts of 
snake venom, submaxillary gland of male mouse, and S-180 mouse sarcoma. 
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Levi-Montalcini won the Nobel Prize, which was published in the journal of the 
Tissue Culture Association with the consideration of its editor, Gordon Sato, that 
the award to Levi-Montalcini and Cohen was “ an affirmation of the growing 
importance of cell culture in biological research” (Levi-Montalcini, 1987). 
1.2 Brain Spheroid in In vitro Neurotoxicology 
In 1950s Garber and Moscona showed that a single cell suspension taken from the 
fetus at a specific time from mammalian or avian sources can reaggregate on 
constant gyratory agitation to form a three dimensional structure called a spheroid 
(Moscona, 1952, Garber and Moscona, 1972). Close observation of the spheroids 
demonstrated that they could reproduce the complex cellular organization and 
development of the tissue from which the cells had been isolated. In monolayer 
cell culture, the cells lost their phenotype as they remain in the culture for a long 
time. However, the brain spheroid restricts cell division and stimulates 
morphological and biochemical differentiation similar to in vivo development 
(Seeds et al., 1980). The dissociated cells are avid to attach with their counterparts 
to form neurospheres, and the cells within the neurosphere are able to migrate and 
to interact with the neighbouring cells by direct cell- cell junctions and through 
the exchange of nutritional and signaling factors. This environment enables the 
cells to form tissue-specific structures such as synapses and myelin . Under 
certain environmental conditions, the cells within the neurosphere can migrate 
and reorganize themselves to form aggregates which histologically resemble the 
tissue from which the cells had been isolated (DeLong, 1970). The maturation 
process of the neurosphere makes it a suitable model in evaluating the effect of 
some chemicals on the developmental maturation of the neurosphere and whether 
these chemicals can produce structural or functional defects. 
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1.3 Cellular development in the CNS 
Stem cells are the cells which have the ability first to proliferate and make 
identical copies of themselves, several times for several generations, and second 
to differentiate into the cell lineages of the tissue they are derived from 
(pluripotency and multipotency in case of embryonic stem cells and neural stem 
cells respectively), third they can regenerate the tissue and organ they resided in 
(Ahmed, 2009). Stem cells are present in all tissues to some extent, under strict 
growth control to maintain them, to prevent over growth and tumour formation 
and to mobilize them during injuries in a bid to compensate and replace the cell 
loss (Evans and Potten, 1991). 
All the cells in the central nervous system are formed from the neuroectoderm, 
the neural plate, which located along the dorsal midline of the developing 
embryo. This neuroepithelium is a single layer of pseudostratified epithelium 
which grows and proliferates continuously to close the developing neural groove 
and form the hollow neural tube. The neural tube later on gives rise to the 
ventricular system of the CNS, while the epithelial layer will form the neuronal 
cells and glial cells (Clarke, 2003). The neuroepithelial stem cells differentiate 
into neural cells at first, then into glial cells. Neural differentiation is an early 
event in mammalian embryogenesis. It appears that the neural plate formed by 
suppression of signals that induce non-neural differentiation, examples for these 
signals are bone morphogenic proteins (BMPs) and transforming growth factors- 
β (TGF-β) superfamily molecules (Wilson and Edlund, 2001). Several molecules 
that enhance neural differentiation such as noggin, follistatin, and chordin are 
BMP- antagonists. BMPs suppress neural fate differentiation of neuroepithelium 
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and there are two receptors for BMPs: BMPR-1A and BMPR-1B. The expression 
of these two receptors is inhibited by sonic hedgehog (Panchision et al., 2001) 
The differentiation of neuroepithelium proceeds in a temporal way, which is 
specific for each region of the developing embryo (Rao, 1999). This patterning of 
the neural tube is thought to start from the stage of neural plate development by 
inductive cellular interactions which form organizing centres in both poles 
(Altmann and Brivanlou, 2001), the ventral and the dorsal one. These specialized 
cells release signals, sonic hedgehog (Shh) and (BMPs) in variable 
concentrations, to form a gradient of signal concentration. This induces the 
expression of patterning genes in the adjacent cells of neuroepithelium in a 
concentration dependant manner. These genes encode homeodomain transcription 
factors, and their expression divides the cells into different domains (Kobayashi et 
al., 2002). These patterning genes may specify the identity of the neurons and 
might control the duration of neurogenesis during each developmental process. 
The neural tube in the human is formed during the third and fourth weeks of 
gestation. Initially, the neuroepithelium consists of a single layer of neural stem 
cells. These cells proliferate symmetrically and asymmetrically to enrich the pool 
of neural stem cells and to provide more progenitor cells from which more mature 
neuronal and glial cells develop. The signals which determine the symmetry and 
asymmetry are still unknown (Jan and Jan, 1998), presumably, BMPs are 
involved. Retroviral labelling studies have shown that 48% of the dividing cells in 
Ventricular Zone (VZ) remain in colonies suggesting self- renewal in this area 
(Cai et al., 1997). The active division of these progenitor cells is controlled by 
apoptosis to maintain a constant population but the mechanisms are not clarified 
yet (Raoul et al., 2000). 
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The neural stem cells in the neuroepithelium locate at the luminal surface of the 
neural tube called the Ventricular Zone (VZ). These stem cells start to proliferate 
generating the neuroblasts which accumulate in this zone and activate a series of 
genes which are involved in neuronal differentiation. These genes also activate 
the expression of specific cascades of factors which control neuronal 
determination and differentiation in different areas in the neocortex. The newly 
matured neuroblasts migrate beyond the VZ of the neuroepithelium with the aid 
of the radial glial cells which provide the essential substrate for neuronal 
migration (Clarke, 2003). The radial glial cells extend from the ventricular surface 
to the outer pial surface of the neural tube, guiding neuronal migration away from 
the VZ and forming a second zone called the SubVentricular Zone (SVZ) as 
shown in the figure below. 
 
Figure 1: The neuroepithelium in the neocortex of the brain (Clarke, 2003) 
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When the formation of neuroblast has stopped, the remaining cells in the 
neuroepithelium will differentiate into glioblasts. Clonal studies pointed out that 
most of the glial cells originate from the stem cells of the neuroepithelium (Barres 
and Barde, 2000) and these cells migrate to the adjacent area, the SVZ, to reside 
there and proliferate and differentiate into astrocytes and oligodendrocytes. 
Lineage tracing studies showed that most of the progenitors in the germinal 
matrix are glial precursors that differentiate into either astrocytes or 
oligodendrocytes (Levison and Goldman, 1997). The glioblast formation ceases 
after birth shortly, then the VZ disappears throughout the neuroaxis and most of 
the remaining neuroepithelium differentiate into ependymal cells. Ependymal 
cells line the ventricular system of the brain and the central canal of the spinal 
cord throughout adulthood. These cells have multiple cilia at their apical surfaces 
which help the cerebrospinal fluid to pass effectively through these regions. The 
SVZ also decreases in size and persists adjacent to the ependymal cell layer 
throughout all ventricular region. 
In CNS development, the temporal patterning leads to the generation of neuronal 
cells before oligodendrocytes. In spinal cord development, it appears that these 
two cells develop from the same precursor and the final step in cell differentiation 
relies on extrinsic signals and activation of specific transcriptional factors (Jessell, 
2000). There are two main groups of transcriptional factors which determine 
cellular fate, which are the homeodomain factors such as NKx2.2 (Vetter, 2001) 
and the basic helix-loop-helix family of transcription factors such as Olig1 and 
Olig2 (Zhou et al., 2001). The expression of Olig transcription factors is 
controlled by extrinsic factors, such as Shh, and their expression leads to the 
formation of oligodendrocytes. With the progression of development, Olig1 and 
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Olig2 expression continues and starts to overlap with homeodomain 
transcriptional factor NKx2.2, these cells with double expression migrate from the 
midline and differentiate into oligodendrocytes. Olig1 and Olig2 mutant mice 
showed absence of oligodendrocytes, the stem cell progeny which normally 
differentiate into neuronal cells then into oligodendrocyte. Instead they developed 
into interneurons and then into astrocytes (Zhou and Anderson, 2002). 
The expression of the pro-gliogenic transcription factor might be controlled 
through receptors on the surface of the cells such as notch. A notch ligand- 
jagged-1 which is signalled by neurons suppresses the oligodendrocyte phenotype 
(Rogister et al., 1999). When the number of neurons become enough, jagged-1 is 
diminished and pro-oligodendrocyte signals enhance oligodendrocyte formation 
and stimulate myelination. When the neural precursor has committed to the 
oligodendrocyte lineage, the final step to differentiate into myelin forming cells 
needs the presence of SOX10. Lacking this factor in the neural stem cells leads to 
failure in axon myelination (Stolt et al., 2002). 
1.4 Neuronal Migration 
Neuronal migration is an important process in the development of the nervous 
system that determines the final position of the neurons, and also provides the 
basis for the subsequent contact with other cells to complete the neural circuitry. 
This process is so complicated, started by instruction from extracellular 
compartment which cause activation of certain receptors with their downstream 
signalling pathways, and this enables the newborn neurons to migrate through the 
developing nervous system until they reach their final destination. The migratory 
cycle of the neuron is defined by leading process dynamics (see below), by which 
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process the migration is directed, and somal translocation involving the migration 
of the nucleus, perinuclear organelles and materials takes place (Valiente and 
Marín, 2010). This cycle is not applied to all the neurons, some classes of neurons 
may modify and change some of the basics of the cycle depending on the 
pathways by which the neurons migrate. For example, pyramidal cells in cerebral 
cortex, pass through three different phases during their migration towards the 
cortical plate (Kriegstein and Noctor, 2004) during which the pyramidal cells 
adopt different morphologies each of which require special molecules whose 
disruption might lead to neurological deficits (LoTurco and Bai, 2006).  
1.4.1 The leading process dynamics 
Several experiments have studied the behavioural dynamics of the leading process 
of the migrating neurons. Figure (2) shows that the leading process has a special 
morphology, reflecting their ability to adapt to different environment. The rear 
part of the nucleus and the proximal part of the leading process are enriched with 
actin and myosin filaments. The migration cycle starts with extension of the 
leading process, dilatation of the perinuclear area and forward movement of the 
nucleus and adjacent organelles, such as Golgi complex and the centrosomes. 
This simple dynamic is applied to some cells such as pyramidal cells which 
migrate radially (Rakic, 1972), but in case of tangentially migrated neurons, such 
as the interneurons and immature enteric neurons, these have distinct leading 
process morphology, all of which have branched leading processes (Marín and 
Rubenstein, 2001). The branches continue to extend and retract until one of them 
has been selected. At this time, the nucleus and perinuclear organelles move 
forward until reaching the branching point as shown in figure (2), then the branch 
selected to be the leading process continues to grow and extend its branch while 
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the other branches start to retract, and the cycle is repeated (Martini et al., 2009). 
Thus, the guidance cues control the orientation and the frequency of branching to 
form a new leading process, to change the direction of migration without having 
to change the orientation of the preceding leading process. This migration 
guidance differs from that described for axon growth, in which the growth cone 
steering controls movement direction (Lin and Holt, 2007). 
 
Figure 2 : The cell biology of neuronal migration (Valiente and Marín, 2010) 
The branching of the leading process has been suggested to be the general 
strategy for neuronal migration, which may be in certain conditions suppressed, 
like that during the glial guided radial migration (Marín et al., 2006). The figure 
below (3) shows the steps of glial guided radial neuronal migration of pyramidal 
cells. The radial glial cells which are located at the VZ are the progenitors of 
cortical neurons. They send out a long branch that extends from the VZ to the pial 
surface over the marginal zone (MZ). The newly born neurons start to polarize 
and migrate close to the radial glial cells at VZ; when they actively interact with 
the radial glial cells (Kriegstein and Noctor, 2004), at the SubVentricular Zone 
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(SVZ), the migrating neurons stop their migration toward the cortical plate (CP) 
and begin to change their morphology to be multipolar neurons by preventing the 
interaction with the radial glial fibres (Elias et al., 2007). The cells at this stage 
form multiple processes around the cells and start to make tangential 
displacements. After that, the cells return back to be polarized and acquire bipolar 
morphology and migrate through the intermediate zone (IZ) toward the CP. One 
of the proteins which regulates this process is GTP binding protein-Rnd2. 
Knocking down this protein lead to disturbed transition of migrating neurons from 
multipolar to unipolar cells and the cells which manage to polarized appear to 
have multiple leading processes (Heng et al., 2008). The migrating neurons at this 
phase in the IZ are in close contact with the long process of the radial glial cell, 
the interaction between these cells is by connexin Cx26 and Cx43. Silencing these 
two proteins might result in the same abnormalities as knocking down Rnd2. 
The stability of the leading process depends on a system of microtubules which 
are longitudinally arranged to link the leading edge of the cells with the soma. 
This arrangement provides structural support for the leading process and allows 
the flow of vesicles required for intracellular communication. This system is 
directly controlled by a novel microtubule associated protein (MAP) called p600 
(also known as Ubr4) which interacts with the endoplasmic reticulum (ER). 
Knocking down this protein resulted in the absence of ER in the leading process 
and excessive reduction in acetylated tubulin which made the leading process to 
have a wavy appearance and affected migration (Shim et al., 2008) as shown in 
figure (3). These findings support the notion that the stability of microtubules and 
membrane trafficking are essential for the leading process. 
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The signalling mechanism that controls leading process branching still unknown, 
but work in cerebellar granular cells indicated that Ca
+2
 and cAMP might 
modulate this process. Increasing the intracellular concentration of Ca
+2
 or 
stimulating adenlyl cyclase increased leading process branching. On the other 
hand, reducing intracellular concentration of Ca
+2
 decreased the frequency of 
branching (Kumada et al., 2009). 
 
Figure 3: Glial guided radial migration. The steps in the wild type, RGC (radial glial cell) which 
reside in the ventricular Zone (VZ) send out a long process extending from VZ to the marginal 
zone (MZ). 1: The newly born neuron becomes bipolar and interacts with RGC. 2: The migrating 
neuron stops migration and becomes multipolar. 3: The neuron returns back to bipolar type and 
interact with the RGC by Connexin 43and 26 (Cx43, 26). The other figures show the 
abnormalities in migrating cells when there is a deficiency in one factor which control cell 
migration.(Valiente and Marín, 2010). 
1.4.2 Nucleokinesis 
While the leading process determines the direction of migration, effective 
neuronal migration is performed only when this is followed by translocation of 
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cell soma, the small organelles and the nucleus. Translocation of soma occurs in 
two phases, one following the other. In the first step, there is a swelling or 
dilatation of the cytoplasm in the proximal part of the leading process, towards 
which the centrosomes and the Golgi complex move. This is followed by forward 
movement of the nucleus to invade the cytoplasmic swelling (Solecki et al., 
2004), as shown in figure (2). The movement of the nucleus and the centrosomes 
is highly controlled and relies mainly on a rich microtubule array that extends 
between them. The microtubules surrounding the nucleus are tyrosinated, which 
mean that they are dynamic while the microtubules which located in the anterior 
pole of the nucleus, near the centrosomes, are acetylated which mean that they are 
more stable (Solecki et al., 2004).  
It has been suggested that the microtubules surrounding the nucleus are anchored 
to the centrosome, which is the microtubule-organizing centre of the cell. 
Therefore, it was thought that the pulling force of the microtubules on the nucleus 
converge at the centrosome (Higginbotham and Gleeson, 2007). However; 
another study pointed out that the microtubules are not attached to the nucleus but 
instead they are extending distally toward the leading process, and this fact was 
confirmed by the finding that the nucleus moves forward passing the centrosomes 
(Umeshima et al., 2007). Therefore; the exact mechanism which explains nuclear 
movement is not fully revealed. 
Microtubules Associated Proteins (MAPs) and other related proteins are crucial 
regulators for the movement of the organelles. Regardless of the exact function of 
MAPs and the other proteins in soma translocation, they are unlikely to be the 
only force which propels the nucleus and the organelles forward. It has been 
shown that there are Myosin II filaments behind the nucleus of the migrated 
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neurons, and the pharmacological blocking of its ATPase activity inhibits nuclear 
movement, suggesting that the contraction of actomyosin filaments might move  
the nucleus forward (Schaar and McConnell, 2005). 
1.4.3 Cell adhesions in neuronal migration 
Neural migration in the developing nervous system requires dynamic regulation 
interaction is integrin-mediated adhesion in many cell types, but the exact 
mechanism of this system in neuronal migration is unclear (Lauffenburger and 
Horwitz, 1996). Cell adhesion dynamics in the CNS has been well studied in the 
glial guided neuronal migration. The locomotion occurs in several steps, in which, 
there is a breakage and formation of new cell adhesions between the migrating 
neurons and the radial glia. Because of this unique property, the integrins, a 
family of cell adhesion receptors  mediating cell- cell and cell- ECM interactions, 
have been speculated to have a role in this process (Huang, 2009). Integrin 
heterodimer α3β1 are expressed in migrating neurons and α3 integrin gene 
knocking down resulted in abnormal cytoskeleton dynamics and slow radial 
migration (Schmid et al., 2004).  
Other studies showed that gap junction proteins Connexin 26 and 43 are found 
concentrated at the points of contact between the migrating neurons and the radial 
glia and their downregulation can result in abnormal radial neural migration (Elias 
et al., 2007). These junctions are well known in their capability in electrical and 
chemical cellular coupling, or releasing of some materials from the cells to the 
extracellular space. The dynamic adhesions between the migrating neurons and 
the radial glia, which is provided by the gap junctions, help in stabilizing the 
leading process of the migrating neurons along the radial glia (Elias et al., 2007). 
Limited information is available about the mechanism of controlling the dynamics 
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of gap adhesion, but it was thought that the C-terminal tail of connexin is essential 
for this process. It has been shown that this domain interacts with several types of 
cytoskeleton proteins and it has been thought that it can regulate mobility in 
several cell types (Cina et al., 2009). 
1.5 Dendrite Growth 
The nervous system is composed of a huge number of neurons with different 
characteristic afferent and efferent projections and dendritic morphologies. In 
general, the neurons in various parts of the nervous system show different patterns 
of dendritic arbors with highly specialized membrane properties. As the dendrites 
represent the site of synaptic contact, dendritic development determines the 
number and pattern of synapses in each neuron. Consequently, any defect in 
dendrite growth might result in neurodevelopmental disorders. 
In the first stage of nervous system development, the neurons are formed and 
migrate to their final destination. The neurons then elaborate their axons and 
dendrites in a pattern which is cell specific. Finally, the neurons make special 
contacts with other cells - the synapses. In many cases, early synaptic connections 
are remodelled by neuronal activity to result in the mature pattern of neuronal 
connectivity (Katz 1996).  
More than a century ago, Ramon y Cajal proposed that the dendrites (he described 
them as protoplasmic processes) are special morphological structure which 
receive neuronal input (Cajal, 1995). Before elaboration of dendrites, the neurons 
undergo polarization in which axon and dendrites are specified with their distinct 
functions and morphologies. In most neurons, the development of the axon occurs 
before the development and arborisation of dendrites (Cajal, 1995), although 
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some neuronal types adopt their specific programs of dendritic development at an 
earlier stage. In general, dendrite morphogenesis, can be defined in four steps 
(Puram and Bonni, 2013), as shown in the figure (4): 
First, the dendrites extend from the cell body into their target by using guidance 
cues to steer toward them. During that time, the dendrites grow to attain length 
and width. Whereas the dendrites and axons extend with actin based structure, 
dendritic shafts are rich in microtubules and have dendrite specific microtubule 
associated proteins (MAP), which play an important role in regulating dendritic 
size and stability (Harada et al., 2002). Second, as the dendrites grow and extend 
further, branching is essential to cover the target field. Dendrites can ramify 
several times, with extensive secondary and tertiary branches. Primarily, dendrite 
branching occurs through interstitial branching in which the branches appear from 
the side of a pre-existing dendritic shaft. Branches appear at first as filopodia then 
become cone like structures and extend to become stable branches (Dailey and 
Smith, 1996). Third, as the dendritic arbor reaches the defined area, dendritic 
growth would be restrained, giving rise to the mature shape of the dendritic tree 
(Gao et al., 1999). Fourth, dendrites differentiate into a special structure to house 
the synapses, as in formation of dendritic spines in hippocampal pyramidal 
neurons or formation of dendritic claws in cerebellar granular neurons (Puram and 
Bonni, 2013). Finally, pruning, is an important step in establishing the mature 
dendritic tree, refers to modification of arbors through retraction and elimination 
of unwanted dendrites. For example, in rodent cerebellum, the exuberant 
dendrites are pruned to establish their mature shape and undergo postsynaptic 
differentiation (Cajal, 1995). The process of pruning exempts the properly 
innervated dendrites, leaving them for full maturation (Ramos et al., 2007). 
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Figure 4: The steps of dendritic growth and arborization (Puram and Bonni, 2013) 
Once the newly formed neuron is polarized, early dendrites sprout and start to 
branch to form the dendritic tree. At the same time, filopodia formed from the 
new dendritic shaft, some of these filopodia will be stabilized and form the 
dendritic spines, depending on whether or not they participate in synapse 
formation (Togashi et al., 2002). The shape and size of the dendritic tree reflects 
the function of that neuron (Jan YN, 2001). For example, when hamlet, a 
transcription factor in Drosophilia, is expressed in a multidendritic neuron, it will 
change it into a simple dendritic neuron. This shows that the intrinsic program of 
the neurons is controlled genetically. In general, the extent of dendritic 
arborisation is regulated by the intrinsic program and the extrinsic environmental 
factors: 
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1.5.1 Extrinsic cues regulate dendrite formation 
Developing neurons are surrounded by a complex environment containing other 
neurons, glia. Afferent input of axons from other neurons, which arrive before or 
at the start of dendritic growth have a potential effect on dendritic development, 
since early exposure of the dendrites to neurotransmitters and action potential 
regulate the growth of the dendritic tree (Wong and Ghosh, 2002). The neurons 
also encounter several growth factors such as neurotrophins during development 
which strongly stimulate dendritic growth. 
1.5.1.1 Neurotrophins 
Neurotrophins are one of the molecular signals which control the growth of 
dendrites. These include four groups of growth factors which are: nerve growth 
factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
and neurotrophin-4 (Arevalo and Chao, 2005). These factors play an important 
role in nervous system development. They interact with two types of receptors, 
Trk tyrosine kinase receptors (TrkA, TrkB and TrkC) and p75 neurotrophin 
receptors (p75
NTR
). These two receptors signal independently or together to 
regulate neuronal survival, cell differentiation and synaptic plasticity. The Trk 
receptor can interact with ion channels and p75 can associate with membrane–
associated Nogo receptors, which are involved in axonal regeneration (Chao, 
2003). The neurotrophins and their receptors are highly expressed in the 
developing nervous system when there is active neuronal growth and cell 
differentiation. Also, these factors demonstrated a dramatic effect on axonal 
growth of the peripheral and central nervous system (Snider, 1994). Adding 
neurotrophins to slices of cortex caused an increase in the length and complexity 
of dendrites of cortical pyramidal neurons (McAllister et al., 1995). In addition to 
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neurotrophins, there are many other factors which are involve in dendrite growth 
and maturation, such as Semaphorins (Sema3A), Cpg15 gene expression, 
Epherin, Osteogenic proteins, Notch protein, and cell adhesion molecules 
(McAllister et al., 1995). 
A general hypothesis stated that the growth of the axon is supported by a group of 
trophic factors and matrix molecules while dendrite growth is supported by 
another set of signals (Goldberg, 2004), as shown in the figure (5) . For example,  
sympathetic and cortical neurons show dendritic growth in response to bone 
morphogenetic proteins (Withers et al., 2000). Similarly, other adhesion and 
matrix molecules may stimulate axon growth but not dendrites, for example, 
chick retinal ganglion cells (RGCs) cultured on top of glial endfeet showed 
growth of axons, while RGCs cultured on top of glial somata showed growth of 
dendrites only (Bauch et al., 1998). 
1.5.2 Intrinsic factors regulating dendrite formation 
Different neuronal types encounter the same environment during development. 
However, an intrinsic program within the neurons regulates their interpretation of 
the external cues and forms distinct pattern of dendritic trees. For example, 
neurotrophin-4 induces dendrite growth and increases its complexity in cortical 
pyramidal neurons layer V, but has no effect on layer IV neurons. Brain derived 
neurotrophic factor (BDNF) highly stimulates dendrite arborisation in layer IV 
and moderately affects the neurons in layer V (McAllister et al., 1995). 
Differential expression of neurotrophin receptors may explain the different 
response of each cortical layer to different neurotrophins, explaining that cell-
intrinsic mechanisms control the cell response to the external cues (Puram and 
Bonni, 2013).  
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Figure 5: Extrinsic factors control hypothesis (a) and intrinsic factors control hypothesis (b) on 
axonal and dendritic growth (Goldberg, 2004) 
Intrinsic refers to a phenotype expressed independently from the environment.  
Many intrinsic phenotypes are programmed at the progenitor stage and 
maintained throughout part or all the life of the neurons. The expression of the 
complement of receptors of survival, growth and initial axonal guidance may be 
intrinsic to the neurons. For example, BDNF is able to enhance axonal growth 
from retinal ganglion cells (RGCs). If BDNF is removed for few days and added 
again, RGCs are still able to respond to this growth factor and axonal growth is 
stimulated. This demonstrates that the responsiveness to BDNF is intrinsic to the 
cells (Goldberg et al., 2002). The differences in the intrinsic phenotypes of the 
adjacent neurons make them respond differently when they are exposed to the 
same environment, and this lead to appearance of variable neuronal patterns. 
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Thus, the same growth factor has a different axon or dendritic effect on different 
neurons, this explain the diversity in their final phenotype (Goldberg, 2004). 
Regarding the intrinsic control of axon and dendrite growth, in the CNS, most of 
projection neurons extend axons at first, which are then followed by dendrite 
arbor growth. This suggests that axon and dendritic growth in vivo are separated 
by time. Another fact about the intrinsic control has come from in vivo studies 
showing that embryonic spinal projection neurons are able to regenerate their 
axons after injury, whereas this ability is lost completely after birth (Saunders et 
al., 1992). Other study using explant slice cultures showed that young explants 
illustrated better axon regeneration than the older explants (Chen et al., 1995). 
Therefore, it appears that there is a developmental modification in neuronal 
ability to regenerate their axon, but these studies are confounded by the 
simultaneous changes which occur in the extrinsic glial environment during 
development which inhibit axon growth and regeneration (Schwab and Bartholdi, 
1996). However, the lack of successful regeneration of axons in studies designed 
to overcome the CNS glial cues confirm the intrinsic regulation for axon growth, 
For example, axon regeneration in adult RGCs take 2 months through a peripheral 
neuronal graft (Bray et al., 1987). These experiments also were confounded by the 
finding that reactive astrocytosis, may contribute to developmental changes 
through residual axon growth inhibitors. Therefore, it is difficult to explain 
developmental modification in axonal growth whether due to intrinsic or due to 
environmental changes. 
1.6 The Time of Brain Development 
Brain development in humans occurs from sixth week of gestation to several 
years after birth as shown in the figure (6). In the CNS, the organs build by cell 
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proliferation, migration and differentiation. The neurogenesis of specific neuronal 
populations has been shown in rodent brain and the results were extrapolated to 
human brain (Bayer et al., 1992). This study showed that different brain areas 
develop at different times, and even in a single brain area, groups of neurons 
develop at different times and at a variable rate. For example, cerebellar Purkinje 
cells develop during embryonic days 13-15 of gestation in rat which corresponds 
to 5-7 week of gestation in humans, on the other hand, granular cells are formed 
later,  about 4-19 postnatal days, which correspond to 24-40 week of gestation in 
human (Bayer et al., 1992).   
 
Figure 6: Illustrate the brain growth spurt in humans and rats, the units of time for humans are 
months and for rats days (Ikonomidou and Turski, 2010) 
 
Figure 7: Illustrate brain development  adopted from (Rice and Barone Jr, 2000) 
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2.1 Teratogenesis and Malformation 
A congenital anomaly is an anatomical, metabolic or functional defect in the 
newborn due to several factors, such as maternal exposure to infectious agents, 
drugs or due to genetic or environmental factors. It is the cause of high mortality 
and long lasting disability for surviving children and has a significant impact on 
families, social communities and health care. 5% of all the newborns have a birth 
defect, 3.2 million birth defects are registered annually, 270,000 newborns died 
by 28 days of age in 193 countries in 2010 due to congenital anomalies (WHO, 
2012). 90% of these birth defects are of unknown cause and the confirmed causes 
account for only 10 %. Drugs as a cause for these congenital malformations 
represent only 1% or less of all congenital defects (De Santis M., 2001). 
Teratology is the science that deals with developmental abnormalities which 
result from maternal exposure to physical, chemical or environmental factors 
during pregnancy which affect normal development, differentiation and/or 
behaviour. A teratogen is that factor which causes an irreversible effect on the 
development of the embryo anatomically and/or functionally. Therefore, a 
teratogen may be a xenobiotic which includes a wide range of chemicals that are 
used during pregnancy or to which a pregnant women is exposed such as 
pharmacological materials, cosmetics, food additives, heavy metals, cigarette 
smoking. Also, it can be other factors, for instance, stress, nutritional deficiency 
or infection with some viruses (cytomegalovirus and rubella) which can cause 
developmental abnormalities to the foetus (Stegmann and Carey, 2002).  
This science was brought to light in the 1920s when piglets were born from 
mothers which ate a diet deficient in vitamin A; those piglets suffered from 
several congenital anomalies including absence of eyes (Hale, 1933). In the 
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human, the first confirmed case reported to have congenital malformation was 
due to pelvic X irradiation of the pregnant mother (Goldstein L, 1921). After 
several decades, Gregg  (1991) was the first to report a case of congenital cataract 
due to infection of the mother with Rubella virus in Austria, but the evidence 
which proved that chemicals can cause foetal defects occurred after 
administration of high doses of a folic acid antagonist (aminopterin) which was 
used to induce abortion; the aborted foetuses and the living children showed 
multiple malformations (Tiersch, 1952). About 10 years later, the thalidomide 
disaster happened, in which  thalidomide was used as an antiemetic drug during 
pregnancy from 1957-1961, more than 10000 children from mothers who had 
taken the drug exhibited variable anomalies ranging from Amelia (absence of the 
limb), phocomelia (shortening of the limb), absence of the ear and deafness and 
others. These birth defects happened especially when the drug was taken during 
day 35-50 of gestation (Branch, 2004). Thalidomide had minimal effect on the 
adults but it was very toxic to the embryos (McBride, 1961). From that time, the 
regulatory agencies especially the Food and Drug Administration (FDA) in the 
USA instigated the requirement to study the drugs thoroughly on animals before 
marketing them and they issued guide lines for perfect evaluation of drugs for 
human use (Goldenthal, 1966), identification of teratogenic agents is crucial in 
preventing birth defects, since 10% of all the congenital malformations are due to 
teratogens (Brent, 1995) which affect the quality of life for millions of individuals 
in the world and also can cost billions of dollars in health care every year. Many 
studies were undertaken to identify the teratogencity and embryotoxicity of these 
compounds. 
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Wilson (1959) summarized 6 principles for teratology and these are as follows: 
1- The susceptibility of the conceptus to the teratogen depends on the 
genotype and how it interacts with the environment: 
The differences in the genetic composition, environmental factors, metabolic 
pathways and the placental features explain inter and intra-species variability 
in response to teratogens     (Schardein, 1993). 
2- The susceptibility of the conceptus depends on the gestational age at 
which it is exposed to the teratogens 
This principle brings to light the concept of the critical period of 
organogenesis which is day 22-55 of human gestation, and is the most 
sensitive period to drugs. Before that time the embryo either reacts with the 
drug and grows normally, or dies, so it follows the role either all or none. 
When the exposure occurred in the early part of the critical period, this leads 
to damage to the CNS, and when there is late exposure, this leads to 
urogenital malformation and growth retardation. Lastly, after organogenesis 
the foetus will be less vulnerable to teratogenesis, rather it causes a functional 
deficit (Bailey et al., 2005), figure (1). 
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Figure 8: Demonstrates the critical periods in human development (Keith L. Moore, 2016) 
3- Teratogens act in different ways to produce developmental abnormalities, such 
as modification in the cell matrix, cell membrane, changes in the transport 
processes and cell migration, alteration in RNA and protein synthesis or 
interference with energy resources. Also each teratogen can act in different ways 
and it is not necessary that a specific cellular change is related to specific 
teratogen (Bailey et al., 2005) 
4- The final manifestations of a developmental abnormality are malformation, 
growth retardation, fetal death or functional impairment   
5- Several factors affect the ability of any agent to influence the development of 
the conceptus which are the nature of the agent itself, the dose and the duration of 
exposure, the rate of placental transfer, and maternal metabolism of that agent in a 
bid to eliminate it (Polifka and Friedman, 1999). 
6- The final manifestation of developmental abnormality depends on the dose of 
the teratogen. The teratogenicity appears when the dose exceeds the lower limit -
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the threshold (Brent, 1995). Each teratogen has its own threshold; if the conceptus 
is exposed to a dose lower than that of threshold there will be no effect but once it 
is exposed to a higher dose, this will affect its development in a dose dependent 
way 
Also Branch (2004) realized that when a teratogen is described, three principles of 
it must be considered: 
1- The teratogen may be organ specific. 
2- The teratogen could be species specific. 
3- It can be dose specific. 
FDA categorized drugs according to their pregnancy risk in to five categories 
(Briggs et al., 2012): 
Category A: Controlled studies in women showed no evidence of risk to the fetus 
(in the first and other trimester) 
Category B: Animal studies showed no foetal risk but there are no controlled 
studies on pregnant women. 
Category C: The drug has foetal risk, but there are no controlled studies in the 
human, the drug can be administered when a benefit outweighs the risk. 
Category D: The studies confirmed that the drug showed a positive fetal risk, the 
uses of these drugs is restricted to life threatening condition when safe drugs are 
not effective. 
Category X: The drug is contraindicated in pregnant women, the risk outweighs 
the benefit, the risk has been demonstrated in both animal and human. 
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2.2 Mechanism of teratogenesis 
Some of the mechanisms which are involved in teratogenesis are folate 
antagonism, neural crest disruption, endocrine disruption, oxidative stress, 
specific receptor or enzyme mediated teratogenesis (Van Gelder et al., 2010). In 
general, the teratogenicity and embryotoxicity of any drug is often not due to the 
parent compound (which is then called the proteratogen), but due to toxicity of 
the intermediate metabolites that are produced through bioactivation by 
cytochrome P450, prostaglandin H synthase and lipoxygenase. The metabolites 
are usually into electrophilic materials and/ or free radical reactive intermediates 
that oxidize or covalently bind to the macromolecules of the cells (protein, lipid 
and DNA) which may lead to cell death (Juchau et al., 1992).  
The teratogenic effect of any drug depends on the balance between the teratogenic 
activity of the intermediates and the protective mechanisms, such as maternal 
proteratogen elimination, embryonic detoxification, cytoprotection against 
oxygen reactive species and repairing of the damaged cells (Wells et al., 1997). 
2.3 Teratogenic testing: 
Before the thalidomide tragedy, chemicals were tested by what is called the Litter 
test, in which the animals, usually male and female rodents, were exposed to the 
chemicals during the reproductive cycle and monitored for two successive 
pregnancies. Foetal survival was the only parameter for toxicity (Ujházy et al., 
2005). The thalidomide disaster in the early 1960s instigated governments and 
scientific communities to test chemicals more thoroughly. Since that time, drug 
teratogenicity testing has been a subject of great interest, to discover harmful 
drugs and to save the developing embryos. The Food and Drug Administration 
(FDA) established guidelines which made the tests more comprehensive than 
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before. Since then, in 1994, new testing protocols were issued with acceptance by 
the International Conference of Harmonization (ICH) (Branch, 2004). Given the 
complexity of the reproductive system and the large number of tissue targets 
where birth defects or postnatal effects could be induced, there was reason for the 
standardization of the tests and there followed international acceptance (Tandon 
and Jyoti, 2012). 
Embryo foetal development is a very sophisticated process; it involves many 
events such as gene expression, cellular proliferation, interaction, migration, 
differentiation, organ formation and the achievement of the physiological 
functions of the embryo. The ideal test is one which can provide full information 
about the whole process of embryonic development.   
In general, there are two types of teratogenesis testing: 
1- In vivo tests 
The main advantage of using animals for product safety tests is that it is an 
inclusive model of all the factors that are involved in human exposure. Dosing 
can be by the oral or parenteral route, and the chemical is distributed and 
submitted to physiological and biochemical mechanisms that determine the 
concentration of the chemical or its active metabolite at the affected organs. 
Orally administered chemicals are first distributed in the liver to be modified into 
a water soluble compound so that the chemical can be eliminated from the body 
with the waste products. Sometimes, the liver metabolizes chemicals into long 
lasting active metabolites, which can be toxic in their own right, such as 
cyclophosphamide to acrolein and phosphoramide mustard (Garattini, 1985a), or 
they can be converted to toxic reactive metabolites in a remote organs such as the 
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nephrotoxicity of S-cysteine conjugates of haloalkenes (Chen et al., 1990). These 
interactions are not available in the in vitro models.  
Using animals for product safety testing does not necessarily predict human 
toxicity. An example for that is the anti-viral drug fialuridine which caused 
hepatic failure in the human, but this was undetected in preclinical animal studies 
(Colacino, 1996). Another example is the anti- allergy drug 6,8- diethyl-5-
hydroxy-4-oxo-4H-1- benzobyran-2-carboxylic acid (DHBC), which induced 
mild hepatotoxicity in the human, which was not predicted by laboratory animal 
tests (Clarke et al., 1985). These interspecies differences are due to differences in 
pharmacokinetics, drug metabolism, and organ perfusion rates (Garattini, 1985b). 
Therefore, it is impossible to rely completely on animal data until humans are 
exposed, and it is necessary to attempt to evaluate the human risk of these 
chemicals by any of those scientifically valid models. 
In vivo tests can give a wide range of information about development, while in 
vitro tests reflect only one aspect of the process. Therefore, a combination of 
more than one test can provide a good view (Piersma, 2006). In vivo teratogenic 
testing is impractical for the huge number of chemicals that are produced annually 
because it could be highly expensive, time consuming, require large amount of 
chemicals to be used in the experiments and needs a large number of animals to 
be sacrificed. The advantages of In vitro methods are their being cheaper, quicker 
and they can serve as a pre-screen test for all the compounds to rank which need 
further studies by in vivo methods.  
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2. Alternative methods: 
The drive to develop alternatives to animal studies in developmental toxicity has 
been increased in the last decades. The increased interest in this field stemmed 
from Russell (1959) who proposed the principle of 3 R,s (Reduction, Refinement, 
Replacement). The European Union white paper suggested the harmonization of 
testing requirements for chemicals marketed before September 2001 
(Registration, Evaluation, Authorization of Chemicals- REACH) which involves 
about 30,000 chemical (Hartung et al., 2003). If these substances were tested by 
animal based methods, this would need 12.8 million animals and cost about 11 
billion dollars for a period extending to up to 45 years (Hartung et al., 2003). The 
estimated number of chemicals that humans are exposed to exceeds 50,000 and 
there are more than 400 new chemicals introduced in to the market annually  
(Bournias-Vardiabasis, 1994). The alternative test methods in developmental 
toxicity include cell culture, organ culture and whole embryo culture. Cell culture 
can be the simplest and easiest and sometimes does not require animals.  These 
tests reflect information about only one mechanism and can detect the effect of a 
drug on only one aspect of development, such as cell proliferation (Pratt and 
Willis, 1985) or cell adhesion (Braun et al., 1979).  Flint and Orton (1984) used a 
high density of embryonic limb bud cells and brain cells to see the effects of 
xenobiotics on the differentiation of these cultured cells. However, this method is 
unable to provide enough information about the whole integrated system and its 
regulatory mechanisms.  
While organ culture can present some parts of organogenesis in vitro, this method 
requires animal materials which make it laborious. The animal organs may 
involve lung, intestine, reproductive organs, limb bud etc (Faustman, 1988). In 
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the case of whole embryo culture, this provides an example of a complete in vitro 
alternative test. It presents embryogenesis in its full complexity from cell division 
and proliferation to pattern formation (Piersma, 2006). 
Wilson  (1978) summarized the main criteria for the ideal in vitro test: 
1- Simple, easy and give interpretable results. 
2- Rapid, use large number of samples. 
3- Yield less false positive results. 
4- Relevant to teratogenic mechanism. 
5- Have some aspects of progressive development. 
6- Can use different kinds of agents. 
7- The used organism should be capable to absorb, circulate and excrete 
chemicals. 
More than 30 in vitro tests using vertebrates and invertebrates have been proposed 
for assessing embryotoxicity (Tandon and Jyoti, 2012). Three of them have been 
validated, which are limb bud micromass-MM (Flint and Orton, 1984), rat post-
implantation whole embryo culture- WEC (New et al., 1976), and the embryonic 
stem cells EST (Spielmann, 1997). 
2.4 Chick Micromass System 
Micromass culture is a good example of using cell culture. This test was devised 
by Umansky (1966) when he used undifferentiated mesenchymal cells of the 
chick embryo limb and cultured them in small volume in high concentration, 
when they formed numerous small foci of differentiated chondrocytes in a 
background of undifferentiated cells. The Micromass system involves some of the 
main mechanisms in development which are cell division, movement, cell-cell 
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communication, cell-matrix interaction and differentiation (Flint, 1983, Umansky, 
1966). Therefore it has been proposed as a good screening test for detecting 
toxicity (Spielmann et al., 2001). This system is based on culturing cells from 
mesencephalon or limb of different species such as the rat (Flint and Orton, 
1984), mouse  (Tsuchiya et al., 1991) and chick (Wiger et al., 1988). In the 
micromass system, Formation of chondrocytes and neural cells is used as an end 
point, therefore, the ability of chemicals to disrupt the normal differentiation of 
primary cells can be identified with the aid of other cytotoxicity tests. 
Chick can be considered as an attractive species in screening purposes because of 
its rapid development, and the avoidance of mother sacrifaction. Also, chick 
micromass system has been proven to be efficient in teratogen detection 
(Atterwill et al., 1991). It has been observed that there is no significant 
differences between rat and chick micromass systems in detecting teratogens 
(Brown and Methods, 1995, Brown and Wiger, 1992). For this purpose, sodium 
valproate and lithium carbonate have been used to detect their embryotoxicity on 
both cardiac and neural chick micromass systems. 
2.4.1 Materials and Methods 
2.4.1.1 The source of cells 
Chick cells: Chick embryonic cardiomyocyte and neural cells were obtained from 
5 day old embryos of white fertile Leghorn chicken eggs. These eggs were 
purchased from (Henry Stewart Company. UK) 
2.4.1.2 Eggs storage and Incubation 
White fertile Leghorn chicken eggs were stored in a cooled incubator at 12
ₒ
C to 
suspend the embryonic development (SLACK, 2006). These eggs should be used 
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within 2 weeks from the first day being placed in the incubator. For each 
experiment, at least 2 dozen eggs were kept (for 5 days) in the warm incubator on 
an automatic egg turner with the broader ends faced up. The temperature was 37
ₒ 
C and the relative humidity was 100%. The day of incubation was regarded as day 
0.  
2.4.1.3 Cardiomyocytes and Neural cell culture 
In the day of explantation, the eggs were swabbed by 70% alcohol then 
transferred to a class I laminar flow hood which was cleaned by Trigene 10% and 
sterilized by 70% ethanol. By gentle striking of eggs with the broader end of 
sterilized forceps the egg shell was broken and peeled off; the vitelline and 
chorioallantoic membranes were removed to reveal the embryo which was lifted 
up and placed in a 100ml Petri dish containing Hank’s Balanced Salt Solution 
(HBSS). Under the dissecting microscope, the heart and midbrain were removed 
and placed in Bijou tubes containing 50% Horse Serum/HBSS. When all the eggs 
had been explanted and 24 hearts and midbrains were collected, the hearts and 
brains were washed twice with HBSS to remove the excess of horse serum. 2 ml 
0.05% Trypsin and 0.02% EDTA was added to both these tubes and kept inside 
the incubator at 37
ₒ 
C, 5% CO2 and 100% humidity for 20 minutes with frequent 
shaking to enhance cellular disintegration, after that 8 ml of full culture medium 
(Dulbecco Modified Eagle Medium-DMEM, 10% Foetal Bovine Serum, 
Glutamine, penicillin and streptomycin) (see appendix 1) was added to stop the 
action of Trypsin and centrifuged at 1500 rpm for 5 minutes. The supernatant was 
aspirated and 1 ml medium was added to the pellet with frequent resuspension by 
pipette to produce a cellular suspension. A cell count was performed using a 
haemocytometer and the cell number was fixed on 3*10
6
/ml. 20µl cell 
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suspensions were placed at the bottom of each well of the 24 well plate, first left 
column was left without cells, with only media, then the cells were left for 2 hours 
to allow cellular attachment followed by adding 500µl medium. The drug was 
added 24 hours after cell seeding in a concentration double the required dose in a 
further 500µl medium. The treatment was for 6 days. The media  changed every 3 
days. 
2.4.1.4 Cardiomyocytes Contractility Scoring 
In the Cardiac Micromass System, the contractile activity of the cardiomyocytes 
was recorded every 24, 48 and 144 hours after cell seeding by using an inverted 
microscope and scoring depending on the number of contracting foci in the well. 
If the whole well shows contracting foci a score 3 is given, and the number of 
contracting foci decreasing the score decrease accordingly and becomes zero 
when there are no contracting foci.  
The score  
0 No contractile activity 
1 Few contracting foci in the well 
2 Numerous contracting foci in the well 
3 All the well is contracting 
2.4.1.5 Neuronal processes number 
1*10
5
 cells from the trypsinized midbrain were seeded on glass coverslips which 
were coated with Poly D-Lysine and Laminin and left for 6 days, after that, 3 
photos were taken blindly (for each coverslip) for the neurospheres that formed 
over these coverslips which start to attach and send neurites between them, as 
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shown in the figure (17). Neurite number was determined by using ImageJ 
software. 
2.4.1.6 Resazurin Assay  
Resazurin, a 7 –hydroxy-3H- phenoxazin-3-one 10 oxide redox dye (Bueno et al., 
2002) has been used to detect bacterial and yeast contamination in milk and to 
detect semen quality for 50 years (Erb and Ehlers, 1950). It is also called the 
Alamar Blue test. The Resazurin test is easy, simple, rapid, performed by a one-
step procedure, sensitive (it can detect viability even for 80 cells), efficient and 
cost effective (O'Brien et al., 2000). Non fluorescent blue resazurin is reduced by 
the action of mitochondrial enzymes (O'Brien et al., 2000); also cytosolic, 
microsomal enzymes can contribute to this reaction (Gonzalez and Tarloff, 2001), 
into fluorescent  pink material called resorufin, then the fluorescence can be 
detected by optical density and the amount of fluorescent produced is directly 
related to the number of viable cells. This test is ideal for cells in primary cell 
culture, since the resazurin is not toxic to the cells and the test can be repeated 
several times per day. In addition to that, the cells can be reserved for other tests. 
Further reduction of resorufin produces colourless, non-fluorescent product which 
can be the cause of under estimation of large numbers of viable cells  
The cell viability test was performed on the 6
th
 day of the cell culture by 
aspiration of the media and adding pre-warmed resazurin solution (see appendix 
1) to each well and placing in the incubator at 37°C, 100% humidity, 5% CO2 for 
one hour. Optical density was measured by using FLUOR star plate reader with 
an excitation filter wavelength of 530±10nm and emission filter wavelength of 
590±12.5 nm, and a gain of 60. The obtained data of optical density indicates the 
amount of resorufin produced by the cultured cells which was plotted from the 
 38 
 
resorufin standard curve to know the exact amount of resorufin produced. After 
that, 300µl of Kenacid blue fixative (see below) was added to each well overnight 
for the Kenacid blue assay. 
2.4.1.7 Resazurin Standard Curve 
Different concentration of resorufin solution: 2000ng/ml, 1000ng/ml, 500ng/ml, 
250ng/ml, and 125ng/ml were prepared in HBSS. 500µl of each concentration 
was added to each well leaving the first column of the 24 well-plate as a blank. 
The optical density was measured with the excitation filter wavelength 0f 
530±10nm and emission filter wavelength of 590±12.5 nm, with a gain of 60. The 
data were plotted on a graph and the values were linked by the best fit straight 
line. 
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Figure 9: Resazurin assay standard curve 
2.4.1.8 Kenacid Blue 
Kenacid blue dye binds to cellular protein which is proportional to the total 
protein in the whole cell number in culture media (Clothier et al., 2006). This dye 
combines with NH3
+
 terminal ends of the protein molecules (de St Groth et al., 
1963). This assay is based on the idea that if a chemical or drug has an effect on 
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protein production, or membrane integrity, this will affect the rate of cell growth 
and cell number. 
Kenacid Blue protein assay 
After the resazurin assay, kenacid blue fixative (300µl) (see appendix 1) was 
added to each well and left to evaporate overnight, 500µl of kenacid blue working 
solution (see appendix 1) was added to the wells and kept on the plate shaker for 
2 hours. At this time the kenacid blue dye will react with cell protein. Excess dye 
was removed by rinsing the well with kenacid blue washing solution (see 
appendix 1) then agitating the plate on the plate shaker for 20 minutes. The 
washing solution was replaced with 500µl kenacid blue desorb (see appendix 1), 
and left on the shaker for 1 hour to take the dye from the surface. The solution 
was transferred into a 96 well plate, and the optical density was determined by 
using ASYS HITEC Expert plate reader with reading filter 570nm and reference 
filter 405nm. 
Kenacid Blue Standard Curve 
In order to measure the amount of protein, a Kenacid blue standard curve was 
plotted by using bovine serum albumin (BSA). 2.4 mg BSA dissolved in 3 ml 
distilled water followed by adding 7 ml 100% ethanol to obtain 70% ethanol, 
240µg/ml BSA. By adding 6ml 70% ethanol to 3 ml 240µg/ml solution, 80µg/ml 
BSA was obtained, then a serial dilution of this solution was done to obtain 70, 
60, 50, 40, 30, 20, 10µg/ml. The 24-well plate was left in the refrigerator 
overnight to allow the ethanol to be evaporated, 300µl of kenacid blue fixative 
was added to each well overnight and the same steps were performed as described 
in the kenacid blue protein assay. The data were plotted on a graph and the values 
were linked by the best fit straight line.  
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Figure 10: Kenacid blue assay standard curve 
2.4.1.9 Drug preparation 
Sodium Valproate and Lithium Carbonate stock solutions were prepared by 
dissolving them in Hank’s Balanced Salt Solution (HBSS) and distilled water 
respectively. Different stock solutions were prepared at high concentration, the 
final required concentrations are: 500, 750, 1000, 1500, and 2000µM for each. 
The drug was added on the next day of the culture system. The first left column 
was without cells or drug, we only put media. The second column of the 24 well-
plate was left without drug as control, as shown below. The stock solutions were 
kept in the fridge. 
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Figure 11: 24 well- plate showing the way of adding drugs, the left black column left as blank 
(only media), Green column as control (No drugs were added, only the solvent), the other blue 
columns are the treated groups, and the red arrow represent the direction of increasing the doses. 
2.4.1.9 Statistical analysis  
The raw data of 3 experimental repeats was analysed by using one way ANOVA 
test, because these parametric data belong to more than 2 groups and is normally 
distributed, then Dunnet’s multiple comparison test to check the significance of 
difference. When the P value was >0.05 it was considered to be not significant. 
All statistical analysis was done by using Prism software version 6. 
2.4.2 The results 
1. Cardiomyocyte Micromass System 
Different doses of Sodium Valproate (SV) were used to test the effect of these 
drugs on beating activity of the differentiating cardiomyocytes. It appears that 
with increasing the dose, (F (5,36)=40.01, p<0.0001), and with increasing the 
duration, (F (2,36)=52.49, p<0.0001), the inhibitory effect of this drug became 
more significant. Statistical analysis shows that 750µM causes significant 
reduction in the beating score of the cardiomyocyte after 6 days when compared 
with that of control, (concentration versus time: F (10,36)=4.595, p<0.0003, post- 
hoc: 750µM vs control: p<0.01). While the doses 1000 and 1500µM show their 
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inhibitory effect 48 hours and 6 days after drug treatment, and the highest dose, 
2000µM inhibit beating activity of differentiated cardiomyocytes from the first 
day (24 hours), (2000µM vs control: p<0.0001) . 
SV effect on cell viability appeared to be significantly affected at 1500 and 
2000µM when compared with the control, (F (5,12)=91.82, p<0.0001, post-hoc: 
1500µM vs control: p<0.0001), however, its significant effect on total protein 
amount revealed only at 2000µM, (F (5,12)=7.803, p=.0018, post-hoc: 2000µM 
vs control: p<0.01), figure (12). 
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Figure 12: Sodium valproate effect on cardiac micromass. A- beating score 24, 48, and 144 hrs 
after drug treatment. B- Resazurin assay. C- Kenacid blue assay, and  a video showing a 
contracting focus. The data here is represented by mean ± S.E, n=3 (average 4 wells  from each 
experiment). *sign of significance when the P<0.05, ** when P<0.01, *** when P<0.001, **** 
when P<0.0001.The data was analysed by using two way ANOVA for  beating score analysis, and 
One way ANOVA for  resazurin and Kenacid blue assays, then Dunnett’s multiple test was 
performed  to compare the mean of control group with that of treated groups. 
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On the other hand, Lithium Carbonate has significant effect on the beating score 
of differentiating cardiomyocytes with increasing the dose, (F (5,36)=43.72, 
p<0.0001), and with increasing the  duration, (F (2,36)=35.96, p<0.0001). Only at 
1500µM, a significant reduction in the beating score appeared 48hrs after 
treatment, (concentration versus time: F (10,36)=8.217, p<0.0001, post-hoc: 
1500µM vs control: p<0.05), but, at 2000µM, the inhibitory activity of Lithium 
appeared earlier after 24 hours of treatment, (2000µM vs control: p<0.05). The 
viability of differentiating cardiomyocytes, (F (5,12)=4.644, p=0.0137, post-hoc: 
2000µM vs control: p<0.05), and total protein amount, (F (5,12)=5.782, 
p=0.0061, post-hoc: 2000µm vs  control: p<0.01) were reduced significantly only 
at highest dose which seems to be significantly reduced when compared with 
control group, figure (13). 
 
 
 
 
 
 
 
 44 
 
2
4
h
rs
4
8
h
rs
1
6
6
h
rs
2
4
h
rs
4
8
h
rs
1
6
6
h
rs
2
4
h
rs
4
8
h
rs
1
6
6
h
rs
2
4
h
rs
4
8
h
rs
1
6
6
h
rs
2
4
h
rs
4
8
h
rs
1
6
6
h
rs
2
4
h
rs
4
8
h
rs
1
6
6
h
rs
0
1
2
3
A
L ith iu m  C a rb o n a te  d o s e s
B
e
a
ti
n
g
 s
c
o
re
5 0 0
7 5 0
1 0 0 0
1 5 0 0
2 0 0 0 M
C o n tro l
**** ****
****
* *
 
C
o
n
tr
o
l
5
0
0
7
5
0
1
0
0
0
1
5
0
0
2
0
0
0

M
0
2 0 0
4 0 0
6 0 0
8 0 0
B
L ith iu m  C a rb o n a te  d o s e s
R
e
s
o
r
u
fi
n
 n
g
/m
l *
C
o
n
tr
o
l
5
0
0
7
5
0
1
0
0
0
1
5
0
0
2
0
0
0

M
0
2 0
4 0
6 0
8 0
C
L ith iu m  C a rb o n a te  d o s e s
P
r
o
te
in

g
/m
l
**
 
Figure 13: Lithium carbonate effect on cardiac micromass. A- beating score 24, 48, and 144 hrs 
after drug treatment. B- Resazurin assay. C- Kenacid blue assay, and  a vedio showing a 
contracting focus. The data here is represented by mean ± S.E, n=3 (average 4 wells from each 
experiment). *sign of significance when the P<0.05, ** when P<0.01, *** when P<0.001, **** 
when P<0.0001. The data was analysed by using two way ANOVA for beating score, and one way 
ANOVA for resazurin and Kenacid blue assays, then Dunnett’s multiple test was performed  to 
compare the mean of control group with that of treated groups. 
2. Brain Micromass System 
Sodium Valproate in brain micromass culture reduce cell viability, (F 
(5,12)=9.130, p=0.0009, post-hoc: 2000µM vs control: p<0.01), and total protein 
amount, (F (5,12)=8.280, p<0.0014, post-hoc: 2000µm vs control: p<0.01), 
significantly only at the highest dose, while its effect on neuronal process number 
appeared to be at lower doses, 1000µM, (F (5,12)=136.9, p<0.0001, post-hoc: 
1000µM vs control: p<0.05), figure (14). 
Similarly, the same effect was observed after lithium treatment on cell viability, 
(F (5,12)=7.092, p=0.0027, post-hoc: 1500µM vs control: p<0.05), and total 
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protein amount, (F (5,12)=5.397, p=0.0079, post-hoc: 2000µM vs control: 
p<0.01), figure (15). 
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Figure 14: Sodium valproate effect on brain micromass. A- Resazurin assay. B- Kenacid blue 
assay. C- Neuronal process number. The data here is represented by mean ± S.E, n=3 (average 4 
wells from each experiment). *sign of significance when the P<0.05, ** when P<0.01, *** when 
P<0.001, **** when P<0.0001. The data was analysed by using one way ANOVA, then, 
Dunnett’s multiple test was performed to compare the mean of control group with that of treated 
groups. 
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Figure 15: Lithium carbonate effect on brain micromass. A- Resazurin assay. B- Kenacid blue 
assay. C- Neuronal process number. The data here is represented by mean ± S.E, n=3 (average 4 
wells from each experiment).  
*sign of significance when the P<0.05, ** when P<0.01, *** when P<0.001, **** when 
P<0.0001. The data was analysed by using one way ANOVA, then, Dunnett’s multiple test was 
performed to compare the mean of control group with that of treated groups. 
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Figure 16: Morphological changes on brain micromass culture after treatment with Sodium 
Valproate. A, B represent the control group which show the neurosphere (NS) and how these NSs 
are connected to each other (black arrow) and notice the large population of neural cells as shown 
inside the white circle, C represents the treated group with 1000µM shows the disappearance of 
neuronal processes between the NSs. D represents the treated group with 1500µM showing floated 
(dead) cells inside the black circle. E&F treated group with 2000µM showing disintegrated NSs 
and small floated neurospheres. The scale bar is 100µm for all photos but for B it represents 
250µm.  
NS
S 
NS 
NS
S 
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Figure 17: Chick Brain Micromass, 1*10
5
 cells from trypsinized midbrain seeded on coated glass 
coverslips illustrates the effect of Lithium treatment. A & B represent the control group, which 
show the normal spherical appearance of neurospheres, and how they attached with each others by 
neuronal processes, C: represents the treated group with 1500μM, and D represents the treated 
group with 2000μM lithium, these figures show the reduction in the number of neuronal processes 
between the neurospheres.  The scale bar is 100μm. 
2.4.3 Discussion 
2.4.3.1 Sodium Valproate 
SV appears to have a significant effect on the beating score of differentiating 
cardiomyocytes, this reduction is time and dose dependent, and appeared to be 
significant within the therapeutic range, 400-800µM (Chiu et al., 2013). There 
was significant reduction in beating score at the dose of 750µM, this indicate that 
cardiac micromass culture is a sensitive in-vitro method to test the embryotoxicity 
of the drugs. Also, its effect on cell viability and protein content was not 
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significant at lower doses, but those end points started to be reduced significantly 
at high doses. SV is well known in its teratogenic potential, SV administration 
during pregnancy associated with broad spectrum of congenital diseases, 
including cardiac and neural tube defects (Nau, 1994). SV is well known as 
Histone Deacetylase inhibitor (HDAC) (Gurvich et al., 2005), SV has been 
reported to cause chromatin condensation, changes in gene expression and cell 
death by apoptosis (Phiel et al., 2001) and leads to DNA methylation which result 
in change in gene expression which can associate with several developmental 
anomalies (Detich et al., 2003). SV has been recorded to inhibit mesodermal 
differentiation of embryonic stem cells (Murabe et al., 2007a) and resulted in 
oxidative stress and release of free radicals (Na et al., 2003) which may explain 
the reduction in cell viability and total protein in both cardiac and brain 
micromass culture systems. 
2.4.3.2 Lithium Carbonate 
In general, lithium  carbonate can  be considered as a  weak teratogen, however, it 
has been reported that lithium treatment may associated with developmental 
abnormalities in the heart (Giles and Bannigan, 2006) and the nervous system 
(Jurand, 1988). These experiments reveal that Lithium Carbonate has no 
significant effect on the beating score of differentiating cardiomyocytes in the 
doses which are close to therapeutic doses, which is 600-1200µM (Su et al., 
2007b), it inhibitory effect on beating score of differentiated cardiomyocytes 
appeared only at first at 1500µM, 6 days  after lithium treatment and at 2000µM 
appeared after the first  day of treatment.  
 Lithium acts by several mechanisms; it inhibits glycogen synthase kinase-3 
(GSK-3) thereby affecting gene transcription leading to anti-apoptotic activity and 
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by which cell structure integrity can be improved (Chin et al., 2005) and might be 
a cause of teratogenesis (Giles and Bannigan, 2006). Also lithium prevents the 
conversion of Inositol 1,4,5 triphosphate (IP3) into myoinositol by blocking the 
Inositol monophosphatase (IMPase), this leads to depletion of inositol from the 
cells. Dampening of the phosphoinositol (PI) cycle causes downregulation in 
MARCKS which is actin binding protein, its down regulation is essential in 
stabilizing the cell membrane (Machado‐Vieira et al., 2009). It has been 
postulated that pretreatment supplement with myoinositol can prevent the 
teratogenic effect of lithium (Giles and Bannigan, 2006) and (Giles and Bannigan, 
1999). IP3 in developing heart regulates pace maker activity, enhance 
cardiogenesis, and controlling myocardial contraction by enhancing calcium 
release and influx, therefore, inhibition on PI cycle can disturb early 
developmental events of the heart and great  vessels (Kockskämper et al., 2008). 
Additionally, lithium is well known drug as neuroprotective agent, it induces 
BDNF production (Hashimoto et al., 2002), and control the release of GDNF in 
vivo and in vitro (Paratcha and Ledda, 2008) which are  involve in maintaining 
cell survival and many other cellular activities. Moreover, lithium has an anti-
apoptotic activity in several mechanisms, like enhancing Bcl2 protein, 
downregulation of P53 (pro-apoptotic protein) (Chen and Chuang, 1999). Also, it 
can activate PI3K/Akt, MEK/ERK pathways which stimulate the release of anti-
apoptotic factors (Chiu et al., 2013), these may explain our finding that lithium 
has no significant effect on cell survival and total proteins throughout all the 
doses except in the highest doses in both cardiac and brain micromass system. 
Finally, microsystem system has been used to detect the toxicity of herbicides, 
insecticides and mycotoxins (Daniels et al., 1996). To overcome species 
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difference in chick micromass system, and to rely on cells which have the 
capability to undergo most of the important processes in embryonic development, 
human neural stem cells have been suggested which are also reflect to some 
extent the normal cellular status, and not derived from tumours. The rest of this 
thesis will aim to establish a system using human neural stem cells to test drugs 
for neurotoxicity.  
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Chapter 3 
Methods of Developing of Human Neural 
Stem Cell Culture as a Model in In vitro 
Neurotoxicology  
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3.1 The Neural stem cell niche 
Embryonic Neural Stem Cells (NSCs) in vivo undergo time dependant changes in 
their microenvironment (which can also be called their niche) to enable them to 
fulfil their roles in the development of the CNS. NSCs have the capability to 
proliferate (self- renew) and to differentiate into the three major CNS lineages; 
astrocytes, oligodendrocytes, and neurons. NSCs have been the subject of 
intensive investigation because of their potential use in therapy of 
neurodegenerative disorders such as Parkinson disease and multiple sclerosis 
(Hall et al., 2008). Because of the scarcity of primary human tissue from which 
NSCs can be isolated, the need to develop a protocol to culture them in vitro has 
been escalated. As a first step toward accomplishing this goal, it is essential to 
know the composition of their niche in developing CNS and to identify the factors 
that regulate their growth and differentiation. The observation that the NSCs are 
not randomly distributed throughout the brain is one of the important clues for the 
nature of these factors. They are located in Ventricular and Subventricular zones 
in the developing CNS and in the Subependymal zone of the adult CNS (Temple, 
2001). Studies on niche in different organisms and various tissues have shown 
that there are common signalling molecules which are involved in maintenance of 
stem cell populations and enhance their growth in cell culture. These molecules 
include growth factors, cell-cell signalling molecules, adhesion molecules and 
extracellular matrix molecules (ECM) (Li and Xie, 2005).  
The evidence that laminins have a direct contact with adult NSC through the basal 
lamina of the blood vessel in SVZ (Kerever et al., 2007) and with the embryonic 
NSC in VZ, highlights the likelihood of involvement of this ECM in NSC 
regulation (Lathia et al., 2007). Laminin  acts through the interaction with the 
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integrin family of receptors, which are the key regulators of all aspects of cellular 
processes such as cell proliferation, survival, migration and differentiation (Qin et 
al., 2004). Integrins are transmembrane αβ heterodimers which make 
conformational changes with ligand binding that lead to downstream effects, like 
actin polymerization and growth factor signalling (Qin et al., 2004). The elevated 
expression of integrin, especially the laminin-binding α6β1 heterodimer, is used 
for the isolation of stem cells from more differentiated cells (Fujimoto et al., 
2002). Integrin β1 has been shown to maintain prostatic stem cells (Heer et al., 
2006). Integrin-laminin interaction has been shown to regulate migration of 
human NSC in an integrin α6-dependant way (Flanagan et al., 2006). 
Isolation of NSCs from CNS was first described by Reynolds through a 
neurosphere formation assay (NFA) (Reynolds and Weiss, 1992). The idea behind 
NFA is that the cells which have the ability to form the neurosphere (NS) are stem 
cells since they have the ability to proliferate (self-renew) and to differentiate into 
the main cell types in the CNS. These two criteria confirm cell ‘stemness’. NS are 
spheroid 3D structures consisting of cells with a rich extracellular matrix. These 
NS produce their own ECM molecules (laminin, fibronectin, chondroitin sulphate 
proteoglycans) and growth factors (Fibroblast growth factor- FGF and Epidermal 
growth factor-EGF) (Lobo et al., 2003). Initial cell-cell contacts are retained by 
the proliferating cells, and the NS can create a niche which is more relevant 
physiologically than 2D culture models, and also can allow dynamic changes in 
the environment such as changes in growth factors or nutrient materials (Ahmed, 
2009). The important features of NFA are; the identification of NSC, the 
simplicity, as a starting point in studying the neurodevelopment, and it can offer a 
model to screen chemicals and drugs for brain tumours and CND diseases.  
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3.1.1 Role of Growth factors 
1- Basic Fibroblast Growth factor (bFGF) and Epidermal Growth factor 
(EGF) 
Progenitors from developing brain of different species can grow in vitro in the 
presence of several growth factors, by which, the cells can preserve their 
capability to proliferate and differentiate into neurons and glial cells (Armstrong 
and Svendsen, 1999). The factors which stimulate these cells to proliferate are 
complex, and they are likely to involve contact and diffusible molecules 
(Svendsen et al., 1998), although it is well known that Epidermal growth factor 
(EGF) and Fibroblast growth factor (FGF) are important mitogens in stimulating 
these cells to proliferate. The receptors of these two factors are expressed in the 
highly proliferating NSCs of the adult brain (Doetsch et al., 2002, Frinchi et al., 
2008). Supplementation of these mitogens to aged mouse brain stimulates 
proliferation of NSCs (Jin et al., 2003). Deletion of them from the genome results 
in reduction of proliferation of these cells (Zheng et al., 2004).  
During early stages of embryogenesis, the neural tube is composed of a 
homogenous population of cells, the neuroepithelial stem cells, which reside in 
Ventricular zone (VZ) and lack the markers for any differentiated cells, such as 
neurons, or glial cells. These cells can be maintained and proliferate in culture 
with the presence of basic FGF (bFGF) (Qian et al., 1997). There is undetectable 
or low expression of EGF receptors in the ventricular zone neuroepithelial stem 
cells, therefore, it has been difficult to generate neurospheres from these stem 
cells by EGF alone (Pevny and Rao, 2003). As development progresses, by 
proliferation of neuroepithelial cells and migration of differentiated cells, the 
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subventricular zone (SVZ) will be demarcated, and a new population of stem cells 
can be isolated and maintained in culture (Reynolds and Weiss, 1992, Reynolds 
and Weiss, 1996), this type of stem cell has been called EGF-responsive stem 
cells, since there is high expression of EGF and EGF receptors in this area. Both 
EGF and FGF are able to stimulate their growth to form neurospheres (Vescovi et 
al., 1993).  
Both FGF and EGF can be used to drive the stem cells to form neurospheres, but, 
a combination of these factors is able to generate more neurospheres than either 
factor alone (Lobo et al., 2003). It seems that there is a synergistic effect of both 
EGF and FGF on NSCs proliferation (Kelly et al., 2005). It has been proposed 
that EGF responsiveness of the cells could be primed by exposure to FGF 
(Ciccolini and Svendsen, 1998). 
2- Role of Heparin 
Heparin is also one of the important factors for the growth of NSCs in vitro. It has 
been shown that heparin is required for the growth of progenitor cells of primary 
tissue of the mesencephalon, combined with FGF-2 (Caldwell and Svendsen, 
1998). Heparin appears to potentiate the action of EGF and FGF on rat embryonic 
neural progenitor expansion when these factors used individually or in 
combination. However, its potential effect was higher when these factors were 
combined (Kelly et al., 2005). FGF’s are typically found bound to heparin 
sulphate components in the extracellular matrix (Gospodarowicz and Cheng, 
1986). The importance of this interaction is thought to be due to activation or 
protection of FGF-2 molecules (Mason, 1994). Previous studies failed to generate 
free floating neurospheres from mouse by using FGF-2 alone in the absence of 
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heparin (Reynolds and Weiss, 1992). However, other studies succeeded in 
propagating them from adult murine brain after adding heparin to the growth 
media (Gritti et al., 1996, Caldwell and Svendsen, 1998). 
The following experiment is to demonstrate cell behaviour in the media and to 
describe the neurospheres.  
3.2 Neural stem cell growth and behaviour in media 
3.2.1 Materials and methods 
The foetal material was provided by the Joint MRC)/Wellcome Trust (grant # 
099175/Z/12/Z) Human Developmental Biology Resource (www.hdbr.org). 
Foetal brain tissue was washed, dissociated mechanically into single cell 
suspension (Uchida et al., 2000). Single cell suspension of multipotent NSCs 
were grown in NSC maintenance medium (Dulbecco Modified Eagle Medium- 
DMEM and Ham’s nutrient F12 in 1:1 ratio, bFGF, EGF, Glutamine, Heparin, 
N2, and B27 supplements) in 25 cm
2
 non treated flasks and left in the incubator at 
5% CO2, 100% humidity, 37C° for several days. 
3.2.2 Result and discussion 
Our findings demonstrate that NSCs aggregate to form spherical structures which 
are called neurospheres, the progeny of neurosphere are variable in size, as shown 
in the figure (18) below. Neurospheres can grow more to become darker in the 
centre as they enlarge, the dark core suggesting necrotic event which may occur 
due to reduction in the amount of nutrition from the external medium (Bez et al., 
2003). The cytoarchitecture of the neurosphere depend on the access of 
neurosphere forming cells to the nutrients in the medium and to the oxygen and 
also to the possibility to eliminate the waste products to the outside of the 
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neurosphere. Smaller neurospheres appear translucent and appear healthier. The 
cells in the external layer of the neurosphere may show small cytoplasmic 
processes similar to cilia. The behaviour of the neurosphere described above can 
be explained as an adaptation of NSCs to the in vitro culture environment. The 
NSCs may aggregate to form clusters to survive in the non-physiological 
conditions of the in vitro environment. The cells adapt themselves and optimize 
their interaction to acquire the most advantageous shape, the sphere, from the 
thermodynamic point of view (Bez et al., 2003). The neurosphere itself can be 
considered as a microsystem, in which the cells can survive, grow, and proliferate 
to reach a critical stage by which there is no self-restoration mechanism (Bez et 
al., 2003). Therefore, the neurosphere can be considered as an example of 
environmental adaptability.  
  
Figure 18: Variable sizes of neurospheres appear a few days after keeping NSCs in the medium, 
the larger spheres showing darker zones in the centre which denote cell necrosis, while the smaller 
spheres are transparent. The scale bar is 100µm. 
3.3 Neural stem cell Identification: 
Neural stem cells have the capability to divide, self-renew, and differentiate into 
their main three lineages. The ability of the cells to form neurospheres in vitro 
indicates that these cells are stem cells, because they fulfil the criteria of neural 
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stem cells in dividing and differentiation (Ahmed, 2009). Intermediate filaments,  
nestin, can be considered as an indicator for these stem cells (Miyagi et al., 2006). 
Nestin expression starts from the early embryonic period in the neural stem cells, 
and is used for stem cells identification, isolation, and cultivation as a marker 
protein. This protein can be re-expressed when there is brain injury; therefore, it 
has been used as a quick, early responding marker of brain impairment (Jin-ping, 
2009). The expression of these intermediate filaments is down regulated when 
there is a transition from proliferating neural stem cells into post-mitotic neuronal 
cells (Zimmerman et al., 1994). There are several transcription factors which are 
used as a marker for neural stem cell, such as SOXB1 and three other related 
genes which are SOX1, SOX2, and SOX3. This family universally mark neural 
progenitor and stem cells throughout the vertebrate CNS. SOX2 is highly 
expressed in neuroepithelial stem cells and persists in neural stem cells until 
adulthood. This factor is well known to stimulate neuroectoderm development 
and inhibit mesendodermal development (Thomson et al., 2011). SOX2 
expression has been shown to inhibit cellular differentiation and maintain the 
stem cell characteristics, while inhibiting SOX2 signaling leads to delamination of 
neural progenitor cells from the ventricular zone, which is accompanied by the 
loss of stem cell markers and the starting of expression of neuronal differentiation 
markers (Graham et al., 2003). SOX2 knock down in mouse leads to death around 
the implantation stage (Miyagi et al., 2006). 
Other transcriptional factors used in addition to SOX2 to identify NSCs are 
OCT4, Klf4, and c-Myc. These four transcriptional factors are used to reprogram 
human astrocytes (Ruiz et al., 2010) and mouse and human fibroblasts (Kim et al., 
2011) into induced pluripotent stem cells (iPSCs) with similar efficiency to NSCs. 
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Well controlled OCT4 expression leads to generation of tripotent neural stem 
cells which have extensive self-renewing capacity (Kim et al., 2011). Over-
expression of OCT4 alone in adult NSCs can induce pluripotent stem cell (iPS) 
formation, which are similar to embryonic stem cells in vivo and in vitro which 
are able to differentiate into NSCs, cardiomyocytes and germ cells in vitro, but  
are also capable of teratoma formation in vivo (Kim et al., 2009). NANOG is 
another transcription factor which acts, at physiological state, in concert with 
SOX2 and OCT4 to maintain embryonic stem cell identity (Hanna et al., 2010). 
There are some molecular mechanisms which serve to maintain the general 
cellular characteristics of stem cells, such as the ability to divide and to 
differentiate into their lineage. For example, one well-known molecular 
mechanism which is shared by neural progenitor cells is the Notch signalling 
pathway. This pathway seems to play a critical role in preserving the 
stem/progenitor cell pool. During development and in adulthood, Notch1 
expression, or its downstream regulators, like HES-1, prevents neuronal 
differentiation and leads to preservation of the progenitor pool (Graham et al., 
2003). The exact mechanism in which the Notch signalling pathway controls cell 
fate is not well determined. Another study suggested that Notch signalling, rather 
than inhibiting neuronal differentiation and maintaining the stem cell pool, may 
enhance glial differentiation (Gaiano and Fishell, 2002). 
In order to establish the phenotype of cells within our neurospheres, we carried 
out immunohistochemistry (below).  
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3.3.1 Immunohistochemical staining of neurosphere sections 
Neurospheres were collected from the flasks by centrifugation of the culture 
medium and they were fixed using 4% Paraformaldehyde (PFA) for 20 minutes. 
PFA was aspirated after centrifugation. The neurospheres were placed in 2% 
Agarose for a few minutes with gentle stirring of the solution to ensure even 
distribution of the neurospheres. Then the samples were transferred into an 
automatic tissue processor for dehydration, xylene, wax impregnation and wax 
embedding. Using an automatic microtome, 10µm thickness slices were taken 
from these samples and placed on gelatinized slides. 
To prepare the slides for ICC, the slides were submitted into: 
-Xylene 5 min*2 to dissolve wax from the slide, followed by keeping the slides in 
alcohol in different decreasing concentrations to rehydrate the samples as follows: 
-Alcohol 100% 5 min*2 
-Alcohol 90% 5 min 
-Alcohol 70% 5 min 
-Alcohol 50% 5 min 
-Tap water 5 min 
Then the sections were washed for 5 minutes 3 times with 0.01 PBS and 
permeabilized with a solution containing 0.01 PBS, 0.3% triton and 1 % Goat 
serum for 1 hour. The sections were washed again 3 times for 5 minutes. Anti-
nestin primary antibody (Mouse monoclonal –BD Biosciences pharmingen) and 
was added to the sections in 1:1000 dilution and Anti-SOX2 primary antibody 
(Rabbit polyclonal-Abcam) in 1:2000 dilution was added to other sections, then 
the sections were incubated overnight at 4
ₒ 
C. On the next day, the primary 
 61 
 
antibody was washed with 0.01 PBS for 5 min 3 times, and the secondary 
antibody in 1:500 dilution was added in a light protected area for 1 hour followed 
by washing by 0.01 PBS for 5 minutes 3 times, then mounting was performed in 
fluorescent mounting medium. Examination of slides was performed using 
Fluorescent microscope. 
 
 
 
 
 62 
 
    
Figure 19: Immunohistochemistry staining for Nestin and SOX2 in Neurospheres of HNCs, the 
blue colour represent the nuclei stained with DAPI. The images at the bottom are the merged 
images. Left column shows Nestin positive cells in the neurosphere while right column illustrating 
SOX2 positive cells.  
3.3.2 Immunocytochemistry of seeded slides 
In order to compare the phenotype of floating neurospheres with the same cells 
seeded onto slides, immunohistochemistry was carried out.   2*10
4
 were seeded 
over glass coverslips which were coated with PDL and laminin, then NSC 
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maintenance media was added to the wells in which the coverslips were placed 
and left for 6 days, after that the media was aspirated and 4% PFA was added for 
15 minutes to fix the cells. Blocking and permiabilization was performed by 
solution containing PBS, 0.3% triton and 1% Goat serum, then, we followed the 
same steps as in immunohistochemistry. 
  
Figure 20: Immunocytochemical staining for NSCs after plating them on glass coverslips which 
was coated with PDL and Laminin. This figure illustrates the loss of cell stemness after 
attachment since the cells have become Nestin and SOX2 negative. 
  25µm 
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3.4 Neuronal cell Markers 
Neurons are diverse from a functional and morphological point of view, albeit 
they are structurally unique, once they have completed their migration to their 
final destination in the nervous system. The distinct morphology of neurons 
depends on their ability to elaborate elongated cell processes which are known as 
neurites. The growth, maintenance, stability and functionality of these neurites 
depend on subcellular structural organization, the cytoskeleton system, which is 
formed by three main filaments microtubules (neurotubules), intermediate 
filaments (neurofilaments) and microfilaments (actin filaments) (Pannese, 1994). 
The microtubules are 25nm hollow cylindrical structures, serving a variety of 
functional and structural roles, such as formation and control of cell morphology, 
mitosis, cell migration (especially during embryonic development), and cytosolic 
transport of cellular organelles and secretory vesicles (Ludueña, 1997). The 
structural constituent of microtubules is the globular protein tubulin, which 
interacts with a host of accessory microtubule associated proteins (MAPs), 
histones, chaperonins, G proteins and protein kinases. Tubulin is composed of 
two subunits, α and β, to form heterodimers. Six α- and seven β-tubulin isotopes 
have been identified in mammals and birds (Ludueña, 1997). In mammalian and 
avian development, β-tubulin III is considered to be among the earliest neuronal- 
associated cytoskeletal marker proteins. Its expression, before or during terminal 
mitosis in the CNS, is coincident with the lack of expression of this protein in 
other embryonic or adult cells (Katsetos et al., 2003), which indicates that this 
tubulin is controlled by transcriptional factors which are concerned with neuronal 
lineage commitment and morphological differentiation (Dennis et al., 2002). Β-
tubulin III is abundant in the central and peripheral nervous system and in the 
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brain it is prominently expressed during fetal and postnatal development 
(Katsetos et al., 2003). It is widely used  to identify  neurons in developmental 
studies as a neuronal marker (Svendsen et al., 2001). 
3.5 Astroglial cells 
Astroglial lineage consists of protoplasmic and fibrous astrocytes, together with 
specialized astrocytes which have specific development, function, and 
biochemistry, such as radial glial cells. They are related by the presence of glial 
fibrillary acidic protein (GFAP) and their developmental characteristics (Eng et 
al., 2000). 
3.5.1 Radial glial cells 
Radial glial cells are the first glial form in the developing CNS. These cells 
develop earlier and transiently in prenatal and postnatal neurogenesis in 
vertebrates. In general, they are bipolar cells, one of their processes extending to 
the ventricular surface and the other to the pial surface. These cells provide a 
framework during development for migrating neurons (Pentreath, 1999). Thus, 
these cells are essential for the normal construction of the CNS. The radial cell 
processes may provide information between the surface of the ventricles and 
centre of proliferation. Once the neuronal migration is finished, the cells 
transform into protoplasmic or fibrous astrocytes or other type of specialized 
astrocytes (Rakic, 1995). 
3.5.2 Astrocytes 
Astrocytes make up about half of the volume of grey matter (Pentreath, 1999). 
The overall functions of astrocytes in physiological condition are supportive and 
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protective for the neurons, which can be summarized as follows (Pentreath, 
1999): 
1- Taking up, inactivating, reusing neurotransmitters, and having receptors for 
these neurotransmitters and they may release some neurotransmitters. This 
function is critical for controlling synaptic activity. 
2- Releasing growth factors, cytokines, secreting some of the extracellular matrix 
components and some molecules for cell adhesion. This is related to growth, and 
survival of the neurons. 
3- Blood brain barrier formation by their interaction with the endothelial cells of 
brain capillaries. 
4- Potassium siphoning, distributing potassium away from active neurons. 
5- Detoxification of some exogenous and endogenous toxins. 
Injury to the CNS in the form of trauma, degenerative diseases, or chemical 
exposure makes the astrocytes proliferate and hypertrophy. This form of reaction 
is called reactive astrogliosis, which is characterized by increased synthesis and 
expression of GFAP intermediate filaments (Zurich et al., 2004). Astrogliosis can 
be detected before the occurrence of the toxic effect on neurons, therefore it can 
be regarded that GFAP is an early indicator in neurotoxicity (O'callaghan, 1991). 
These reactive astrocytes secrete several molecules which can modulate the 
neurotoxicity of xenobiotics and may have neuroprotective  and 
neurodegenerative effects (Aschner et al., 2002). 
It is well established that GFAP is the principle intermediate filaments (8-9nm) of 
mature astrocytes and it has been proven to be a reliable marker for normal and 
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neoplastic astrocytes. As a member of the cytoskeleton system, GFAP is thought 
to play a role in regulating astrocyte motility and morphology by stabilizing the 
extension of the astrocytes (Eng et al., 2000). 
For the purpose to identify neuronal cells and astrocytes, the same protocol of 
immunocytochemistry in 3.3.2 was performed on cells seeded on a slide, but with 
different antibodies, mouse monoclonal anti-tubulin III antibody (1:500), and 
rabbit polyclonal anti-GFAP antibody (1:800) were added, then goat polyclonal 
secondary antibodies to mouse (1:500) and rabbit (1:500) respectively were added 
(appendix 3).  
 
Figure 21: Immunocytochemistry staining of human neural stem cells, the nuclei stained blue 
with DAPI, Tubulin positive cells are green, and GFAP positive cells are red. The scale bar is 
50µm. 
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3.6 Evaluation of different Extracellular molecules for coating: 
Different ECMs have been used in our study for coating the plates and the slides 
to find out which one is best for the neurospheres and the cells to be attached on 
the surface. Normally NSCs are in the floating state in the medium, otherwise, 
once the cells attach, they would differentiate into their three main lineages; 
astrocytes, neurons, and oligodendrocytes. These ECMs are; Poly D-Lysine 
(PDL), Poly L-Lysine (PLL), Collagen I, and Laminin. 
3.6.1 Materials and methods: 
1- PDD, PLL, and collagen I alone protocol: 
PDL and PLL were used independently at 5μg/cm2 and collagen I was at 10μg/ 
cm
2
. They were dissolved in sterile distilled water, PDL, PLL, and collagen I 
were added to separate plates and left overnight in the hood at room temperature. 
On the next day, the plates were washed with sterile distilled water three times, 
then, the plates were ready for use. Single cell suspensions were added to the 
wells of the plates and left in the incubator at 37C°, 5% CO2, and at 100% 
humidity for several days to see whether the neurospheres were attaching, or not, 
to the bottom of the wells. 
2- PDL and Laminin or PLL and Laminin 
In this protocol, the first coating was with PDL or PLL which followed the same 
steps mentioned above. On the next day, after washing the plates from PDL or 
PLL, Laminin at 2μg/cm2 was added to the wells and left in the incubator at 37C°, 
5% CO2, and 100% humidity for two hours, then the plate was washed by sterile 
distilled water three times, and when it dried, the plate would be ready for use. 
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3.6.2 The results: 
NSCs in the wells which are already coated with PDL, PLL, or collagen I alone, 
aggregated to form floating neurospheres which were not attaching to the bottom 
of the wells as shown in the figure below. In contrast, the cells that were seeded in 
wells which were coated with PDL and laminin or PLL and laminin form a 
monolayer sheet of cells that attached rapidly to the bottom of the wells. The 
figure also demonstrates the morphology of the differentiated cells and how they 
elaborate their processes.  
 
Figure 22: NSCs after seeding them on coated wells, A: PDL, B: PLL, C: Collagen I, D: PDL+ 
Laminin. The scale bar is 100µm. 
A 
D
A 
C
A 
B
A 
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3.6.3 Discussion 
PDL, PLL, and collagen I alone was not enough to enhance cell attachment. It 
seems that the addition of laminin to PDL or PLL is the best to enhance 
attachment to the base of the wells. It was mentioned above that laminin is one of 
the important molecules which are present in the NSCs niche during development 
(Kerever et al., 2007). This molecule also can make interaction with the integrin 
family molecules of the NSCs, which are the key regulators for cell proliferation, 
migration and differentiation (Qin et al., 2004). 
Extracellular Molecules (ECMs), when used in in vitro culture, can enhance 
cellular behaviour. Cell response depends on the cell phenotype and on the type 
of ECMs that have been used. The cells in vitro usually behave better when the 
ECMs used are similar to ECMs which are found in vivo. Cells in this case 
survive for a longer duration with these ECMs, and the existence of such ECMs 
can make the cells grow in the absence of serum and other growth factors 
(Kleinman et al., 1987). 
The ECM is secreted by the cells located within it. It is composed of proteins, 
proteoglycans and hyaluronan. These components interact with each other and 
with the proteins on the outer surfaces of the cells. It has been considered that 
ECM plays a structural role, and it has been shown that ECM is critically 
important in determining the functional responses of the cells toward the 
environment. Thus, in the CNS, ECM plays an important role in regulating 
several functions during development and adulthood. ECMs send signals for cell 
growth, maturation, differentiation, cellular migration, tissue homeostasis and 
tumour cell invasion. These activities are very important in CNS development and 
organization and any disruption of ECM might lead to severe developmental 
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abnormalities (Novak and Kaye, 2000). Several molecules in ECM have been 
reported to control rodent NSC proliferation, migration, and differentiation 
(Kearns et al., 2003). Cells express some receptors on their surfaces for ECM 
components to mediate their response. 
ECM is a component of the NSC niche which regulates their behaviour.  
Permissive substances may underlie the pathway of migration for neurosphere 
differentiation, while the non-permissive substances mark the more sedentary 
cellular zone. Laminin is one of the potent permissive substances for different 
types of cells in vitro. It is mainly present in the basal lamina but it is not present 
in high amounts in adult animal and humans (Novak and Kaye, 2000). It has been 
shown that laminin is present in developing cerebellum and it acts to facilitate 
migration of granular cell precursors from the external granule cell layer into the 
internal granule cells layer (Pons et al., 2001).  
Laminins are large flexible proteins of three polypeptide chains which are 
connected by disulfide bonds. This protein has several domains which facilitate 
its interaction with type IV collagen, heparin sulfate, entactin, and laminin 
receptors of the integrins (Ryan and Christiano, 1996). It is a multifunctional 
protein and it plays roles in development, migration, and differentiation, as it 
interacts with cell surface receptors. Several genes encode the three different 
types of polypeptide chains and mutation or deletion of these genes produces a 
range of congenital abnormalities such as a form of muscular dystrophy and 
epidermolysis bollusa (Novak and Kaye, 2000). 
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3.7 Migration study: 
3.7.1 Materials and methods 
We tried to find out which method is suitable to study cell migration of NSCs, 
two methods were investigated: The first method was by making a scratch with 
the tip of a pipette through a monolayer of cells, which was formed by using a 
single cell suspension placed on a surface coated with PDL and laminin, and the 
second method was by placing the neurospheres on a surface which was already 
coated with the same coating materials (PDL and laminin). This was followed by 
monitoring cell migration from the edge of the scratched monolayer and from the 
edge of the attached neurospheres.     
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Figure 23: Illustrate cell migration in scratch method, the gap between these cells represent the 
scratch. On the right side, there is two merged small neurospheres showing their cell migration. A: 
2days, B: 4 days, C: 6 days after cell seeding. The scale bar is 200µm 
C
A 
A 
B
A 
200µM 
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Figure 24: Two large and one small neurospheres attaching to the surface migrate away from their 
edges. A: 0 hour, B: after 24 hours, C: after 48 hours. The scale bar is 200µm. 
A 
C
A 
B
A 
200µM 
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Figure 25: Migrating neurosphere after its attachment, showing radial cellular migration 10X, 
20X 
200µM 
200µM 
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 Two videos showing neurosphere migration and merging with each other. 
3.7.2 Discussion 
It appears that the first method was less reliable since all the cells were 
differentiated at the time of cell attachment with no more cell proliferation. It 
showed migration and cellular processes for only the cells which resided at or 
near the edge of the scratch, therefore, migration distance was short and did not 
represent the real migration of all cells. On the other hand, using neurosheres, as 
shown in the videos, the cells still had the capability to proliferate, not all the cells 
were differentiated, and they continued to migrate for a long distance away from 
the edge of neurospheres, therefore the second method can be recommended to 
study cellular migration. 
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4.1 Human Neural Stem Cell source and Cryopreservation 
The human embryonic and foetal material was provided by the Joint 
MRC)/Wellcome Trust (grant # 099175/Z/12/Z) Human Developmental Biology 
Resource (www.hdbr.org). It was stored in a special  medium composed of 70% 
Neural Stem Cell maintenance medium (DMEM, F12 Ham’s Nutrient, 
Glutamine, B27 supplement, N2 supplement, Basic Fibroblast Growth factor, 
Epidermal Growth factor, and Heparin), 20% Foetal Calf Serum and 10% DMSO. 
The number of cells in each cryovial ranged from 1 to 3*10
6
. Cryovials were 
labelled with the passage number and the date of storage. The vials were kept at 
first in -80
ₒ 
C freezer for one day; then, the cryovials were transferred into liquid 
nitrogen for long term storage. The passage number used was 20-25. 
4.2 Resuscitation of cryopreserved Human Neural Stem Cells 
The stored cryovials of hNSCs were removed from liquid nitrogen and thawed 
rapidly in the water bath at 37
ₒ
C for 2-3 minutes. 3ml NSC maintenance media 
was added then centrifugation was performed at 1200 rpm for 5 minutes, the 
supernatant was aspirated and 1ml NSC maintenance medium was added and 
through re-suspension by pipette, a homogenous cell suspension was produced. 
Cell counting was carried out using haemocytometer. After that, the cell 
suspension was transferred to a non-treated tissue culture flask and more NSC 
medium was added to it. The flasks were kept in the incubator at 37
ₒ 
C, 5% CO2 
and 100% humidity.  
4.3 Subculturing of Human Neural Stem Cells 
The single cell suspension of human neural stem cells was grown in stem cell 
maintenance media (1:1 DMEM and F12 Ham’s nutrient, N2 (1ml of 100X in 
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100ml media) and B27 supplements (2ml of 50X in 100ml media), Glutamine 
2mM, Heparin 5µg/ml, EGF 20ng/ml, and bFGF 10ng/ml), and kept in 25 cm
2
 
non-treated flasks. The flasks were placed in the incubator at 37°C with 100% 
humidity, 5% CO2 for several days.  The cells proliferate to form neurospheres 
which start to increase in size with time. When the diameter of the neurospheres 
became more than 500µm, the culture medium was collected in 15 ml conical 
centrifugation tubes. Centrifugation was performed at 800rpm for 3 minutes. The 
supernatant was aspirated and 1 ml of Accutase was added to the pellet at the 
bottom of the tube to enhance cellular dissociation. The tube was placed in a 
water bath at 37
ₒ
C for 5 minutes with shaking to prevent the neurospheres settling 
down. Cellular dissociation was completed by frequent resuspensions by 
pipetting. 2ml medium were added to the cell suspension to stop the action of 
Accutase followed by centrifugation at 1200 rpm for 5 minutes. The supernatant 
was removed and 1ml medium was added to the pellet and re-suspended to obtain 
a single cell suspension. Cell number counting was performed using a 
haemocytometer, then the cell suspension was transferred into 25 cm
2 
tissue 
culture non treated flasks, 4ml medium was added to the flasks, passage number, 
cell number and the date of splitting were recorded on the flasks. 
4.4 Drug preparation 
A stock solution was prepared for each dose of each drug at high concentration, 
300-500 times the final required concentration (depending on the drug), by 
dissolving the drug in its specific solvent. At the time of the experiment, these 
stock solutions were diluted by the media to achieve the final required 
concentrations to make the volume of the solvent fixed in all concentrations (0.2-
0.3%). Also, the same volume of the solvent was added to the control group. 
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The drug The solvent 
Methyl mercury Distilled water 
Lead  acetate DMSO-Dimethylsulfoxide 
5,5-Diphenylhydantoin (phenytoin) DMSO 
Sodium valproate HBSS- Hank’s Balanced Salt Solution 
Carbamazepine DMSO 
Phenobarbitone DMSO 
Folic acid NaOH 
Melatonin Ethanol 
Lithium carbonate Distilled  water 
Amitriptyline DMEM 
Diazepam Ethanol 
 
4.5 Cell seeding  
48 well plates were used and were coated first with Poly D-Lysine (PDL) and 
laminin as described before. After splitting the neurospheres using Accutase, as 
described previously, the cells were seeded into the wells at 30,000 cells per well 
to form a monolayer, then NSC differentiation medium: 1:1 DMEM and F12 
Ham’s nutrient, N2 (1ml of 100X in 100ml media) and B27 supplements (2ml of 
50X in 100ml media), and Glutamine 2mM containing the drug was added, 500µl 
in each well for 6 days. The media was changed every 3 days. Then, resazurin test 
was performed. 
4.6 Resazurin Assay 
Has been described in chapter 1, 1.2.6  
4.7 Kenacid Blue 
Has been described in chapter1, 1.2.7 
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4.8 Immunocytochemistry 
8 well chamber slides were coated with Poly D-Lysine and laminin as described 
before. In order to perform double immunostaining for Tubulin III and GFAP 
proteins, 20,000 cells were seeded in each well of the slide and 500µl NSC 
differentiation media with the drug in different concentrations were added for 6 
days, with changing media every 3 days. At the end of 6 days, the medium was 
aspirated, and paraformaldehyde (4%) was added for 15 min to fix the cells. 
Permeabilization and blocking was done by Triton (0.25%) and BSA (1%) for 30 
minutes followed by washing with Phosphate Buffered Saline- PBS three times, 
5min for each wash. Primary antibodies, anti-tubulin III (Mouse monoclonal) in 
1:500 dilution and anti-GFAP (Rabbit polyclonal) in 1:800 dilution were added 
together for double staining. The cells were incubated with the antibodies at 4° C 
for 24h in the cold room. On the next day, three washes with PBS (5 minutes 
each) was followed by adding the secondary antibodies in 1:500 dilution for 1h. 
Again the same washing with PBS three times, after that, DAPI in 1:1000 dilution 
was added for 2 minutes then washed with PBS. Non fluorescent mounting media 
was used to cover the slides with suitable coverslips; nail varnish was used to seal 
the coverslips. Lastly the slides were examined by Leica microscope DMIRE2. 
4.9 Neuronal processes length 
Several random photos were taken at 40X magnification by the same microscope 
blindly from each sample for three repeats. By using Volocity software version 
6.3.1 neuronal processes were measured to examine the effect of different doses 
of drug on the length of these processes. 
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Figure 26: The method of measuring the length of neuronal processes by using Volocity software 
version 6.3.1, the length of each neurite appears inside the box which appears beside each neurite. 
4.10 Neuronal proliferation study 
An ultra-low attachment 96 well plate was used. 1x10
4 
cells/100µl stem cell 
maintenance media
 
were seeded in each well, then the plate was centrifuged at 
300 RCF/3 minutes and left for 3 days to form only one neurosphere, after that 
the drug was added to the wells. 10 days later, during which the media was 
changed every three days, the neurosphere sizes were determined by measuring 
the diameter and comparing the mean for each group with that of the control 
group. 
4.11 Cell migration study 
The method mentioned above promoted formation of only one neurosphere in 
each well and with similar sizes. When the neurospheres reached a diameter of 
350-400µm, they were transferred into uncoated 48 well plates to be incubated for 
1 day with stem cell differentiation media and the drugs, 500µl in each well. 
Then, they were transferred into another 48 well plate which was coated with 
Poly D- Lysine and laminin. Normally, the neurospheres attached to the bottom of 
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the wells within few hours and started migration. Photographs were taken at 0, 24 
and 48 hours after incubation. To study migration distance, all the migrated cells 
were outlined, 2 diameters were taken, one perpendicular to the other, and the 
mean of these 2 readings was taken, neurosphere diameter was deducted, then, the 
result was divided by 2 to get the net migration distance, as shown in the figure 
below. 
 
Figure 27: Illustrates the way of measuring the migration distance of the migrating cells from the 
neurosphere. 
4.12 Western Blot Analysis: 
4.11.1 Lowry test: 
For western blots, 48 well plates were used with 10*10
4 
cells seeded in each well, 
6 wells for each group. The drug and media were added on the same day, 500µl in 
each well. On the next day, the cells started to proliferate and form the 
neurospheres. The media and the drug were changed every 3 days. After 6 days, 
the media and the neurospheres were aspirated and placed in the Eppendorf tubes 
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and centrifuged at 13000 RPM for 1 minute. The supernatant was removed and 
the pellets were washed twice with ice cold PBS. A freshly prepared lysis buffer 
and protease inhibitor 1:1 (see appendix 1) was added and mixed with the pellet 
by pipetting up and down to produce a homogenous solution of cell lysate. Some 
of the cell lysate was used for a Lowry protein test and the rest was mixed with 
6X solubilisation buffer (see appendix 1), vortexed and kept in the freezer at -20 
C° to be ready for Western Blotting. 
A Bovine Serum Albumin (BSA) standard curve was prepared by using 1mg/ml 
BSA. 1 ml Lowry solutions (A&B) (see appendix 1) were added for both the cell 
lysate of the samples and the standards. 10 minutes later, 100μl of Folin solution 
and water 1:1 was added and the tubes were incubated at room temperature for 45 
minutes. 200μl of each sample and BSA standard were pipetted in triplicate in a 
96 well plate, as shown the figure.  The plate was read at 750nm. 
 
Figure 28: Illustrate the method of Lowry test, the blue arrows represent the standard samples 
and the reds represent the experimental samples 
4.11.2 Western Blotting: 
For western blot analysis for tubulin III and GFAP proteins, the cell lysate was 
heated at 95°C for 5 minutes followed by vortex mixing and centrifugation at 
13000 RPM for 5 minutes.  6μg protein, were loaded in each well in the precast 
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polyacrylamide gel (4-20%, 12 well comb). The gel was run in 1X electrophoresis 
buffer (see appendix 1) at 175 V for 40 minutes.  After that the gel bands were 
transferred to a nitrocellulose membrane by running in cold transfer buffer (see 
appendix 1) at 100 V for 60 minutes. The membrane was collected after 60 
minutes, and a few drops of Ponceau stain were added to reveal the protein bands. 
The membrane was divided into 2 pieces, one for Tubulin III and GFAP and the 
other was for GAPDH. The membrane was washed quickly with TBST (see 
appendix 1) to remove the Ponceau stain. 5% milk solution in TBST was used as 
a blocking solution to incubate the membrane for 1 hour on a plate shaker at room 
temperature. The primary antibodies (see appendix 3) were diluted in 5% milk 
solution and the dilution was as follow: Anti- tubulin III (mouse monoclonal 
antibody-Abcam) 1:2000, Anti-GFAP (Rabbit polyclonal antibody-Abcam) 
1:20000, Anti-GAPDH (mouse monoclonal antibody-Sigma) 1: 5000. 
Appropriate amounts of these antibodies were used in sealed nylon bags to 
incubate the blots overnight in the refrigerator at 4°C on a plate shaker. On the 
next day, the blots were washed by TBST, 3X quick washes, 3X- 5 minutes 
washes and 3X- 15 minutes washes to remove the non-specific binding. The 
secondary antibodies (see appendix 3) (Goat anti-mouse, and Goat anti-Rabbit- 
Li-Cor Odyssey) were diluted in 5% milk solution in TBST and the dilution was 
1:30000. The blots were incubated with the secondary antibodies for 1 hour on a 
plate shaker at room temperature, after that, the blots were washed with TBST, 
3X quickly, 3X- 5 minutes, and 3X-15 minutes. At the end, the blots were 
scanned by using an Odyssey scanner at resolution of 84μm. 
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4.12 Statistical analysis 
The parametric data which represent three experimental repeats was analysed by 
using Prism version 6. Since we need to make comparison between more than two 
groups, one way ANOVA was performed for the all the data except for cell 
migration, two-way ANOVA was performed - two sets of data were used (1
st
 set - 
after 24 hours, 2
nd
 set - after 48 hours); then Dunnett’s multiple comparison test 
was undertaken to check the significance of difference by comparing the mean of 
the control group with that of experimental group. 
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Chapter 5 
Evaluation of This Model with Neurotoxic 
Chemicals 
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5.1 Neurotoxic Chemicals 
5.1.1 Mercury 
Mercury is present in the environment because of either natural processes or due 
to human activities (anthropogenic). It can be found in three different chemical 
forms: mercury vapour, inorganic mercury salt and organic mercury (Clarkson, 
2002). Methyl mercury (MeHg) has been studied thoroughly because it can reach 
the CNS and result in a neurotoxic effect (Aschner et al., 2007). MeHg is an 
environmental contaminant that has neurotoxic effects on both humans and 
animals (Farina et al., 2010). As a result of methylation of inorganic mercury, 
which is released from local industrial discharge into the aquatic environment, 
MeHg- containing fish represents the major source of human exposure. 
Communities which rely greatly on fish for food are liable to be exposed to highly 
toxic levels of MeHg (Clarkson et al., 2003). For more than 150 years human 
poisoning by MeHg has been reported in the laboratory by accidental exposure 
(Edwards, 1865). Most of the information about the toxic effect of MeHg has 
come from the catastrophic episodes of poisoning which occurred in the 1950s 
and  1960s in Japan (Harada, 1978) by consumption of fish from water which was 
heavily polluted with MeHg daily for long periods. Another major health disaster 
occurred in Iraq in the 1970s, where hundreds of people died and thousands 
became clinically ill when they ate bread made from grain which was treated with 
an organo-mercury fungicide (Bakir et al., 1973). 
 Adult intoxication with MeHg is characterized by damage to focal anatomical 
areas in the brain such as the visual cortex, and the granular layer of the 
cerebellum. Its effect on the peripheral nervous system manifest themselves by 
axonal degeneration with myelin disruption of the sensory branches of peripheral 
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nerve, excluding the motor part (Hunter and Russell, 1954, Takeuchi, 1981). The 
signs and symptoms of adult intoxication (Minamata disease) may  take several 
weeks to be manifested. These include constriction of the visual field, 
paraesthesia to the extremities (glove and stock type) and in perioral area, 
cerebellar ataxia, hearing loss, muscle weakness, tremor and mental retardation 
(Castoldi et al., 2001). On the other hand, the immature CNS is extremely 
sensitive to MeHg and the fetal brain may be affected even if the mother was 
asymptomatic. The effects of MeHg poisoning on the developing brain is diffuse 
unlike that in adult intoxication, with a high dose of MeHg resulting in cerebral 
palsy, blindness, hearing loss, and severe mental retardation (Castoldi et al., 
2001). 
5.1.2 Lead 
Lead (Pb) is a heavy metal that is normally found in the earth’s crust and is 
considered a ubiquitous pollutant in the ecosystem (Nava-Ruiz et al., 2012). 
Environmental levels of Pb have increased 1000 times in the last 3 centuries; the 
maximum increase was in 1950-2000 (ATSDR, 2007). The general population is 
exposed to Pb through air and food, while occupational exposure to Pb occurs in 
workers in Pb refining, battery plants, mines, welding of lead painted metals. Pb 
emissions in developed countries have decreased significantly in the last few 
decades due to the use of unleaded fuel (Jarup, 2003). Blood Pb levels were 
revised in the general population because the results showed the negative effect of 
Pb on child neurodevelopment, therefore, Pb levels which were considered 
hazardous were reduced to 40μg/dl in 1971, 30μg/dl in 1975, 10μg/dl in 1991 
(Bellinger and Bellinger, 2006). In spite of efforts to reduce exposure through 
regulation, excessive exposure still exists and Pb still is a public health concern.  
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The targets of Pb toxicity are cardiovascular, kidney, bone, the haematological 
system, whilst the CNS is the most susceptible system to its effect (ATSDR, 
2007). Children are the most sensitive to the effect of Pb. Pb exposure in utero, 
infancy, and early childhood produces dramatic effects manifested by behavioural 
disturbances, difficulties in learning, reduction in IQ scores even at low doses. 
This is because the developing CNS is more sensitive to PB than the adult CNS 
(Sharma et al., 2015). The high vulnerability of children to Pb toxicity is due to 
the different exposure pathway and due to variable toxicokinetics (Bellinger and 
Bellinger, 2006). Childhood lead exposure contributes to about 600,000 new 
cases of intellectual disabilities yearly, 99% of them are living in developing 
countries (Sharma et al., 2015). In humans, about half of Pb enters the human 
body through the inhalation route, while only 10-15% is absorbed by the oral 
route. In both these cases, 90% of the internalised Pb is retained in the body and 
distributed in the bones (Links et al., 2001). In the human, acute intoxication is 
less common than chronic intoxication and is manifested by central abdominal 
pain, headache, neurological signs; chronic poisoning is characterized by 
sleeplessness, poor attention span, convulsion, vomiting and coma (Bellinger et 
al., 1992). In children, Pb encephalopathy is characterized by lethargy, anorexia, 
vomiting, irritability, mental dullness; in severe cases, exposure for a long 
duration can decrease cognitive function and increase behavioural disorders like 
aggression and hyperactivity (Bellinger et al., 1992, Jarup, 2003, ATSDR, 2007). 
In summary, methyl mercury and lead acetate have been chosen because they are 
well known in their neurotoxicity, as mentioned above. They have been used to 
evaluate human neural stem cell model in predicting their neurotoxicity, and to 
know at which level it can detect their toxicity. 
 91 
 
5.2 The results 
5.2.1 Mercury 
Our study shows that Methyl mercury MeHg affects cell viability and total 
protein content of cultured cells. It appears that cell viability significantly reduced 
from the dose of 2.5µM, (F (7,16)=26.99, p<0.0001, post-hoc: 2.5µM vs control: 
p<0.001), also, total protein amount was reduced significantly from the same 
dose, (F (7,16)=98.06, p<0.0001, post-hoc: 2.5µM vs control: p<0.0001) as 
shown in the figure 29A and B. However, MeHg reduced neurite length 
significantly at lower doses (1μM) than that of cell viability and protein, (F 
(5,12)=69.55, p<0.0001, post-hoc: 1µM vs control: p<0.05). Similarly, the 
neurosphere sizes were reduced significantly from the that dose, (F (5,12)=85.25, 
p<0.0001, post-hoc: 1µM vs control: p<0.05). This means that neurite length and 
neurosphere sizes are more sensitive measures than cell viability and total protein 
amount. Neurite length and neurosphere reduced more with increasing the doses 
as shown in figure 29C and D and figure 30. 
In the case of the effect on GFAP and tubulin III proteins in the western blot, it 
appears that MeHg significantly increases GFAP from the dose of 1μM, (F 
(5,12)= 64.02, p<0.0001, post-hoc: 1µM vs control: p<0.05), while in the effect of 
MeHg on tubulin III protein, it seems that this protein is reduced significantly at 
the same dose, (F (5,12)= 6.574, p<0.0036, post-hoc: 1µM vs control: p<0.05), as 
shown in figure 29E and F and figure 31. Regarding the effect on cell migration, 
it seems that MeHg at low dose does not have any significant effect on cell 
migration at either 24 or 48 hours of treatment. Cell migration appears to be 
significantly reduced at the dose of 1μM, (concentration vs time: F (5,24)= 1.568, 
p=0.2071, post hoc: 1µM vs control: p <0.05) (24hrs after treatment), and P<0.01 
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(48hrs after treatment), then migration distance reduced more with increasing the 
doses (F (5,24)=35.66, p<0.0001) and with increase the  duration, (F 
(1,24)=228.4, p<0.0001). 
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Figure 29: Effect of Methyl Mercury at different doses on A: Resorufin production, B: Total 
protein. Mean± SE., n=3 (average 6 wells from each experiment), C: The length of neuronal 
processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size 
changes with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP 
(Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days 
after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 30: The effect of different doses of  Methyl Mercury on the sizes of neurospheres. This 
figure illustrates photos of 24 wells of the same plate at the same magnification. The scale bar is 
700µm. 
 
Figure 31: Western blot analysis for hNSC cultured cells illustrating GFAP, Tubulin III, and 
GAPDH proteins after adding methyl mercury. 
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5.2.2 Lead 
Our study found that Lead (Pb) caused significant reduction in cell viability at a 
dose of 75μM, (F (7,16)=3.587, p=0.0163, post-hoc: 75µM vs control: p<0.05). It 
appears that cell viability was severely affected with increasing the doses. 
However, total protein amount was reduced significantly at 50µM, (F (7,16)= 
12.12, p<0.0001, post-hoc: 50µM vs control: p<0.05), as shown in figure 32A and 
B.  Pb treatment results in significant reduction in neurite length and neurosphere 
sizes from the dose of 25μM, (F (5,12)=23.07, p<0.0001, F (5,12)=43.88, 
p<0.0001 respectively, post-hoc: 25µM vs control: p<0.05), figure C and D. 
Regarding its effect on GFAP and tubulin III proteins, it seems that this chemical 
has no significant effect on tubulin III protein, but it increase GFAP significantly 
at 25μM, (F (5,12)=5.144, p<0.0094, post-hoc: 25µM vs control: p<0.05), and the 
GFAP expression increased significantly with increasing the doses, figure 32E 
and F and 33. In case of its effect on cell migration, it appears that Pb has no 
significant effect at the dose of 5μM, however, it reduce migration distance with 
increasing the dose, (F (5,24)=26.14, p<0.0001), and with increasing the duration, 
(F (1,24)=199.4, p<0.0001). Lead reduces migration distance 48 hours after 
treatment at the dose of 10μM, (concentration vs time: F(5,24)=1.944, p=0.1, 
post-hoc: 10µM vs control: p<0.05) and has no significant effect 24 hours after 
treatment, but at 25, 50 and 75μM, Pb causes highly significant reduction in cell 
migration 24, and 48 hours after treatment, figure G. 
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Figure 32: Effect of lead acetate at different doses on A: Resorufin production, B: Total protein. 
Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal processes. 
Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size changes 
with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP (Western 
Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days after drug 
treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 33: Western blot analysis for hNSC cultured cells illustrating GFAP, Tubulin III, and 
GAPDH proteins after adding Lead acetate. 
5.3 Discussion 
5.3.1 Mercury 
Methyl mercury (MeHg) is well known as environmental neurotoxicant for both 
humans and animals. Transplacental passage of MeHg readily occurs in humans 
and the developing CNS is more vulnerable to its neurotoxicity (Costa et al., 
2004, Grandjean and Landrigan, 2006). High affinity of MeHg for sulfhydryl 
(thiol) groups makes proteins and peptides containing cysteines vulnerable to 
structural and functional changes. Combination of MeHg with sulfhydryl group in 
enzymes leads to inhibition of these enzymes (Rocha et al., 1993). Also, 
combination of MeHg to thiol groups in non- protein compounds such as 
glutathione GSH disturbs the antioxidant GSH system of the cells. Therefore, 
these facts represent the keys to the mechanism of MeHg neurotoxicity (Aschner 
and Syversen, 2005). 
In this study, it appears that MeHg affects cell viability and total protein in a dose 
dependant way. MeHg can cause cell death in two ways, either by apoptosis 
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(programmed cell death) (Nagashima, 1997, Bulleit and Cui, 1998, Ceccatelli et 
al., 2010) or by necrosis (Miura et al., 1987, Nakada and Imura, 1983). The dose 
of MeHg determines the type of cell death; cell death at lower doses is by 
apoptosis, while at higher doses, is by necrosis (Castoldi et al., 2000). It seems 
that high doses of MeHg >5μM cause rapid impairment in mitochondrial activity 
and also causes plasma membrane lysis which results in massive cell necrosis. At 
low doses, the cell death seems to be by apoptosis (Castoldi et al., 2001) which 
appears to be caspase dependant (Chang et al., 2013). 
Regarding the effect of MeHg on neurite length and cell migration, microtubule 
integrity is important in the development of the CNS such as cell proliferation, 
migration to form cortical layers of the cerebrum and cerebellum, neurite 
formation, extension and stabilization. MeHg appears to affect the cytoskeleton 
especially microtubules. MeHg has been found to have a high affinity for 
sulfhydryl groups, to depolymerize microtubules in vitro, and inhibit their 
assembly (Sager et al., 1981). Cytoskeleton fragmentation and neural network 
disruption have been shown in cultured cerebellar granular cells when exposed to 
MeHg, and it seems that these effects appear earlier than cell death (Castoldi et 
al., 2000). MeHg interference with microtubules is clear by the findings in the 
autoptic brains of full term infants from the Iraq outbreak in 1970s, who were 
exposed in utero to MeHg in early pregnancy, these include, brain size reduction, 
abnormal neuronal arrangement and alteration in cerebral cortex alignment 
(CHOI et al., 1978). MeHg caused a dose dependant reduction in cell migration, 
which is consistent with the finding of Kunimoto when he used cerebellar granule 
neurons and explained the reduction in cell migration due to extensive cell death 
(Kunimoto and Suzuki, 1997). 
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Calcium ions play an important role in cell death in the CNS. Ca
+2
 overload has 
been shown to trigger cell death either by apoptosis or by necrosis. The 
mechanism by which Ca
+2 
causes this problem is unknown, but raised calcium 
ions may lead to activation of degradative enzymes like proteases, endonuclease, 
phospholipase, mitochondrial dysfunction, and disruption in the cellular 
cytoskeleton (Orrenius and Nicotera, 1993). MeHg has been reported to affect 
Ca
+2
 homeostasis and elevate Ca
+2
 intracellularly in cerebellar neuron cultures 
(Okazaki et al., 1997, Oyama et al., 1994), as shown in figure 33. Calcium 
channel blockers, such as nifedipine and MVIIC, delay MeHg induced elevation 
of Ca
+2
 significantly. Also, the Ca
+2
 chelating agent BAPTA protects granule cells 
from cell death induced by MeHg. Additionally, in agreement with these findings, 
voltage gated Ca
+2
 channel blockers prevent the appearance of neurological 
disorders in rats which received MeHg in vivo (Sakamoto et al., 1996). 
The results show that MeHg reduced neurons (tubulin III protein) in a dose 
dependant way; this can be explained by MeHg accumulating in astrocytes to 
induce cell swelling and inhibit excitatory amino acid uptake (Aschner et al., 
2000). Glutamate represents the major excitatory neurotransmitter in the 
mammalian CNS. However, glutamate at high levels in the synaptic space is 
considered as a toxin, which causes injury and death to neuronal cells (Meldrum, 
2000). MeHg causes a significant reduction in glutamate uptake in astrocyte 
cultures; the efflux of glutamate from astrocytes increased significantly, which 
lead to increased glutamate in the extracellular space and accelerated excitotoxic 
neurodegeneration (Aschner et al., 2007). Glutamate neurotoxicity, which is 
referred to as excitotoxicity, is due to over-activity of N-methyl D-asparatate 
(NMDA) glutamate receptors which result in an increase in Na
+
 and Ca
+2
 influx 
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(Pivovarova and Andrews, 2010), figure 33. Increased intracellular Ca
+2
 leads to 
activation of certain pathways which lead to cell death and to the generation of 
oxidative stress and neurotoxicity (Ceccatelli et al., 2010). In vitro co- application 
of nontoxic dose of MeHg and glutamate results in neuronal damage like that of 
excitotoxic damage (Matyja and Albrecht, 1993). Neuronal damage can be 
explained also by astrocytes dysfunction (Brookes, 1992). 
 
Figure 34: Mechanism of MeHg induced oxidative stress. It inhibit glutamate reuptake by the 
astrocytes which led to increase in glutamate in the extracellular spaces, and it increase Ca
+2
 and 
and Na
+
 influx which induce excitotoxicity by over activate NMDA receptors  (Farina et al., 
2011). 
Our study shows that MeHg causes a dose dependant increase in astrocytes 
(GFAP). As MeHg is a neurotoxic chemical, this may cause astrocytes to be 
reactive and increase the synthesis of GFAP, which is called reactive astrogliosis, 
and which occurs after injury, either due to trauma, diseases, genetic disorders, or 
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due to chemical exposure, as in the case of MeHg (Eng et al., 2000). Astrogliosis 
considered as an early sign of neurotoxicity (Zurich et al., 2004, O'callaghan, 
1991). Reactive astrocytes are able to release bioactive substances to modulate the 
neurotoxicity of these chemicals, some of them have neuroprotective while the 
others may have neurodegenerative potentials (Aschner et al., 2002). 
5.3.2 Lead 
In spite of remarkable success in abating lead (Pb) exposure, Pb remains an 
important health problem to children in both developed and developing countries 
(Bellinger, 2013). Pb is an ubiquitous environmental pollutant that can pass 
through the placenta and can cross the blood brain barrier to induce neurotoxicity. 
Exposure to Pb, even at low doses, can be hazardous (Yu et al., 2011). The results 
reported here show that lead decreases cell viability and total protein  
significantly at 50μM and more, and this can explained by Pb leading to 
mitochondrial and Golgi apparatus dysfunction (Strużyñska et al., 2001) and Pb 
exposure can result in cell death by apoptosis, which has been described before 
when cerebellar cells were exposed to it (Sharifi et al., 2002). Pb can affect the 
nervous system by several pathways; Pb is able to pass through the blood brain 
barrier due to its capability to substitute for calcium ions, therefore Pb gains entry 
into the cells through one or more of the various types of Calcium channels 
(ATSDR, 2007). Within the cells, Pb interferes with calcium release from the 
mitochondria leading to formation of a permeability transition pore which 
enhances programmed cell death and mitochondrial self- destruction (Mason et 
al., 2014). Additionally, Pb interferes with the phosphorylation of protein kinase 
C (PKC) which is activated due to increased intracellular Ca
+2
 concentration and 
Diacylglycerol (DAG), which in turn increases cell permeability to water and 
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other ions, which result in oedema and cell damage (Bressler and Goldstein, 
1991). 
Oxidative damage is another important mechanism of lead neurotoxicity; 
experimental evidence has shown that Pb induces oxidative stress through the 
disruption of pro-oxidant/anti-oxidant balance (Daniel et al., 2004, Villeda-
Hernandez et al., 2006). The reduction of antioxidant activities might be due to 
the high affinity of Pb for sulfhydryl groups or metal cofactors in antioxidant 
enzymes (Gurer and Ercal, 2000). It has been shown that Pb causes significant 
reduction in the activity of superoxidase dismutase (SOD) and catalase (CAT) in 
rat and mouse brains (Nehru and Kanwar, 2004). Moreover, it has been found that 
Pb exposure during pregnancy reduces SOD, glutathione perioxidase (GPx) and 
glutathione (GSH) in rat brains (Wang et al., 2006), figure 35. 
The two important pathways which are concerned with Pb are those for 
calmodulin and PKC. Ca
+2
 binds to calmodulin and also converts it to its active 
form, while Pb displace Ca
+2
 bound to calmodulin; Pb activation of calmodulin 
results in protein phosphorylation altering the cAMP messenger pathways (Goyer, 
1997). Normally, Ca
+2
 activates PKC, which is a serine threonine protein kinase 
involved in dendritic branching, neurotransmitter synthesis and synaptic 
transmission (Bressler et al., 1999). This might explain the significant reduction 
in neurite length. 
Several neurotransmitters also are affected by Pb interaction during development 
of the CNS. In animals exposed to low doses of Pb during development, high 
level of dopamine and catecholamine neurotransmission have been observed in 
the cerebral cortex, cerebellum, and hippocampus. While rats exposed to high 
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dose of Pb have a decrease in dopamine and catecholamine neurotransmission in 
the same areas of the brain (Devi et al., 2005), figure 35. 
Pb enters astrocytes from receptor-operated and voltage-dependant Ca
+2
 channels 
which mediate Pb uptake into the cells; Pb is deposited in the lysosomes, nucleus, 
and other organelles of astrocytes, a process which might be occuring through Pb-
binding proteins (Tiffany-Castiglioni and Qian, 2001). Astrocytes play an 
important role in protecting neurons against Pb neurotoxicity (Harry et al., 1996); 
this may explain there was no significant effect on tubulin III protein ( the 
neuronal cells). GFAP in these result was increased significantly and in a dose 
dependant way. As it was suggested by O’Callaghan that this intermediate 
filament can be considered as an early sign of neurotoxicity (O'callaghan, 1991). 
The increase in this protein represents astrogliosis, in which the astrocytes react to 
the toxic insult by an increase in synthesis of GFAP and the astrocytes become 
hypertrophied and increased in number (Strużyñska et al., 2001). Several studies 
confirm that rat brain exposed to Pb showed an increase in the concentration of 
GFAP as well as the number of astrocytes (Strużyñska et al., 2001, Tiffany-
Castiglioni and Qian, 2001). 
 
Figure 35: Mechanisms of lead toxicity (Nava-Ruiz et al., 2012) 
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It can be concluded that HNSC culture method can detect the neurotoxicity of 
methyl mercury at low level (1µM) in most of the end points that were tested and 
the neurotoxicity of lead acetate at 10µM in cell migration.  
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Chapter 6 
Evaluation of This Model with Anti-epileptics 
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6.1 Anti-epileptics and Teratogenesis 
Epilepsy is a common brain disorder characterize by recurrent seizures; it affects 
about 1% of the whole population and the highest incidence is in the first year of 
life (Hauser, 1994). Anti-epileptic drugs (AEDs) are used to control seizures but 
they are also used in the treatment of other neurological and psychiatric disorders 
such as bipolar disorders, migraine, movement disorders, and neuropathic pain 
(Rogawski and Löscher, 2004b). AEDs act on ion channels, metabolic enzymes, 
neurotransmitter transporters in the CNS. They change the bursting activities of 
neurons, prevent spread of epileptic activity and decrease synchronization 
(Rogawski and Löscher, 2004a). Additionally, AEDs interfere with neuronal 
migration, cell differentiation and plasticity, and they can lead to neuronal cell 
death in the developing brain in rodent (Olney et al., 2004). 
About 3 to 7 out of 1000 pregnant women have epilepsy (Viinikainen et al., 
2006); these women should have medication to control seizure activity; otherwise 
it will be harmful for both, the mother and the baby. The convulsion itself carries 
a lot of risks to the fetuses; it can cause intracranial haemorrhage and alteration in 
fetal heart rate (Fountain, 2009). Therefore; continuation of antiepileptic drugs is 
mandatory to save the life of the mother and her baby.  
It is well known that the use of antiepileptic drugs during pregnancy can cause a 
wide range of congenital abnormalities (Meador et al., 2006); the original reports 
about the association between these drugs and congenital anomalies goes back to 
the 1960,s (Mullers-Kuppers, 1963). Meador et al. (2008) state that a 
monotherapy regimen for epileptic pregnant women can increase the incidence of 
congenital anomalies in their children threefold compared to that of healthy 
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women and polytherapy makes the incidence higher than that of monotherapy. 
Nearly all antiepileptic drugs are not safe and not free from teratogenic potential 
(Prabhu et al., 2008). The teratogenicity of these drugs is also dose dependant 
(Tomson et al., 2011). 
6.1.1 Mechanism of action of antiepileptics 
1- Interaction with ion channels 
The main target of AEDs is the voltage-gated ion channel, because these channels 
are critical in determining the excitability of neurons and regulation of 
neurotransmitter release. By AEDs interaction with ion channel, they inhibit 
epileptic bursting activities, seizure propagation and synchronization. Sodium or 
calcium blockage with facilitation of potassium channels results in control of 
seizure activity in epileptic animal models (Tatulian et al., 2001). 
Voltage gated sodium channels are composed from several subunits, which 
undergo conformational modification when the neuron is depolarized at the action 
potential threshold. This modification changes the channel into the open 
conductive state to allow sodium influx for only few milliseconds. Channels 
inactivate quickly and could be reactivated after repolarization. This quick 
changing between open and closed status of sodium channels is important for 
both the normal brain and for seizure discharge (Leach et al., 1986). Phenytoin 
and carbamazepine act by changing voltage gated sodium channels. Blockage of 
these channels can also be achieved by sodium valproate. These drugs do not 
affect the physiological activity of the neurons, but they inhibit the frequent 
repetitive firing. This means that these drugs do not make any impairment in 
general brain function. Also, these AEDs decrease the output of transmitter at the 
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synapses but they do not alter the excitatory or inhibitory synaptic responses 
(Prakriya and Mennerick, 2000). 
Voltage gated calcium channels have two types; high voltage-activated (HVA) 
and low voltage-activated families. HVA can only be opened when there is a 
strong depolarization and can regulate calcium and neurotransmitter release from 
the presynaptic neuronal terminals, so it reduces neuronal excitability. 
Phenobarbitone blocks this type of calcium channel (Barker and Rogawski, 
1993). The low voltage-activated channels (T-type) control neuronal firing and 
regulate bursting and intrinsic oscillations (Perez-Reyes, 2003). In ‘absent 
seizures’ there is abnormal oscillatory behaviour (Huguenard, 1996). This type of 
calcium channel generates a low threshold spike of calcium and stimulates a burst 
of action potential with the aid of sodium channels in thalamic reticular neurons 
(Suzuki and Rogawski, 1989). Sodium valproate is effective in the treatment of 
seizures by blocking this type of channel (Sankar and Holmes, 2004). 
2- Interaction with neurotransmitters: 
Several AEDs act by inhibition of synaptic activities or by reducing synaptic 
excitation. By interaction with neurotransmitter receptors and the ion channels 
which regulate the neurotransmitters, these drugs can reduce bursting and seizure 
spread. There are two neurotransmitter systems which are the target of AEDs; the 
inhibitory GABAergic system and the excitatory glutamatergic system. AEDs 
exert their anticonvulsant action either by enhancing the inhibitory system 
mediated by GABA (γ-amino butyric acid) receptors or blocking the excitatory 
glutamate receptors (such as N-methyl-D-aspartate – NMDA, α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid – AMPA, kainite, group I 
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metabotropic receptors) (Kaindl et al., 2006). There are other neurotransmitter 
systems which are also involve in controlling seizure activities such as the glycine 
system, monoamines, neuropeptides, galanin, neuropeptide Y, adenosine, 
serotonin and histamine (Rogawski and Löscher, 2004a). 
6.1.2 GABA inhibitory system 
Inhibitory synapses are essential in regulating the excitatory neurons and 
preventing synchronized epileptiform discharge (Miles and Wong, 1987). 
Mediating GABA inhibition is the major mechanism of action of AEDs. GABA 
stimulates chloride-permeable GABAA receptors and slower metabotropic G-
protein-coupled GABAB receptors. Therefore, any compound that blocks GABAA 
receptors can be considered as a proconvulsant. Mutations of this subunit have 
been associated with broad spectrum of epilepsy syndromes like childhood 
absence epilepsy, febrile convulsion, Dravet’s syndrome, and Juvenile myoclonic 
epilepsy (Wallace et al., 2001, Cossette et al., 2002).  
Barbiturates like phenobarbitone modulate GABAA receptors. Phenobarbitone at 
the clinically relevant concentration makes the channels  open  for a 
proportionally longer duration (Macdonald and Olsen, 1994), Barbiturates act on 
both sodium and calcium channels (Barker and Rogawski, 1993). 
6.1.3 Glutamate Excitatory system 
Glutamate receptors are glutamate-gated cation channels which facilitate 
excitatory neurotransmission in the CNS (Dingledine et al., 1999). The 
compounds that block NMDA, AMPA, and kainite receptors are effective 
anticonvulsants in epileptic animal models (Rogawski et al., 2003). AMPA and 
kainite receptors control seizure propagation and regulate seizure induced brain 
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damage (Meldrum, 1995). Kainate receptors also mediate glutamate release from 
excitatory afferent neurons and reduce GABA release from inhibitory 
interneurons (Lerma et al., 2001). 
Drug GABA 
system 
Glutamate 
receptors 
Sodium 
channels 
Calcium 
channels 
Sodium valproate +  + + 
Phenytoin   +  
Carbamazepine  + +  
Phenobarbitone + + + + 
 
6.1.4 The Anti-epileptics 
1- Sodium Valproate 
Sodium Valproate (SV) is Valproic acid sodium salt. It was discovered by 
accident as an anticonvulsant in 1963 when SV was used as a solvent for other 
compounds which were administered to animals used in experimental models of 
epilepsy. Since then, SV has been used for different types of seizures. It is used 
for the treatment of epilepsy in more than 100 countries (Loescher, 2002). SV is 
also used as a mood stabilizing agent in bipolar mood disorder and it is 
recommended by many psychiatric and pharmacological societies as a first line 
drug for treatment of acute mania and as maintenance therapy for the prevention 
of mania and sometimes recommended for depression (Fountoulakis et al., 2005). 
In addition to that SV is prescribed as prophylactic drug against headaches in 
migraine (Chronicle and Mulleners, 2004) and has been proposed for the 
treatment of cancer (Blaheta et al., 2002), Alzheimer Disease (Tariot et al., 2002) 
and also it is used for the treatment of latent HIV infection (Lehrman et al., 2005). 
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6.1.4.1 Mechanisms of action of SV 
1- SV administration causes an increase in the inhibitory neurotransmitter 
GABA by direct inhibition of GABA transaminase which is responsible 
for GABA breakdown (Maitre et al., 1974). Potentiation of GABA 
signaling can prevent seizure activity while inhibiting GABA signaling 
can cause seizures, therefore, this can explain the anticonvulsant property 
of SV 
2- SV  indirectly inhibits slow sodium currents and calcium currents (De 
Sarro et al., 1992). Sodium and calcium channels are very important in 
neuronal excitability. SV has been reported to block neuronal excitability 
and action potential firing  (McLean and Macdonald, 1986). SV acts to 
normalize neuronal firing and to increase the threshold of neural 
discharge. This mechanism can explain the action  of this drug in migraine 
(Casucci et al., 2008). 
3- SV is a potent inhibitor for HDACs (Histone Deacetylase) (Phiel et al., 
2001). The discovery of this fact opens a wide window to understand the 
teratogenecity of this drug and to explain its uses in cancer and treatment 
of latent HIV infection.  
 111 
 
 
Figure 36: The targets of VPA (valproic acid) and its potential use in medicine (Terbach and 
Williams, 2009) 
 
Figure 37: The chemical structure of VPA (valproic acid) and its related compounds (Terbach and 
Williams, 2009) 
2- Phenytoin 
Phenytoin-PHN (Diphenylhydantoin) is the most common drug that used for 
treatment of epilepsy; it was used as an anticonvulsant in the 1930s (Merrittt and 
Putnam, 1938). PHN exert its anticonvulsant action at serum level 10-20μg/ml, 
 112 
 
which correspond to 40-80μM, without causing sedation or interfering with the 
normal CNS function (Yaari et al., 1986). It is highly effective and is the drug of 
choice for several types of epilepsy (Temiz et al., 2009). PHN is well known in its 
teratogenicity for different species such as rabbit (Danielsson et al., 1992), rats 
and mice (Finnell and Dansky, 1991) as well as humans (Dansky and Finnell, 
1991). Because it is well documented concerning its teratogencity in humans and 
animals, it is placed in FDA pregnancy category D (Ozolins et al., 1995). 
Maternal exposure to PHN during pregnancy increases the risk of having a child 
with congenital anomalies by two to three fold with a characteristic anomaly Fetal 
Hydantoin Syndrome (Ozolins et al., 1995), which is characterized by different 
signs such as facial, skull abnormalities, like short nose, low nasal bridge, 
hypertelorism, epicanthal fold, low hair line, hypoplasia of distal phalanges and 
nails. This syndrome can be observed in 10% of PHN treated mothers (Ornoy, 
2006). The exact mechanism for its teratogenicity is unknown and needs to be 
clarified. The pattern of birth defects in humans, rabbits, rats and mice is similar; 
this suggest that the teratogenicity follows the same pathway (Azarbayjani et al., 
2006). Azarbayjani thought that PHN teratogenicity is mostly related to excessive 
generation of reactive oxygen species or to impaired antioxidant defence 
mechanisms.  
3- Carbamazepine 
Carbamazepine (CBZ) is an iminostilbene structurally related to tricyclic 
antidepressants (Ambrósio et al., 2002) and shares some clinical similarities with 
structurally unrelated  valproic acid, which has a short chained fatty acid structure 
(Beutler et al., 2005). Since its introduction in clinical practice for treating 
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epileptic patients in the mid-1960s, it has become the most frequently prescribed 
first line drug for the treatment of generalized tonic-clonic and partial seizures 
(Loiseau, 1995). Additionally, CBZ can be used in the treatment of neuropathic 
pain (Sindrup and Jensen, 1999) and psychological disorders (Albani et al., 1995). 
In spite of being effective and safe in treating epileptic patients, 30-40% of 
patients do not respond completely to CBZ treatment (Shorvon, 1996). 
Sometimes, CBZ may cause side effects. Acute toxicity at therapeutic doses affect 
the central nervous system and gastrointestinal system, causing sedation, ataxia, 
dizziness, nausea, vomiting, constipation, and diarrhoea. While chronic treatment 
with CBZ may lead to alteration in plasma lipids, hyponatraemia, increased 
appetite and weight gain, reduced white blood cell number and allergic reactions 
(Albani et al., 1995). The mechanisms by which this drug causes these side 
effects are not clear. The mechanism of action of this drug is still not known but it 
is widely accepted that this drug acts by more than one mechanism. It has been 
thought that it may block or enhance voltage gated Na+, Ca+2, and K+ channels, 
and it may modify uptake, release, receptor binding of neurotransmitters in 
serotonergic, dopaminergic, and glutamergic systems (Ambrósio et al., 2002). It is 
most commonly used in Europe by women of child bearing age; it can increase 
the risk of major congenital anomalies by 3.3%, the main congenital anomalies 
that associated with CBZ are spina bifida, cardiovascular, and other minor 
anomalies; but in general, it is less teratogenic than Valproate (Jentink et al., 
2010b). 
4- Phenobarbitone 
Phenobarbitone (PHB) (phenyl-ethyl-barbiturate-acid), also known as 
phenobarbital, is one of the oldest anticonvulsants. It was first discovered by 
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German chemist Emil Fischer (Kwan and Brodie, 2004). The anticonvulsant 
activity of PHB was published by German physician Alfred Hauptmann in 1912 
(Kumbier and Haack, 2004). At that time, bromide was used as standard drug for 
treating epileptic cases. Hauptmann used PHB for severe cases that were resistant 
to bromide, he found that PHB reduce the frequency of seizures and decrease 
their severity. Eventually PHB became the drug of choice in treating epilepsy 
around the world. 
PHB was first approved by the FDA in 1939 (Salas, 2012). It is commonly used 
as an anti-epileptic for all the types of epilepsy except petit mal (absence seizure), 
as a sedative, for treatment of hyperbilirubinemia and insomnia. Animal studies 
on chicks and rodents have shown that maternal exposure to PHB at several times 
the average human dose might lead to increased risk for cleft palate, cardiac 
defect, and other major structural defects (Finnell and Dansky, 1991). Also, 
animal studies showed that the number of major structural defects was directly 
related to the exposure doses of PHB during pregnancy (Finnell et al., 1987). 
While the animal data confirmed the teratogenicity of PHB, human data is not 
clear. It has been shown that in utero exposure to PHB may result in long lasting 
neurobehavioral effects in the human such as impairment in cognitive 
development (van der Pol et al., 1991) and low IQ scores (Reinisch et al., 1995). 
Instead of that, the embryo toxicity and teratogenicity of PHB seem to be less 
than that of other AEDs in animal models (Holmes et al., 2001). In vivo and in 
vitro animal studies demonstrated that PHB is associated with biochemical and 
morphological abnormalities (Bergey et al., 1981b). Several studies on the 
association of PHB with major congenital anomalies in the human have been 
published (Pennell, 2008). The same author showed also that the risk of having a 
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baby with a birth defect is higher when PHB was combined with another 
antiepileptic, polytherapy. An epidemiological study showed that PHB drug 
exposure during the first trimester is associated with major and minor structural 
defects (Salas, 2012). Postnatal exposure to PHB especially during the first 3 
years of life may lead to impairment in cognitive function which persists 
throughout adulthood (Reinisch et al., 1995). A pattern of minor structural defects 
has been identified with the use of AEDs known as fetal anticonvulsant 
syndrome, with similar features to the syndrome being identified in infants of 
mothers who are exposed to PHB during pregnancy. These features include nail 
hypoplasia, midface hypoplasia, depressed nasal bridge, hypertelorism, and 
epicanthal fold (Salas, 2012). Other studies found an association between PHB 
exposure during pregnancy and facial clefts and cardiovascular defects (Arpino et 
al., 2000) and it increased the risk of having infants with a smaller head 
circumference and low birth weight (Dessens et al., 2000). 
Mechanism of action of Phenobarbitone: 
PHB acts as anticonvulsant by increasing the threshold for stimulating the motor 
cortex and by inhibiting seizures in the cortex, thalamus, and limbic system. PHB 
works by facilitating GABA, an inhibitory neurotransmitter; it stimulates GABA 
binding to GABA-A receptors which leads to hyperpolarization of neuronal cell 
membranes and thus it prevents propagation of seizure activity (Salas, 2012). 
Additionally, PHB decreases the effect of glutamate, the excitatory 
neurotransmitter in the brain (Platt, 2007). PHB increases the time of the chloride 
channel to be in the open state (Macdonald and Olsen, 1994) and also PHB acts 
on both sodium and calcium channels (Barker and Rogawski, 1993). 
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The anti-epileptics have been chosen because most anti-epileptics are well known 
in their teratogenicity, sodium valproate or phenytoin administration during 
pregnancy associate with high rate of congenital anomalies. While the other, 
(Carbamazepine and phenobarbitone), are less teratogenic. Therefore, human 
neural stem cell culture model was used to test if it can predict the neurotoxicity 
of these anti-epileptics at their therapeutic level. 
6.2 Results 
6.2.1 Sodium Valproate 
SV at doses of 250, 500, 750 and 1000µM, which lie around the therapeutic range 
(400-800µM) had no significant effect on the resazurin assay when compared 
with the control group, (figure 38-A&B), At 1000µM, the protein content was 
reduced significantly, (F(7,16)=17.27, p <0.0001, post-hoc: 1000µM vs control: 
p<0.01) and at higher doses, 1500, 2000, and 2500µM there was a highly 
significant reduction in both cell activity, (F (7,16)=40.16, p<0.0001, post-hoc: 
1500 vs control: p<0.0001), and protein content when compared with the control 
group (1500µM vs control: p<0.0001), which would indicate that valproate is 
very toxic at these doses.  
On the other hand, figure 38-C shows no significant effect of SV on the length of 
neuronal processes, except at the dose of 2000µM when there was significant 
reduction in the neuronal length when compared with the control group, (F 
(5,12)=8.637, p=0.0011, post-hoc: 2000µM vs control: p<0.05). Figures 38-D and 
39 show that SV has a highly significant effect on the sizes of neurospheres 
through all the doses, including the therapeutic doses 500µM, (F (5,12)=23.21, 
p<0.0001, post-hoc: 500µM vs control: p<0.01, and 750µM vs control: p<0.001), 
probably due to its anti-proliferative action on the neural stem cells.  
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SV seems to have no significant effect on tubulin III protein in all doses in spite 
of the non-significant increase in therapeutic range, while SV decreases GFAP 
significantly at high doses 1500µM, (F (5,12)=3.657, p=0.0305, post-hoc: 
1500µM vs control: p<0.05, and 2000μM vs control: p<0.01), figure 38-E and F 
and figure 40. In the case of cell migration, SV has no significant effect on cell 
migration after the 1
st
 24 hours at all the doses, but the detrimental effect was 
significant with increasing the duration, (F (1,24)=148.6, p<0.0001), and with 
increase concentration, (F (5,24)=8.041, p=0.0001). From the doses of 1000µM 
there is significant reduction in migration distance when compared with the 
control, (concentration vs time: F (5,24)=1.611, p=0.1953, post-hoc: 1000µM vs 
control: p<0.05), 1500µM vs control (p<0.01), and 2000µM vs control (p<0.001) 
after 48 hours of treatment, figure 38-G. 
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Figure 38: Effect of Sodium Valproate at different doses on A: Resorufin production, B: Total 
protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal 
processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size 
changes with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP 
(Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days 
after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 39: The effect of different doses of sodium valproate on the sizes of neurospheres. This 
figure illustrates photos of 24 wells of the same plate at the same magnification, the scale bar is 
700µm. 
 
Figure 40: Western Blot analysis for the cells after Sodium Valproate treatment showing the 
bands of Tubulin III, GFAP, and GAPDH proteins, illustrating the progressive reduction in the 
band of GFAP with increasing the dose of the drug. 
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6.2.2 Phenytoin 
PHN was used in doses which lie slightly below, within, and above the 
therapeutic range (40-80µM). Figure 41-A and B show that the doses of 20, 50, 
100, and 150µM have no significant effect on both resorufin production, and 
protein amount, respectively when compared with the control, but, the resorufin 
production significantly reduced in the dose range, 200, 330, and 660µM, (F 
(7,16)=43.26, p<0.0001, post-hoc: 200µM vs control: p<0.0001), and protein 
amount start to be affected significantly from the dose of 200µM, (F 
(7,16)=8.959, p=0.0002, post-hoc: 200µM vs control: p<0.01). It seems that PHN 
has no significant effect on the length of the processes around the therapeutic 
doses; however, it cause highly significant reduction at the dose of 150µM, (F 
(5,12)=21.54, p<0.0001, post-hoc: 150µM vs control: p<0.001), figure 41-C.  
The neurosphere sizes were affected severely by PHN in all doses, in which there 
is highly significant reduction in the sizes of the neurospheres from the dose of 
20µM when compared with that of control group, (F (5,12)=299.9, p<0.0001, 
post-hoc: 20µM vs control: p<0.001), figure 41-D. GFAP decreased significantly 
at 100μM dose, (F (5,12)=11.67, p=0.0003, post-hoc: 100µM vs control: p<0.05), 
and the GFAP expression decreased significantly with increasing the doses, while 
tubulin III protein started to decrease significantly at 150μM, (F (5,12)=8.953, 
p=0.0010, post-hoc: 150µM vs control: p<0.05), figure 41-E and F and 42. 
Regarding cell migration, it appears that PHN reduces cell migration in direct 
proportion to the duration, (F (1,24)=126.3, p<0.0001), and to the dose, (F 
(5,24)=32.83, p<0.0001). Ph seems to reduce migration distance significantly at 
50μM, (concentration vs time: F (5,24)=2.475, p=0.0607, post-hoc: 50µM vs 
control: p<0.01) after 24hrs  and p<0.0001 after 48 hours, figure 41-G. 
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Figure 41: Effect of Phenytoin at different doses on A: Resorufin production, B: Total protein. 
Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal processes. 
Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size changes 
with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP (Western 
Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days after drug 
treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
 122 
 
 
Figure 42: Western Blot analysis for the cells after Phenytoin treatment showing the bands of 
Tubulin III, GFAP, and GAPDH proteins. 
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6.2.3 Carbamazepine  
At the dose range 5-100µM, CBZ has no significant effect on resorufin 
production, taking into consideration that the therapeutic dose of this drug is 25-
50µM. However, at high doses of 250µM-1mM the resorufin production was 
reduced significantly when compared with the control, (F (7,16)=104.9, 
p<0.0001, post-hoc: 250µM vs control: p<0.0001). However, total protein amount 
was not significantly affected until the dose of 500µM and 1mM in which there is 
highly significant reduction in total protein amount when compared to control 
group, (F (7,16)=18.49, p<0.0001, post-hoc: 500µM vs control: p<0.0001), as 
shown in figure 43-B. 
The effect on the length of neuronal processes appears to be not significant in all 
doses except at 200µM where they appears to be a highly significant reduction, (F 
(5,12)= 30.04, p<0.0001, post-hoc: 200µM vs control: p<0.0001), as shown in 
figure 43-C. The sizes of the neurospheres started to be reduced significantly also 
at 200μM, (F (5,12)=8.715, p=0.0011, post-hoc: 200µM vs control: p<0.05), 
figure 43-D. GFAP and tubulin III proteins was not affected significantly in all 
doses except in the last extreme dose 375μM at which they were reduced 
significantly, (F (5,12)=4.190, p=0.0196, post-hoc: 375µM vs control: p<0.05) for 
GFAP and (F (5,12)=3.562, p=0.0332, post-hoc: 375µM vs control: p<0.05) for 
Tubulin III, figure 43-E,F and 44. CBZ seems to reduce cell migration at 100μM, 
(F (5,24)=0.8282, p=0.5422, post-hoc: 100µM vs control: p<0.05), and there was 
no increase in significance with increasing the dose or increase the duration and 
its effect appears just 48 hours after treatment, figure 43-G. 
 
 124 
 
C
o
n
tr
o
l 5
2
5
5
0
1
0
0
2
5
0
5
0
0

M
1
m
M
0
2 0 0
4 0 0
6 0 0
8 0 0
A
C a rb a m a z e p in e  d o s e s  M
R
e
s
o
r
u
fi
n
 n
g
/m
l
****
*****
****
 
C
o
n
tr
o
l 5
2
5
5
0
1
0
0
2
5
0
5
0
0

M
1
m
M
0
2 0
4 0
6 0
8 0
B
C a rb a m a z e p in e  d o s e s  M
P
r
o
t
e
in

g
/m
l
****
****
   
C
o
n
tr
o
l
2
5
5
0
1
0
0
2
0
0
3
7
5
 
M
0
1 0
2 0
3 0
4 0
5 0
C
C a rb a m a z e p in e  d o s e s  M
N
e
u
r
o
n
a
l 
p
r
o
c
e
s
s
e
s

m
 ****
****
 
C
o
n
tr
o
l
2
5
5
0
1
0
0
2
0
0
3
7
5
 
M
0
2 0 0
4 0 0
6 0 0
8 0 0
D
C a rb a m a z e p in e  d o s e s  M
N
e
u
r
o
s
p
h
e
r
e
 s
iz
e
s

m
 *
 ***
 
C
o
n
tr
o
l
2
5
5
0
1
0
0
2
0
0
3
7
5
 
M
0 .0 0
0 .0 3
0 .0 6
0 .0 9
E
C a rb a m a z e p in e  d o s e s  M
G
F
A
P
 *
C
o
n
tr
o
l
2
5
5
0
1
0
0
2
0
0
3
7
5
 
M
0
3
6
9
1 2
F
C a rb a m a z e p in e  d o s e s  M
T
u
b
u
li
n
 *
 
2
4
h
rs
4
8
h
rs
2
4
h
rs
4
8
h
rs
2
4
h
rs
4
8
h
rs
2
4
h
rs
4
8
h
rs
2
4
h
rs
4
8
h
rs
2
4
h
rs
4
8
h
rs
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
G
C a rb a m a z e p in e  d o s e s
M
ig
ra
ti
o
n
 d
is
ta
n
c
e

m
C o n tro l
25
50
2 0 0
3 7 5 M
1 0 0
*  * *
 
Figure 43: Effect of Carbamazepine at different doses on A: Resorufin production, B: Total 
protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal 
processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size 
changes with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP 
(Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days 
after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 44: Western Blot analysis for the cells after Carbamazepine treatment showing the bands 
of Tubulin III, GFAP, and GAPDH proteins. 
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6.2.4 Phenobarbitone 
It appears that PHB has no significant effect on cell viability and total protein of 
the cells in the dose range 100μM-2000µM. However, it reduces both these 
parameters at the extreme doses 3000 and 4000µM in which there is a significant 
reduction in cell viability, (F (7,16)=10.97, p<0.0001, post-hoc: 3000µM vs 
control: p<0.05) and total cellular protein, (F (7,16)=3.911, p=0.0113, post-hoc: 
3000µM vs control: p<0.05), figure 45-A and B. The figure 45-C shows that PHB 
has no significant effect on the process length except in high dose 2000µM, in 
which there high significant effect on neuronal processes length, (F (5,12)=7.598, 
p=0.0020, post-hoc: 2000µM vs control: p<0.01). In other hand, PHB seems to 
reduce the neurosphere size at a significant rate at the doses of 1000µM, (F 
(5,12)=8.715, p=0.0011, post-hoc: 1000µM vs control: p<0.05) and (2000µM vs 
control p<0.0001) when compared with that of control group, figure 45-D.  
Neuronal cell population, which is represented by Tubulin III protein, appears to 
be not affected in all doses of PHB, but the astrocyte population, which was 
marked by GFAP was reduced only at high doses 1000µM, (F (5,12)=9.598, 
p=0.0007, post-hoc: 1000µM vs control: p<0.05) and (2000µM vs control 
p<0.01), figure 45-E,F and 46. In the case of cell migration, PHB has no 
significant effect on migration except at high dose 2000µM and only after 48hr 
from drug treatment there is high significant reduction in cell migration when 
compared with the control group, (concentration vs time: F (5,24)=1.057, 
p=0.4099, post-hoc: 2000µM vs control: p<0.001), figure 42-G. 
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Figure 45: Effect of Phenobarbitone at different doses on A: Resorufin production, B: Total 
protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal 
processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size 
changes with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP 
(Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days 
after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 46: Western Blot analysis for the cells after Phenobarbitone treatment showing the bands 
of Tubulin III, GFAP, and GAPDH proteins. 
6.3 Discussion 
6.3.1 Sodium Valproate 
Sodium valproate has several therapeutic applications as an anticonvulsant, anti-
manic and anti-cancer drug and is also used for migraine prophylaxis. Its use in 
pregnancy has been shown to carry risks to the developing embryo and could 
result in a wide spectrum of developmental anomalies such as neural tube defects, 
craniofacial, cardiac and genital birth defects (Nau et al., 1991) and  (Nau, 2008). 
The first report which suggested teratogenicity of valproate in the human was 
published in 1980, which demonstrated the association of sodium valproate intake 
during pregnancy with neural tube defects (meningocele and meningomyelocele) 
(Dalens et al., 1980).  
SV appears to have no significant effect on cell activity or total protein levels at 
the doses which locate around the therapeutic range. However, at higher doses 
(1500, 2000, and 2500µM) SV caused a highly significant reduction in both these 
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parameters and appears to be very toxic. It has been reported that SV can stop the 
cell cycle at phase G0/1 and can arrest cell proliferation and induce apoptosis in 
vitro (Pandolfi, 2001). This may explain the reduction in cell activity and total 
protein only being apparent at high doses. However; Chiu et al. (2013)  pointed 
out that SV supplement within or close to the human therapeutic dose  results in 
hyperacetylation of histone which leads to changes in chromatin and alters 
transcriptional activity, modulates gene expression, enhances cell differentiation 
and increases apoptosis (Phiel et al., 2001). Gurvich et al. (2005) suggest that the 
teratogenesis of SV is through its inhibition of Histone Deacetylase (HDAC). 
Furthermore, SV causes demethylation of DNA which occurs due to acetylation 
of H3 histones. DNA demethylation leads to alteration in gene expression  and 
various congenital anomalies (Detich et al., 2003). Therefore; it appears that these 
reports can explain only the results of high doses since the resorufin and protein 
amount was not affected in the dose range 500-1000µM. It may be that in the in 
vitro model there is no bioactivation of the drug, which make its effects appear 
mainly at high doses. 
The results show that SV had no significant effect on the length of neuronal 
processes at low doses. SV acts in a way similar to the action of neurotropic 
factors on CNS cells by stimulating the ERK pathway (extracellular signal 
regulated kinase). This is involved in neurite growth, neural stem cell 
proliferation and maturation, neurogenesis and neural regeneration and it also 
regulates neural survival. Moreover, SV has been shown to increase the level of 
protective bcl-2 protein in the CNS which enhance cell survival when exposed to 
adverse stimuli and promotes neuronal regeneration (Hao et al., 2004). This may 
explain the tendency to increase the process length at the doses which are near the 
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therapeutic range especially at 750µM. Murabe et al. (2007b) also supported this 
finding that SV can enhance neuronal differentiation in embryonic stem cell 
culture. Additionally, what mentioned above might explain that SV makes no 
significant changes on neuronal cell population which represented by Tubulin III 
protein. However, it decreases GFAP protein significantly at 1500 and 2000μM 
doses.  
This model of human neural stem cells can predict the anti-proliferative action of 
SV, even at its therapeutic doses, where there was a highly significant reduction 
in the sizes of treated neurospheres when compared with that of control group 
(Fig 37-D & 38). This study also shows that the neurosphere size decreased with 
increasing doses of SV. This may give human neural stem cell culture an 
advantage over other in vitro tests with its capability to predict neurotoxicity and 
teratogenicity of drugs. 
On the other hand, SV seems to reduce cell migration significantly at 1000µM 
and above (figure 37-G). The inhibition of cell migration is thought to be due to 
the indirect inhibition by SV of Glycogen Synthase Kinase 3 beta (GSK-3β) in 
the Wnt signaling pathway, which is involved in neural proliferation and cell 
migration (Blaheta et al., 2002, De Sarno et al., 2002). This inhibition is probably 
due to the changes in gene expression which are involved in several cell 
activities(Bosetti et al., 2005). Again, this model shows its ability to detect 
neurotoxicity of SV through this end point, which is related to one of the 
important cellular events in embryonic development that might be affected to 
produce anatomical and/or physiological defects in the growing embryo. 
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6.3.2 Phenytoin 
Phenytoin (PHN) was used as antiepileptic drug for more than 60 years. It acts by 
stabilizing the cell membrane of neurons undergoing seizure activity through 
inhibition of sodium influx to inside the cells and thus will prevent spreading 
seizure (Tunnicliff, 1996). It is well known for its teratogenicity and can cause a 
wide variety of anomalies in offspring. Several mechanisms have been proposed 
to explain this. One of these mechanisms involves the  formation of toxic 
intermediate metabolites, when PHN is bioactivated by Cytochrome P450 to 
arene oxide intermediates which should be detoxified by Glutathione S-
Transferases, otherwise they will covalently bind to embryonic protein and result 
in teratogenesis (Ozolins et al., 1995). In the second mechanism, PHN is bio-
activated by peroxidase, such as Prostaglandin H Synthase and Lipoxygenase, to 
free radicals which form reactive oxygen species that oxidize embryonic protein, 
DNA, and lipid which initiate teratogenesis. Also, the anti-folate activity of PHN 
can explain its toxicity (ibid). Additionally, unmetabolized PHN itself may 
interact with some receptors reversibly and induce congenital abnormalities 
(Ozolins et al., 1995). 
It appears from the results reported here that PHN does not affect the viability and 
protein content in doses from 5-200µM, taking in consideration that the 
therapeutic doses of PHN is 40-80µM (Yaari et al., 1986). But, it shows a 
significant reduction in cell viability and protein content at the dose of 250, 330 
and 660 µM. It appears that these doses are extremely toxic by causing distortion 
in cellular morphology and cell death. The cytotoxicity of PHN can be attributed 
to its inhibition of Ca
+2
 influx (SOHN and FERRENDELLI, 1973) which cause 
severe damage to the cytoskeleton (Schlaepfer, 1977). Furthermore, it inhibits or 
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change the phosphorylation status of Microtubule Associated Proteins (MAPs) 
which are involved in cell division, movement, the growth of neural processes 
and axons, transport of materials along the axons and dendrites, and also 
participates in preserving cell morphology (Bahn et al., 1993). Perturbation of 
cellular cytoskeleton by phenytoin might explain the tendency of this drug to 
decrease the length of neuronal processes with increasing the dose to be highly 
significant at high doses and explain the significant reduction in migration 
distance even at low therapeutic doses 50μM when compared with the control 
group.  
6.3.3 Carbamazepine 
Carbamazepine (CBZ) has been used for treatment a variety of disorders such as 
epilepsy, neuropathic pain, mania and other psychological illnesses. It is known to 
be a teratogen (Shepard et al., 2002) particularly causing neural tube defects, 
cardiovascular and urinary tract anomalies. It appears from the results that CBZ 
has no effect on both the cell viability and cell proteins especially in the doses 
which lie below, within, and slightly above the therapeutic dose. Normally, the 
therapeutic serum level which used as a target for treatment in epilepsy and mood 
disorders is 25-50µM (McNamara, 2001). But, at the dose 250µM and more, CBZ 
starts to affect cell viability, in which the resorufin production reduced 
significantly and the protein amount decreased to high extent. 
CBZ can modify the release, uptake, transmission and receptor binding of 
neurotransmitter in serotonergic, dopaminergic, and glutaminergic neurons 
(Ambrósio et al., 2002), therefore, modulation in neurotransmitters can affect 
critical aspects in CNS development, since neurotransmitters regulate 
proliferation of NSCs, control cell migration and cell differentiation (Nguyen et 
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al., 2001), this may explain the significant reduction in neurosphere sizes and in 
migration distance at 100μM dose which reside near the therapeutic dose. Also, it 
is well known as a HDAC inhibitor, like Sodium Valproate (Beutler et al., 2005), 
and its teratogenicity may be related to its anti-HDAC activity. CBZ has been 
identified to cause apoptosis to cultured cerebellar granular cells, by making DNA 
fragmentation in in a ladder pattern in a concentration dependant manner (Gao et 
al., 1995) and it is toxic to cultured hippocampal neuron in higher than the 
therapeutic doses (Araújo et al., 2004). It seems that its neurotoxicity is due to the 
blocking of NMDA-activated current, since this neurotoxicity can be prevented 
by NMDA treatment (Gao and Chuang, 1992). 
The results show that CBZ has a tendency to increases tubulin III but is 
statistically not significant, this agrees with the finding of (Murabe et al., 2007b) 
who pointed out that CBZ treatment for embryonic stem cells can enhance 
neuronal differentiation. On the other hand, CBZ appears to be toxic on astrocytes 
and neurons just at extreme high doses 375μM. In general, CBZ seems to have 
less developmental neurotoxicity in comparison with other AEDs. Its 
teratogenicity and embryo toxicity appears in poly therapy especially when 
combined with phenytoin by which the children of epileptic mother exposing to 
CBZ and PHN have lower developmental and language scores (Kaindl et al., 
2006). 
6.3.4 Phenobarbitone 
PHB is widely used in medicine for pregnant women and neonates for variable 
purposes including epilepsy. PHB can be used orally or by injection. The dose in 
adult is 60-240mg/day, which is the lowest dose to decrease its side effect. This 
dose is used to achieve a constant therapeutic plasma concentration at 40-130μM 
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(Finnell et al., 1987). Previous in vitro animal studies have shown biochemical 
and morphological changes in cultured neuronal cells after chronic exposure to 
PHB (Serrano et al., 1988). In our study, the neuronal marker, tubulin III, was not 
significantly affected by all the doses of PHB and the astrocyte marker, GFAP, 
was affected just at high doses. However, it was confirmed that PHB has 
neurotoxic effect in vitro and in vivo (Yanai et al., 1979, Bergey et al., 1981b). 
The neurotoxic mechanism of PHB is unclear, but there is a hypothesis that PHB 
blocks the action of trophic factors which are critical for neuronal survival, these 
growth factors are present in vivo and in vitro (Brenneman et al., 1987). Another 
mechanism is the blockage of electrical activity, which might reduce cell viability 
(Bergey et al., 1981a). Also, growth cone elongation process is dependent on Ca
+2
 
influx (Bolsover and Spector, 1986), and as mentioned before, PHB acts by 
inhibiting this influx into the neurons, prolonged inhibition may explain the 
reduction in neuronal process growth and branching (Serrano et al., 1988). 
Overall, it seems that neurotoxicity of PHB appears just with chronic exposure, 
more than 2 weeks (Neale et al., 1985, Bergey et al., 1981b, Serrano et al., 1988) 
and despite of its developmental neurotoxicity, its teratogenic effect on embryos 
is less than any other AEDs (Holmes et al., 2001). These studies pointed out that 
neurotoxicity of PHB is dose and time dependant, the toxicity increase with 
increasing the dose and the duration. This may explain the significant reduction in 
cell survival, total protein amount, cell migration, and other parameters only at 
high doses. 
Overall, human neural stem cell culture model is sensitive in detecting the 
neurotoxicity of sodium valproate and phenytoin within their therapeutic level, 
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while the neurotoxicity of carbamazepine and phenobarbitone were detected only 
at high levels 
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Chapter 7 
Evaluation of This Model with Anti-oxidants 
and anti-oxidants with Anti-epileptics 
 
 
 
 
 
 
 
 
 
 
 137 
 
7.1 The Anti-oxidants 
7.1.1 Folic acid 
Folic Acid (FA), pteroyl-L-glutamic acid, vitamin B9, folate, is made up of a 2-
amino-4-hydroxypterine (purine and pyrazine parts fused to form a pterin ring). 
The pterine moiety is fully oxidized, in vivo is reduced to 7,8 dihydrofolate 
(DHF), DHF is subsequently reduced to 5,6,7,8 tetrahydrofolate (THF), which is 
converted enzymatically into 5-methyltetragydrifolate (5-MTHF) (Gliszczyńska-
Świgło, 2007). Reduced forms of FA act as cofactors for the biosynthesis of 
purine, pyrimidine, and DNA (Stanger, 2002). The biochemical role of folate is 
well established in DNA synthesis and repair. It also, catalyses the reactions 
concerned with metabolism of nucleic acids and proteins (Stokstad, 1988). 
 
Figure 47: Folate, homocysteine, methionine metabolism; DHFR, dihydrofolate reductase; 
MTHF, methyltetrahydrofolte; MTHFR, methyltetrahydrofolate reductase (Van Gelder et al., 
2010). 
This vitamin has antioxidant properties (Gliszczyńska-Świgło, 2007) and by this 
activity, it has been proposed that FA can reduce the incidence of several diseases 
such as cardiovascular diseases (Verhaar et al., 2002), neurological and 
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psychiatric diseases (Alpert and Fava, 1997), and neural tube defects (Olney and 
Mulinare, 2002). It has been suggested that the protective properties of FA are 
related to its anti-oxidant activities (Joshi et al., 2001, Gliszczyńska-Świgło, 
2007) and due to its free radical scavenging activity (Joshi et al., 2001), since it 
has been recognized that free radicals play major roles in the oxidative stress 
which leads to several diseases (Stocker and Frei, 1991). FA has been reported to 
have activity against radical mediated oxidative damage in human blood (Stocker 
et al., 2003). As mammals do not have the necessary enzymes to produce FA de 
novo (Murray, 1999, Friedrich, 1988), its presence should depend entirely on 
external supplementation in the diet. Good sources of FA are green leafy 
vegetables, mushrooms, and liver (Gliszczyńska-Świgło, 2007) 
7.1.2 Melatonin 
Melatonin (N-acetyl-5-methoxytryptamine) derived from serotonin and is the 
main secretory product of the pineal gland at night. It was discovered by Lerner in 
1958 (Lerner et al., 1958). Its effect is well known with regard to circadian 
rhythmicity and reproductive function (Reiter et al., 2009, Dominguez‐Rodriguez 
et al., 2010). Additionally, it has been discovered to have direct free radicals 
scavenger activities and to detoxify the highly reactive hydroxyl radical (OH) in 
vitro (Tan et al., 1993). Reiter (1998) reported that melatonin acts as free radical 
scavenger for a wide range of free radicals. Moreover, it can reduce oxidative 
stress by stimulating antioxidant enzymes by mechanisms which are mediated by 
membrane receptors or through nuclear or cytosolic binding sites (Tomás‐Zapico 
and Coto‐Montes, 2005). 
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Figure 48: Mechanism of action of melatonin in nitro-oxidative stress. The oxygen reactants are 
in red, nitrogen reactant in blue, and chlorine reactant in green.  Melatonin is reported to 1. 
Scavenge the reactants marked with an asterisk. 2. Stimulate (↑) the anti-oxidative enzymes, like 
glutathione peroxidase (GPx). Glutathione reductase (GRd), and superoxide dismutase (SOD). 3. 
Increase the level of glutathione (GSH). 4. Inhibit the prooxidative enzymes nitric oxide synthase 
(NOS) and myeloperoxidase (MPO) (Reiter et al., 2009, Tomás‐Zapico and Coto‐Montes, 2005). 
NO., nitric oxide; CAT, catalase; 
1
O2 , singlet oxygen; O2
.-
, superoxide anion radical; GSSG, 
oxidized glutathione; hy, photic energy. 
Because of these properties, melatonin treatment has been tested to know if it can 
reduce the oxidative damage which happens in several neurological disorders and 
it seems to be effective (Reiter et al., 1998). Moreover, the ability to scavenge 
free radicals extends into its metabolites (Galano et al., 2013). In mammals, 
melatonin is not only produced by the pineal gland, but also by the retina and 
gastrointestinal tract (Reiter, 1991). The brain tissue expresses the key enzyme 
which is involved in melatonin synthesis, arlyalkylamine N- acetyltransferase 
(AA-NAT) (Jimenez‐Jorge et al., 2007) and a report suggests that its production 
is from glial cells (Liu et al., 2007). Its high concentration in the brain may be 
related to its neuroprotective function (Hardeland, 2012). Melatonin is not only a 
mammalian product, but could also be produced in non-mammalian vertebrates 
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and invertebrates, and therefore, it could be ingested (Reiter, 1998). The 
physiological concentration of melatonin is from 10
-9 
to 10
-11
M and the 
pharmacological concentration is 10
-7
-10
-5
M (Hill and Blask, 1988).  
Several diseases that happen during pregnancy may get benefit from melatonin 
treatment. Of particular note is preeclampsia, a major disorder which develops in 
5-7% of all pregnancies all over the world, which is characterized by elevated 
systolic and diastolic blood pressure and proteinurea in the second half of 
pregnancy (Brown et al., 2001). Given the antioxidant activity of melatonin, and 
ready transfer of melatonin from maternal to foetal circulation, its administration 
may be helpful in reducing the systemic oxidative stress which is associated with 
preeclampsia and it could rescue the developing nervous system of the foetus 
(Wakatsuki et al., 2001).  
In summary, Folic acid and melatonin have antioxidant and free radical 
scavenging activities; therefore, they have protective and reparative effect against 
several diseases, as mentioned before. And as sodium valproate and phenytoin 
treatment associated with oxidative stress; therefore, folic acid and melatonin will 
be added with them to the cells to know if they have protective effect or not. 
7.2 The results 
7.2.1 Folic acid 
Our study shows that FA throughout all the doses which lie below and above the 
therapeutic level has no significant effect on all the end points except the 
neurosphere size, where FA appears to increase the neurosphere size significantly 
at doses ≥50μM when it compared with the control, (F (5,12)=3.624, p=0.0314, 
post-hoc: 50µM vs control: p<0.05), (figure 49- D). 
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Figure 49: Effect of Folic acid at different doses on A: Resorufin production, B: Total protein. 
Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal processes. 
Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size changes 
with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP (Western 
Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days after drug 
treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 50: Western Blot analysis for the cells after Folic acid treatment showing the bands of 
Tubulin III, GFAP, and GAPDH proteins. 
7.2.2 Melatonin 
Melatonin treatment seems to have no significant effect on the end points except 
for the neurite length at the doses 10, 25μM, (F (5,12)=3.520, p=0.0344, post-hoc: 
10µM vs control: p<0.05), and (25µM vs control: p<0.05), and neurosphere size 
at the doses 5, 10, and 25μM, (F (5,12)=8.755, p=0.0011, post-hoc: 5µM vs  
control: p<0.05), in which there are significant increase in neurite length, and 
neurosphere size, when it compared with control group, as shown in figure 51. 
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Figure 51: Effect of Melatonin at different doses on A: Resorufin production, B: Total protein. 
Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal processes. 
Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size changes 
with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP (Western 
Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days after drug 
treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 52: Western blot image showing Tubulin III, GFAP, and GAPDH after Melatonin 
treatment to the cultured cells in different doses. 
7.2.3 Anti-epileptics and Anti-oxidants 
7.2.3.1 Sodium Valproate  
By comparing the result of SV alone treatment, figure 38, with the results of 
adding Folic acid (FA) to SV treated cells, it seems that adding FA makes an 
improvement in most of the end points. It appears that the cell survival and total 
protein amount reduction at 1500μM became not significance, but at 2000µM, 
cell viability was reduced significantly, (F (8,18)=4.143, p=0.0059, post-hoc: 
2000µM vs control: p<0.05) and total protein amount also was reduced 
significantly, (F (8,18)=9.544, p<0.0001, post-hoc: 2000µM vs control: p<0.01) 
respectively. Also, the neurite length appears not significantly affected throughout 
all the doses. In the case of neurosphere sizes, this study demonstrated that FA 
supplement with SV improves neurosphere size since there is no significant 
change in their sizes at 500, 750 and 1000μM compared to the control, but at 
1500µm the size reduction was significant, (F (6,14)=19.85, p<0.0001, post-hoc: 
1500µM vs control: p<0.01). Additionally, GFAP protein reduction became 
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significant at 2000μM, (F (6,14)=2.479, p=0.0758, post-hoc: 2000µM vs control: 
p<0.05), and cell migration appears to be significantly affected at 1500μM, (F 
(6,24)=2.445, p=0.0500, post-hoc: 1500µM vs control: p<0.05), figure 53 and 54. 
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Figure 53: Effect of Sodium valproate at different doses + Folic acid (50µM) on A: Resorufin 
production, B: Total protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The 
length of neuronal processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The 
neurosphere size changes with different doses. Mean ± SE, n=3 (average 10 from each 
experiment), E: GFAP (Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: 
Cell migration 2 days after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 54: Western blot image showing Tubulin III, GFAP, and GAPDH after Sodium valproate 
and folic acid treatment to the cultured cells in different doses 
Similarity, adding melatonin, to some extent had the same effect of adding FA to 
SV treated cells, but in melatonin supplement, it seems that the improvement in 
cell survival and total protein amount reached higher doses, 2000μM, in which, it 
appears to be not significant from control group, and at 2500µM, both cell 
viability, (F (8,18)=8.592, p<0.0001, post-hoc: 2500µM vs control: p<0.0001) 
and also the total protein amount, (F (8,18)=4.412, p=0.0043, post-hoc: 2500µM 
vs control: p<0.01), were significantly reduced figure 55. 
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Figure 55: Effect of Sodium valproate at different doses + Melatonin (10µM) on A: Resorufin 
production, B: Total protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The 
length of neuronal processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The 
neurosphere size changes with different doses. Mean ± SE, n=3 (average 10 from each 
experiment), E: GFAP (Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: 
Cell migration 2 days after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 56: Western blot image showing Tubulin III, GFAP, and GAPDH after Sodium valproate 
and Melatonin treatment to the cultured cells in different doses 
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7.2.3.2 Phenytoin  
PHN treated cells appears to get beneficial effect after adding FA to them, it 
seems that cell survival became not significant at 150 and 200μM unlike what 
happened with PHN treatment alone, however cell survival started to be 
significant at 250µM, (F (8,18)=11.60, p<0.0001, post-hoc: 250µM vs control: 
p<0.01), figure 41. Total protein amount appeared to be not significantly affected 
throughout all the doses. The neurite length reduction at 200μM seems to be 
significant, (F (6,14)=4.849, p=0.0071, post-hoc: 200µM vs  control: p<0.01), 
also, the neurosphere size started to be significant at 100μM when it was 
compared to the control group, (F (6,14)=28.85, p<0.0001, post-hoc; 200µM vs 
control: p<0.05). Our results show no changes on the result of GFAP and tubulin 
III proteins in comparison with PHN treatment alone. Regarding the effect on cell 
migration, it appears that migration distance was significantly reduced at 100µM, 
(concentration vs time: F (6,28)=7.628, p=0.0003, post-hoc: 100µM vs control: 
p<0.0001), figure 57 and 58. 
On the other hand, adding melatonin to PHN treated cells had the same changes 
of adding FA to the cells relatively, except the effect on GFAP was not significant 
at 100μM when it compared to PHN treatment alone, but significantly reduced 
from 150µM, (F (4,14)=8.560, p=0.0005, post-hoc: 150µM vs control: p<0.05), 
figure 59 and 60. 
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Figure 57: Effect of Phenytoin at different doses + Folic acid (50µM) on A: Resorufin 
production, B: Total protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The 
length of neuronal processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The 
neurosphere size changes with different doses. Mean ± SE, n=3 (average 10 from each 
experiment), E: GFAP (Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: 
Cell migration 2 days after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 58: Western blot image showing Tubulin III, GFAP, and GAPDH after Phenytoin and 
folic acid treatment to the cultured cells in different doses 
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Figure 59: Effect of Phenytoin at different doses + Melatonin (10µM) on A: Resorufin 
production, B: Total protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The 
length of neuronal processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The 
neurosphere size changes with different doses. Mean ± SE, n=3 (average 10 from each 
experiment), E: GFAP (Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: 
Cell migration 2 days after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 60: Western blot image showing Tubulin III, GFAP, and GAPDH after Phenytoin and 
melatonin treatment to the cultured cells in different doses 
7.3 Discussion 
7.3.1 Folic acid 
It appears from these findings that folate administration increased the sizes of 
neurospheres from the dose of 25μM and more. It has been considered that 18μM 
of FA is low concentration while >70μM as high concentration (Liu et al., 2010, 
Luo et al., 2013). This means that folate supplement to the medium may stimulate 
neural stem cell proliferation to make the neurosphere larger than those without 
folate supplementation. It has been reported that anti-folate treatment like 
methotrexate inhibits embryonic neural stem cell proliferation in cell culture 
(Kruman et al., 2005), while folate treatment can enhance proliferation in these 
cells (Sato et al., 2006). Liu found that folic acid supplementation to rat 
embryonic NSCs can stimulate them to proliferate and maintain their stemness in 
the presence of basic fibroblast growth factor in the medium. Also, he found that 
FA treatment increased the percentage of nestin/BrdU double positive cells in 
embryonic neurospheres (Liu et al., 2010). This study shows that FA 
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supplementation has no significant effect on GFAP and tubulin III proteins at all 
doses and this may be due to the suggestion that FA supplementation may 
enhance both neurogenesis and gliogenesis through stimulation of Notch1 
signalling pathways in embryonic NSCs (Liu et al., 2010). It has been found that 
genetic disruption of Notch signalling leads to a reduction in NSC markers and an 
increase in neuronal cell markers (Yoon and Gaiano, 2005). However, it has been 
shown that FA supplementation to rat embryonic NSCs enhances the stem cell 
differentiation into neuronal cells at the expense of astrocyte cells (Luo et al., 
2013), which disagrees with our findings. 
Low intake of folate during pregnancy may lead to CNS pathologies (neural tube 
defects) and other neurological disorders which appear later on such as seizures, 
dementia, and depression (Djukic, 2007, Ho et al., 2003, Clarke, 2006). 
Therefore, it is recommended for women who are or may become pregnant to 
take folic acid daily to protect the foetus from having neurodevelopmental 
abnormalities, since FA is involved in several processes in DNA biosynthesis 
such as enhancing de novo pathways (Sato et al., 2006).  
It has been considered that 18μM of FA can be considered as a low concentration 
while >70μM as a high concentration (Luo et al., 2013, Liu et al., 2010), therefore 
the concentration of 50μM of FA was used here as an intermediate value between 
them. 
 It appears that adding Folic acid to  SV cultured cells has to some  beneficial 
effects on the end points that are being testing (figure 53) when compared to the 
results with SV treatment alone figure (38). Since SV has an anti-folate effect 
(Van Gelder et al., 2010), addition of FA can explain this improvement in these 
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parameters. Additionally, FA controls intracellular signalling pathways which 
regulate mitosis and apoptosis (Ho et al., 2003). It has been found that FA 
treatment increased mRNA expression of Notch signalling in neurospheres 
derived from NSCs of the rat (Zhang et al., 2008). The Notch pathway is 
important for cellular communication that involves gene regulation which in turn 
regulates cellular differentiation. The Notch gene has the ability to suppress 
apoptosis and stimulates cell proliferation through a growth factor- mediated 
survival pathway (Liu et al., 2010). This may explain the improvement against the 
neurotoxicity of SV. 
Moreover, by comparing the results of PHN treatment alone figure (41) with the 
results of adding FA to PHN figure (57), it seems that adding FA also allows an 
improvement in the outcome of PHN treatment. PHN has a well- known 
mechanism of action as an anti-folate agent, as it impairs folate absorption and 
reduces methionine synthase activity (Van Gelder et al., 2010). Therefore adding 
folic acid to PHN treated cells can improve the neurological end points that are 
being tested. PHN as mentioned before, can lead to the generation of oxidative 
stress and release free radicals by bioactivation of PHN by cytochrome P450 into 
arene oxide intermediates (Ozolins et al., 1995), FA has antioxidant activity 
(Gliszczyńska-Świgło, 2007) and has free radical scavenging capacity (Joshi et 
al., 2001, Stocker et al., 2003) and these might explain why FA treatment with 
PHN could have some protective effect against PHN teratogenicity. 
7.3.2 Melatonin 
This study demonstrates that melatonin supplementation alone to the cultured 
cells has no significant effect on cell viability and total protein, but, causes a 
significant increase in neuronal process length. It has been assumed that 
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melatonin stimulates dendritogenesis in an organotypic culture of hippocampus 
(Domínguez‐Alonso et al., 2012), and, it can promote neuritogenesis through 
vimentin filament reorganization by protein kinase C (PKC) activation and 
microfilament rearrangement, which are necessary process in growth cone 
formation in neurite outgrowth (Bellon et al., 2007). This study also shows that 
melatonin increases the sizes of neurospheres significantly, which means that 
melatonin stimulates NSCs proliferation. It has been reported that melatonin 
enhanced cell proliferation in embryonic neural stem cells (Fu et al., 2011, 
Sotthibundhu et al., 2010), avian astrocytes (Paulose et al., 2009), dentate neurons 
(Kim et al., 2004b), and mesenchymal stem cells (Zhang et al., 2013). It has been 
suggested that melatonin stimulates proliferation through receptor dependant 
signalling pathways (Fu et al., 2011) by phosphorylating the extracellular 
signalling regulated kinase (ERK1/2), which in turn activates several 
transcriptional factors that regulate the downstream proliferative activity (Pandi-
Perumal et al., 2008).  
By comparing the results obtained from Sodium Valproate treatment in figure 
(38) with the results of adding melatonin (10μM- pharmacological dose) to it 
(figure 55), it seems that melatonin exerts some neuroprotective effects on SV 
treated cells. These results show that melatonin reduced the neurotoxicity of SV 
in regard to cell viability, total protein amount, neuronal process length, 
neurosphere sizes, GFAP and migration distance. SV treatment of chick cardiac 
cells and embryonic stem cells can lead to generation of reactive oxygen species 
(Qureshi, 2012). This may explain the improvement of SV neurotoxicity on 
human treated cells after adding melatonin. As mentioned before, melatonin has 
antioxidant (Tomás‐Zapico and Coto‐Montes, 2005) and free radicals scavenging 
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activity to a wide range of free radicals (Reiter, 1998), therefore, melatonin can 
inhibit apoptosis (Mayo et al., 1998). Moreover, the anti-apoptotic activity of 
melatonin is related to increased expression of Bcl2 and inhibition of caspase-3 
activation (Fu et al., 2011). 
Similarly, melatonin supplementation of PHN treated cells can demonstrate 
beneficial effect against the neurotoxicity of PHN in cultured cells in the end 
points that were tested, see figure (41) for the result of adding melatonin to PHN 
figure (59).   
Lastly, it can deduce that combining either folic acid or melatonin to sodium 
valproate or phenytoin has protective effect in reducing the neurotoxicity of these 
anti-epileptics and cause their toxicity to appear in doses which are higher than 
those when these anti-epileptics used alone.    
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Chapter 8 
Evaluation of This Model with Other 
Neuroactive Drugs 
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8.1 Other Neuroactive Drugs 
8.1.1 Lithium Carbonate 
Lithium is a classic mood stabilizer and has been used for the treatment of bipolar 
diseases for more than 50 years. Now it is used for acute episodes, prevention and 
as a prophylactic drug. It was introduced into the psychiatric pharmacy by John 
Cade in 1949 (Shorter, 2009). Its efficiency in the treatment of bipolar disorder 
was well documented but the exact mechanism of its action in mood stabilization 
was still not clear. Lithium has been registered to be teratogenic since the 1960s 
(Lewllyn A; Stowe Z, 1998). The serum therapeutic concentration in human 
ranges from 600-1200μM (Su et al., 2007b) and there is only a small gap between 
the therapeutic and toxic doses. Chronic administration of lithium may lead to 
developmental malformation (Giles and Bannigan, 2006). This drug is associated 
with a spectrum of developmental anomalies, such as cardiac abnormalities 
including Ebstein anomaly, and increased baby weight. Animal studies showed 
that high doses of lithium can inhibit vasculogenesis  (Giles and Bannigan, 2006). 
In mice, when lithium was given during the critical period of neural tube closure, 
it caused exencephaly, kinking of the spinal cord and dilatation of the ventricular 
system  (Jurand, 1988). Recent studies showed that Lithium has a neuroprotective 
role in many neurological diseases including brain ischemic disease and 
depression. It has been shown that lithium improved the neurological deficits, 
behavioural disorders and can decrease the size of infarcted area in ischaemic 
attacks by enhancing neurogenesis and stimulating hippocampal neural progenitor 
cell differentiation into neural cells in vivo and in vitro  (Kim et al., 2004a). 
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8.1.2 Diazepam 
Diazepam (DZP) is one of benzodiazepine derivatives which has been used for 
treatment of different clinical disorders as an anxiolytic, muscular relaxant, 
sedative-hypnotic and as an anticonvulsant (Haefely et al., 1981).  It has also been 
used in managing preeclampsia and eclampsia (Iqbal et al., 2014). DZP belongs to 
the long acting type of benzodiazepine, which has interestingly been suggested to 
be excreted in breast milk and can also pass smoothly through placenta to the 
fetus (Iqbal et al., 2014). It has been reported that this drug may associate with 
neural tube closure defects in explanted chick embryo (Nagele et al., 1981). Also, 
it can induce exencephaly in the mouse and hamster (Weber, 1984), while in 
human, an epidemiological study has shown that DZP may contribute to various 
congenital anomalies such as neural tube closure defects, cleft palate, pyloric 
stenosis, cardiovascular, skeletal and urogenital anomalies (Kjær et al., 2007). 
Another epidemiological study reported that maternal exposure to DZP might 
resulted in ‘Neonatal withdrawal syndrome’ and embryofetopathy which 
resembles foetal alcohol syndrome (Iqbal et al., 2014). 
Both Diazepam and its metabolite, N-desmethyldiazepam, are pharmacologically 
active and can pass freely through the human placenta because of their 
lipophilicity and they are more highly bound to foetal plasma proteins than to 
maternal plasma proteins (Kunz and Nau, 1984). High concentrations of DZP can 
be found in the brain, lung and heart. Its lipophilicity allows easy penetration to 
the brain white matter and its long retention in the neural tissue make human 
brain tissue a depot for DZP. Neonates can metabolize small doses of DZP slowly 
and it has been shown that DZP and its metabolites can last for at least a week in 
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their active form after administration in a high dose to the mother. The plasma 
half-life in the neonate is about 31 hours (Mandelli et al., 1975) 
8.1.3 Amitriptyline 
Tricyclic antidepressant (TCA) drugs have been used for the treatment of 
depression for over 50 years. Amitriptyline (AMT) after much  research since that 
time is still the leading antidepressant(Barbui and Hotope, 2001). Most of the 
antidepressants act by inhibition of reuptake of neurotransmitters (noradrenaline 
and serotonin) in presynaptic spaces. By this means, the extracellular content of 
these monoamines is increased, which occurs soon after treatment, but the clinical 
effect of these antidepressants occurs slowly over several weeks of continuous 
administration (Nestler et al., 2002). The effectiveness of TCA cannot be 
explained simply by their action on monoamines. The molecular and cellular 
mechanisms of their antidepressant action are still not fully understood. The 
therapeutic level of AMT in human plasma is 0.5-0.8μM (Ziegler et al., 1976) and 
the toxic concentration is more than 3μM (Braithwaite et al., 1979).  
Women have been identified to be at risk of developing depression during 
pregnancy and during the postpartum period. Women who report symptoms of 
depression during pregnancy comprise about 12%. Additionally, of women who 
develop depression in the postpartum period, 40% develop depression originally 
during gestation (Chambers et al., 1996). Studies showed that women who are  
known cases of depression who discontinue treatment during pregnancy show a 
high relapse rate compared to those who continue treatment (Cohen et al., 2006). 
There are significant maternal risks during pregnancy if depression is left 
untreated. Suicides have been reported as a major cause of maternal death in 
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several studies (Shadigian and Bauer, 2005, Oates, 2003). Maternal depression is 
associated with several factors which have a negative impact on foetal wellbeing, 
such as poor attendance at antenatal clinics, smoking, drug abuse, and alcohol 
(Bonari et al., 2004). Moreover, maternal depression may be associated with 
obstetric complications like preeclampsia (Kurki et al., 2000). Maternal 
depression is also associated with poor maternal-infant attachment and poor child 
outcome (Murray and Cooper, 1997). 
These molecules lithium, diazepam, and amitriptyline are weak teratogens. We 
will use these molecules with our cell culture model to test their effect on the end 
points of our experiment. 
8.2 Results 
8.2.1 Lithium 
Lithium treatment seemed to reduce cell survival significantly at the dose of 
3000μM and more, (F (7,16)=11.22, p<0.0001, post-hoc: 3000µM vs control: 
p<0.01). On the other hand, total protein was significantly increased at 500 and 
750μM, (F (7,16)=37.69, p<0.0001, post-hoc: 500µM vs control: p<0.05), and 
(750µM vs control: p<0.05), which is located around the therapeutic plasma level. 
The figure below shows there was no significant effect on neuronal process and 
neurosphere sizes, (F (5,12)=3.091, p=0.0507( and (F (5,12)=4.643, p=0.0137) 
respectively. The results demonstrated no significant effect on tubulin III protein, 
(F (5,12)=0.3989, p=0.8404) but caused a significant dose dependant reduction in 
GFAP protein started from 1500µM, (F (5,12)=11.56, p=0.0003, post-hoc: 
1500µM vs control: p<0.01).  The figure below illustrates that lithium treatment 
caused a significant increase in migration distance 48 hours after treatment at the 
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dose of 750μM, (F (5,24)=4.691, p=0.0040, post-hoc: 750µM vs  control: p<0.05) 
and resulted in significant reduction in cell migration 24hrs after treatment, (F 
(5,24)=4.691, p=0.0040, post-hoc: 2000µM vs control: p<0.05), and 48hrs 
(P<0.0001) after treatment with 2000μM, figure 61 and 62. 
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Figure 61: Effect of Lithium at different doses on A: Resorufin production, B: Total protein. 
Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal processes. 
Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size changes 
with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP (Western 
Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days after drug 
treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 62: Western Blot Image illustrating GFAP, tubulin, and GAPDH after treating the cells 
with Lithium. 
8.2.2 Diazepam 
The results demonstrate that DZP treatment had no significant effect on cell 
survival and total protein at all doses, But from the dose of 100μM, cell survival, 
(F (7,16)=6.568, p=0.0009, post-hoc: 100µM vs control: p<0.01), total protein, (F 
(7,16)=17.74, p<0.0001, post-hoc: 100µM vs control: p<0.001), neuronal process 
length, (F (5,12)=6.351, p=0.0042, post-hoc: 100µM vs control: p<0.05), and 
neurosphere sizes, (F (5,12)=127.5, p<0.0001, post-hoc: 100µM vs control: 
p<0.0001) were reduced significantly when compared with the control group. 
There was no significant effect on both GFAP, (F (5,12)=0.3060, p=0.9000), and 
tubulin III proteins, (F (5,12)=0.4165, p=0.8285). While cell migration distance 
was not affected at any dose other than at the highest dose (200μM) and only 48 
hours after treatment, (F (5,24)=1.301, p=0.2965, post-hoc: 200µM vs control: 
p<0.001), figure 63 and 64. 
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Figure 63: Effect of Diazepam at different doses on A: Resorufin production, B: Total protein. 
Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal processes. 
Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size changes 
with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP (Western 
Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days after drug 
treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 64: Western blot image showing Tubulin III, GFAP, and GAPDH after Diazepam 
treatment to the cultured cells in different doses 
8.2.3 Amitriptyline 
Cell survival,  (F (7,16)=71.80, p<0.0001, post-hoc: 5µM vs control: p<0.001), 
total protein, (F (7,16)=58.27, p<0.0001, post-hoc: 5µM vs control: p<0.0001), 
and neurosphere size, (F (5,12)=9.015, p<0.0009, post-hoc: 5µM vs control: 
p<0.05) were significantly decreased at 5 μM and more. The effect of AMT 
treatment on neuronal process length, (F (5,12)=35.34, p<0.0001, post-hoc: 
2.5µM vs control: p<0.050 appeared to be significant at lower doses; they were 
seen at 2.5μM and more. Also, AMT reduce cell migration distance in time 
dependant way, (F (1,24)=106.9, p<0.0001), and dose dependant, (F 
(5,24)=7.306, p=0.0003). At 2.5µM, AMT reduce and cell migration 
significantly, (concentration vs time: F (5,24)=1.031, p=0.4222, post-hoc: 2.5µM 
vs control: p<0.05). Additionally, AMT appeared to have no significant effect 
either on GFAP, (F (5,12)=0.4591, p=0.7992) or tubulin III proteins, (F 
(5,12)=0.1086, p=0.9883), when compared with the control group, figure 65 and 
66. 
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Figure 65: Effect of Amitriptyline at different doses on A: Resorufin production, B: Total 
protein. Mean± SE. n=3 (average 6 wells from each experiment), C: The length of neuronal 
processes. Mean ± SE. n=3 (average 35 neurons from each experiment), D: The neurosphere size 
changes with different doses. Mean ± SE, n=3 (average 10 from each experiment), E: GFAP 
(Western Blotting); n=3, F: Tubulin protein (Western Blotting); n=3, G: Cell migration 2 days 
after drug treatment, mean ± SE. n= 3 (average 6 from each experiments).  
Significance: * when P<0.05, ** when P<0.01, *** when P<0.001, and **** when P<0.0001. 
A-F statistical analysis was performed by using One way ANOVA, while in G, two way ANOVA 
was performed, then Dunnett multiple test was used to compare the mean of each group with that 
of control group. 
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Figure 66: Western blot image showing Tubulin III, GFAP, and GAPDH after Amitriptyline 
treatment to the cultured cells in different doses 
 
8.3 Discussion 
8.3.1 Lithium Carbonate 
Lithium Carbonate was considered to be a weak teratogenic substance that is 
associated with several congenital anomalies, especially cardiovascular (Giles and 
Bannigan, 2006) and nervous system malformation (Jurand, 1988). Animal 
studies showed that treatment with lithium at a dose close to the human 
therapeutic dose did not demonstrate any congenital defects but higher doses were 
associated with a lot of skeletal, neurological, vascular and cardiac abnormalities 
(Giles & Bannigan, 2006). 
The results reported here reveal that Lithium Carbonate has no significant effect 
on the cell viability at the doses which are close to the therapeutic range, while it 
seems that lithium treatment leads to a significant increase in total protein at the 
doses 500 and 750μM. It has been suggested that Lithium has a neuroprotective 
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effect in mood disorders and has been used for the treatment of these disorders for 
several decades. It acts by inducing several molecular and biochemical effects on 
neurotransmitter signalling, signalling cascades, gene expression, ion exchange 
and hormonal and circadian regulation (Manji and Lenox, 2000). Lithium 
treatment shows an increase in the volume of the grey matter in many areas in the 
brain which are involved in mood regulation, by stimulating proliferation of 
neural progenitor cells and enhancing neurogenesis through different mechanisms 
(Su et al., 2007b). Lithium inhibits GSK directly by binding to its magnesium-
sensitive site (Klein and Melton, 1996) and indirectly by enhancing 
phosphorylation of this kinase (Chalecka-Franaszek and Chuang, 1999). It has 
been postulated that GSK dysfunction is involved in pathogenesis in mood 
disorders (Jope, 2011).  
Moreover, lithium exerts its neuroprotective effect through induction of BDNF 
and stimulation of its receptor. Lithium protects primary cortical neurons from 
glutamate excitotoxicity and using a BDNF neutralizing antibody deprived the  
cells from neuroprotection (Hashimoto et al., 2002). Additionally, Lithium 
controls GDNF in vivo and in vitro, which is involved in maintaining cell 
survival, axonal growth, chemo- attraction, and cell migration (Paratcha and 
Ledda, 2008). This drug has an anti-apoptotic activity by upregulation of mRNA 
expression of the Bcl2 anti-apoptosis protein, decreasing the expression of P53, 
which is a pro-apoptotic protein and reducing mitochondrial release of 
cytochrome c (Chen and Chuang, 1999). Lithium prevents the activation of 
caspase-3 which leads to mitochondrial release of cytochrome c which induces 
apoptosis. Also it can modify NMDA receptor activity (Hashimoto et al., 2003). 
Another mechanism of action for lithium, is activation of PI3K/Akt, MEK/ERK, 
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Wnt/β-catenin pathways which enhance release of anti-apoptotic factors and 
induce growth production (Chiu et al., 2013). These mechanisms may explain the 
significant increase in total protein, neurosphere size, and migration distance in 
the treated cells. 
Lithium appears to not affect the length of neuronal processes even at a high dose 
(2000µM) and this agrees with (Jeerage et al., 2012) who pointed out that lithium 
has no effect on neurite length of rat cortex progenitor cells in this range of doses, 
but at high doses (10mM and more) lithium treatment resulted in significant 
reduction in neurite length. The effect on GFAP and tubulin III proteins would 
indicate that lithium is toxic to astrocytes since GFAP expression decreased in a 
dose dependant way, which may explain its teratogenicity, but had no significant 
effect on tubulin III, since it has neuroprotective effect. 
8.3.2 Diazepam 
Diazepam (DZP) acts in various ways to exert its actions. Its anticonvulsant 
property is explained by reducing action potential firing (Drexler et al., 2010), and 
it enhances GABAergic inhibition in dose dependant way (Skerritt et al., 1984). A 
study on genetically modified mice showed that DZP treatment resulted in 
hypnosis and sedation by acting on GABAA receptors, which are located in 
glutamatergic cortical neurons (Baur et al., 2008). Additionally, it caused Na
+
 
current disruption in the neurons of the CNS (Nagele et al., 1981). DZP has been 
shown to inhibit Ca
+2
 uptake by synaptosomes; therefore, it may result in a 
reduction of neurotransmitter release which results in suppression of spontaneous 
firing (Skerritt et al., 1984). DZP also, enhances the inhibitory transmission of 
synapses and reduces neuronal activity and cerebral cortex excitability, this may 
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explain the key mechanism of DZP to produce sedation and hypnosis (Baur et al., 
2008). 
The therapeutic plasma level of DZP as an anxiolytic agent is 0.35-6.0μM 
(http://www.nhtsa.dot.gov/people/injury/research/job185drugs/diazepam.htm) and 
as an anticonvulsant is around 50µM (Regan et al., 1990). The results show that 
DZP had no effect on cell viability and total cellular proteins at the doses 1, 5, 20, 
50µM, but, there is significant reduction  in those parameters at doses 100µM and 
200µM. Regan et al. (1990) pointed out that DZP has an anti-proliferative action 
on cells lines derived from  mouse cultured brain cortex at a concentration 2-3 
fold higher than the therapeutic concentration. In addition to that, this drug can 
suppress the proliferation of human Glioblastoma cells in a dose dependant way, 
by inducing Go/G1 phase arrest (Chen et al., 2013). This may explain the 
significant reduction in neurosphere size at the doses 100 and 200μM. Regarding 
the effect of DZP on the length of neuronal processes, the results demonstrate that 
DZP has no significant effect statistically on the length, except at high 
doseswhere the length was reduced significantly. Additionally, it appears that 
DZP has no significant effect on both GFAP and tubulin III proteins when 
compared with that of control group. 
In general, DZP is considered to be safe and studies have reported that there is no 
association between DZP exposure during pregnancy and major congenital 
malformation even in the first trimester of gestation (Bellantuono et al., 2013). 
However, another study suggested that that DZP would be safe if it had been used 
in small dose and for short duration and it recommended to avoid DZP 
administration at high doses for long duration (Iqbal et al., 2014). 
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8.3.3 Amitriptyline 
As there are high risks on both mothers and babies if depression is left untreated 
during pregnancy, clinicians have become aware of the importance of treating 
depressed mothers. Several studies have shown fetal exposure to antidepressants 
during pregnancy by placental passage (Hendrick et al., 2003) and through 
amniotic fluid analysis (Loughhead et al., 2014). In general it seems that the 
association between prenatal exposure to antidepressants and abnormal 
development is not clear and needs more investigation and studies. 
It appears that AMT has no significant effect on all the parameters tested at the 
doses which are around the therapeutic level (0.5-1μM). Cell survival and total 
protein were reduced significantly after 5μM. This agrees with (Braithwaite et al., 
1979), who reported that AMT is toxic >3μM. It has been proposed that AMT 
triggers apoptosis in neuronal cells, glioma C6 cells, and even lymphocytes 
(Spanova et al., 1996, Xia et al., 1998, Post et al., 2000). AMT has been shown to 
increase the generation of reactive oxygen species and decrease intracellular 
glutathione levels and consequently it reduces the antioxidant capacity of the 
cells. Also it has been suggested that AMT activates NF-kB subsequently, which 
is a transcriptional factor that when activated induces cell death and it is 
considered as a pro-apoptotic factor (Post et al., 2000). AMT treated cell culture 
showed mitochondrial depolarization, release of cytochrome c and activation of 
caspase-3, which are markers of apoptosis (Lirk et al., 2006). This may explain 
the significant reduction in cell survival, total protein and neurosphere size. 
Moreover, AMT treatment resulted in a significant reduction in the length of 
neuronal processes at the dose of 2.5μM and neurite length reduction was dose 
dependant. This agrees with the studies on chick and rat cerebrum (Farbman et 
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al., 1988). It has been believed that AMT reduces adenylate cyclase, which is 
crucial for neurite growth (Wong et al., 1991). The results also show that AMT 
has no significant effect on both tubulin III and GFAP proteins. This is may be 
due to  this drugs is toxicity which may and trigger cell death for both neuronal 
(Post et al., 2000) and glial cells (Spanova et al., 1996) equally. 
It seems that these neuroactive molecules do not have any toxic effect within their 
therapeutic level and the toxic effect appeared only at high doses which are higher 
than the therapeutic level. 
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Chapter 9 
General Discussion 
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General Discussion 
The development of the nervous system includes a series of sophisticated and 
critical events such as gene expression, neural stem cell proliferation, cell 
interactions, cell differentiation, cell migration and neural process formation and 
elongation (Sanes, 2006). Early exposure of the developing nervous system to 
chemicals which interfere with these events may result in developmental 
neurotoxicity (DNT). There is increasing concern about the association between 
environmental exposure to chemicals and a broad spectrum of congenital 
abnormalities including learning difficulties and neurodevelopmental disorders 
including autism, attention deficit and hyperactivity syndrome (Grandjean and 
Landrigan, 2006). Presently, there are more than 30000 chemicals in the markets 
of Europe, Canada and the USA for which there are little toxicity data (Judson et 
al., 2009). The USA and European Regulatory Agencies developed guidelines for 
in vivo studies to evaluate the developmental neurotoxicity of chemicals (USEPA, 
1998) and (OECD, 2007); these guidelines specify studying behavioural and 
neuropathological endpoints in the offspring of rodents treated with these 
chemical during pregnancy and lactation.  
These traditional in vivo studies (animal based) are impractical for the huge 
number of chemicals that are produced annually. It would be expensive, time 
consuming, requiring a large amount of chemical to be used in the experiments 
and needing a large number of animals to be sacrificed. Therefore, according to 
the 3R principle (Reduction, Replacement, and Refinement) of Russell and Burch 
1959 (Russell WMS, 1959), alternative testing strategies are required to reduce 
animal numbers and to establish other methods which should be cheaper, quicker, 
and yet still sensitive. In 2007 the National Research Council’s (NRC) Committee 
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on Toxicity Testing and Assessment of Environment Agents adopted this strategy 
and cited the need for in vitro tests which can prioritize the chemicals that need 
further investigation (NRC, 2007). REACH (Registration, Evaluation, 
Authorisation and Restriction of Chemicals) legislation also prompted the need 
for a new strategy (Hartung, 2009). Until recently, in vitro tests for studying the 
effects of chemicals on the development of the nervous system were mainly 
limited to transformed cell lines from human or rodents, these cell lines being 
derived from tumours and  not necessarily reflecting  normal neural cells.  
Neural tissue culture was used for the first time more than 100 years ago for the 
purpose of studying neural process growth (Harrison et al., 1907). In order to 
achieve an in vitro test with a high level of predictability for developmental 
neurotoxicology, a test should ideally recapitulate the whole process of 
development of the human nervous tissue, including proliferation, migration, 
differentiation, and synaptogenesis. Deriving such a test is challenging. Human 
neural stem cells have been proposed for this purpose; they can offer several 
advantages over the other in vitro tests in providing a good source of normal cells 
which have the ability to divide and differentiate into the other cells of the central 
nervous system. Also these cells may have a better predictive power in detecting 
human neurotoxicity, since the extrapolation of the results is less (Breier et al., 
2010) as species differences are circumvented (Coecke et al., 2007). 
The end points in neurotoxicology are divided into two groups: general and 
specific. The general tests are related to the basal level of cell functioning which 
are indicators for cell survival. These tests are nonspecific and could be the end 
points for other non-neuronal cells and may be for all eukaryotic cells. These 
include: test for mitochondrial function, total cellular proteins, reactive oxygen 
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species, cell-cell communications, energy regulation (oxidation-reduction status), 
ion transport, cell respiration, …etc. (Harry et al., 1998).  
On the other hand, there are specific end points which are peculiar to the cells of 
the nervous system, such as differentiated neural cells. Among these tests is the 
measurement of process outgrowth which receive the most attention since axonal 
and dendritic processes are the hallmarks of neural morphology and critical in cell 
connectivity and function. Neurite outgrowth is a critical event in nervous system 
development, in which neurons extend specialized processes to establish contacts 
(synapses) and facilitate the flow of information throughout the neural network 
(Sanes, 2006). Neurites refer to both axons and dendrites that are sprouted from 
the cells growing in culture; they are critical in defining the morphology of 
neurons. Abnormalities in the morphology of the neurites have been found after in 
vivo exposure of laboratory rodents to developmental neurotoxicants (Morrow et 
al., 2005). Neurite outgrowth has been studied in vitro using a variety of neural 
cell culture models such as tumour derived or transformed neural cell lines (e.g. 
PC-12) and dissociated primary cultures from developing animals (Radio and 
Mundy, 2008). In the present study, primary neural stem cells have been used as a 
new model to study neurite outgrowth after exposure to chemicals which are 
known to be teratogenic, such as sodium valproate. 
Neuronal proliferation is another event in nervous system development; alteration 
in this by genetic, environmental or chemical influences can result in 
developmental abnormalities and neurotoxicity (Barone Jr et al., 1999). 
Therefore, cell proliferation can be a target for neurotoxicant chemicals and could 
be incorporated as an endpoint in in vitro screening batteries. Neural cell 
proliferation has been used in several studies as an end point to detect the 
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neurotoxic potential of chemicals (Costa et al., 2007, Jacobs and Miller, 2002). 
Cellular proliferation is controlled by multiple factors which affect the cell cycle 
(Ohnuma and Harris, 2003) and represents a potential site of action for chemicals. 
Since the mechanism(s) of action of different chemicals on cell proliferation are 
often unknown, detecting the effect of these chemicals regardless the site of 
action would be a suitable endpoint for screening purposes. 
Cell migration is another essential process in development of the nervous system. 
Neural cells migrate within the developing brain to reach their final position and 
form the correct connections with other cells in the brain. Disturbed neural 
migration during development of the nervous system may result in improper 
neural outcome, as in foetal alcohol syndrome (Guerri, 1998), epilepsy and 
mental retardation (McManus and Golden, 2005). 
Several in vitro methods have been used in studying cell migration such as the 
scratch method in confluent cell monolayers, the transwell method, video 
microscopy, live cell imaging, or hippocampal slice cultures and these have been 
used to observe and track migrating cells. In these techniques, the source of the 
cells is usually either animal or tumour cells, which may not resemble normal 
human cells. Therefore, species differences and the discrepancies between the 
normal and tumorigenic cells are disadvantages of using these techniques in 
neural cell migration assays. 
Levels of GFAP and tubulin III proteins were measured and considered as end 
points. In the case of GFAP, it is well known that this protein is a sensitive and 
early bio marker of neurotoxicity when studied quantitatively and qualitatively 
(O’Callaghan and Sriram, 2005). Injury to the brain causes astrocytes to transform 
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into reactive astrocytes and start to proliferate and result in a state called 
astrogliosis, and this can occur before the appearance of the toxic effect on 
neurons (O'callaghan, 1991). Astrogliosis appears clearly with methyl mercury 
and lead acetate and a reduction in tubulin III protein (neuronal cells) appears 
obvious with methyl mercury. This indicates that this model has the capability to 
detect chemical toxicity. 
Physiological cell death, which is the deletion (by apoptosis) of redundant or 
unsuccessful neurons in the developing nervous system, has been considered as a 
regular phenomenon in brain development. It has been reported that drugs like 
sedatives or anticonvulsants, can stimulate a wave of neuronal apoptosis in the 
developing brain when administered to immature rodents (Bittigau et al., 2002, 
Ikonomidou et al., 1999), such compounds include, phenytoin, valproate, GABA 
receptor agonists (benzodiazepine and barbiturate), and NMDA receptor blockers. 
The developmental period of the human brain which is vulnerable to drug induced 
neuro-apoptosis extends from the 6
th
 month of gestation to several years after 
birth. This coincide with a brain growth spurt as shown in the figure (16) 
(Ikonomidou and Turski, 2010). Exposure to these compounds at therapeutic 
doses during the vulnerable period in the rat, which is the first two postnatal 
weeks, triggers immature neurons to commit cell suicide (apoptosis) (Bittigau et 
al., 2002). 
It is well known that anti-epileptic administration during pregnancy is associated 
with a broad spectrum of congenital anomalies (Meador et al., 2006) and most of 
the anti-epileptics in use are not safe  during pregnancy (Prakash et al., 2008) and 
the  teratogenicity is dose dependant (Tomson et al., 2011). It appears from this 
study that human neural stem cell culture is a sensitive model to predict the 
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teratogenesis of these compounds, especially phenytoin and sodium valproate, in 
which the end points  tested, neuronal process length, neurosphere sizes and cell 
migration, were significantly reduced at the doses which lie within therapeutic 
range. However, phenobarbitone and carbamazepine seem to be toxic only at high 
doses and have no significant effect at therapeutic doses. It has been pointed out 
that carbamazepine is less teratogenic than sodium valproate (Jentink et al., 
2010a). The teratogenicity of carbamazepine appears if it is combined with other 
anti-epileptic (like phenytoin) and it has been found that epileptic mothers who 
received carbamazepine and phenytoin had children with low developmental and 
language scores (Kaindl et al., 2006). Regarding phenobarbitone, it has been 
shown that it is less toxicity than other anti-epileptics (Holmes et al., 2001). 
Additionally, the anti-oxidants, folic acid and melatonin appear to have no 
significant effect on most of the end points, however, they enhance neural stem 
cell proliferation by increasing the sizes of neurospheres, this agree with previous 
study about folic acid (Liu et al., 2010) and about melatonin (Fu et al., 2011), 
which reported that these drugs stimulate neural stem cell proliferation, but 
adding them with sodium valproate and phenytoin has to some extent some 
beneficial effect on the end points by making their toxic effect appear at doses 
which were higher than those when these drugs were used alone 
On the other hand, regarding the effect of other neuroactive drugs (lithium, 
diazepam, and amitriptyline) on the neural stem cell culture, this study indicates 
that these drugs may be safe within their therapeutic doses and the toxicity 
appears only at high doses which are away from the therapeutic doses. Lithium 
has been considered as a weak teratogen and animal studies showed that lithium 
treatment did not result in developmental abnormalities (Giles and Bannigan, 
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2006), but it has a narrow gap between the therapeutic and the toxic dose (Su et 
al., 2007a). Diazepam treatment also has no significant effect on the cultured 
cells, other than at extremely high doses. It has been suggested that diazepam is 
safe even when administered to pregnant women during the first trimester 
(Bellantuono et al., 2013), however, another study showed that benzodiazepine 
treatment could be safe if it has been used in small dose and for a short duration 
(Iqbal et al., 2002). Similarly, amitriptyline appears safe during the therapeutic 
dose, but its association with developmental anomalies remains unclear. 
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Future work 
Study the effects of chemicals and drugs for longer duration, more than 2 
weeks, to study their effect at a chronic level. We recommend also to study 
synaptogenesis, which is an important end point in neurotoxicology, and to 
study cellular distribution within the neurosphere whether it is affected or not. 
Also, the effects of these chemicals on myelination process and microglia 
should be considered. Lastly, Study this model with other models such as 
neural stem cells from mice or rats to compare the sensitivity of this model 
with the others. 
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Appendix 1: Preparation of solutions 
Full culture medium                                                                            500ml 
Dulbecco modified eagle medium-DMEM                                          440ml 
10% heat inactivated foetal bovine serum                                            50ml 
2oomM Glutamine                                                                                   5ml 
50µg/ml penicillin/streptomyecin                                                           5ml 
Resazurin stock solution 
Resazurin 5mg added to 5ml of HBSS to give the Resazurin stock (5ml, 1mg/ml in 
HBSS) then the solution was filter sterilized in to a 50ml universal container.  
HBSS (45ml) with calcium and magnesium was added to create a working 
dilution of 100µg/ml (This stock solution was wrapped with aluminium foil and 
stored at -20° C). This was subsequently diluted 1:10 in HBSS and the tube also 
wrapped in aluminium foil to avoid photo reduction. Resazurin solution 
(10μg/ml) was stored at 4oC and used within 2 weeks. Resazurin solution was 
warmed to 37oC prior to exposure to cells. 
Kenacid blue fixative                                                                        1 litre 
Glacial Acetic acid                                                                              10ml 
Ethanol                                                                                               500ml 
DH2O                                                                                                  490ml 
Prepared and kept at room temperature 
Kenacid blue stock solution                                                              890ml 
Kenacid blue                                                                                        0.4g   
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Ethanol and                                                                                         250ml 
DH2O                                                                                630ml 
Prepared and kept at room temperature 
Kenacid blue working solution                                         50ml 
Acetic acid to                                                                                      6ml 
Stock solution                                                                                     44ml    
It was made up immediately prior to use. 
Kenacid blue washing solution                                                       1 litre 
Glacial acetic acid                                                                              50ml 
Ethanol                                                                                               100ml 
DH2O                                                                                                  850ml 
Prepared and kept at room temperature 
Kenacid blue desorb solution                                                         1 litre 
Potassium acetate                                                                             98.15g 
Ethanol                                                                                               700ml 
DH2O                                                                                                 300ml 
Prepared and kept at room temperature 
Neural Stem cell maintenance media                                             100ml 
DMEM (Dulbecoo’s Modified Eagle Medium )-Sigma                      47.5ml 
Ham’s Nutrient F12 -Sigma           47.5ml 
200mM L- Glutamine- Sigma           1ml 
100X N2- Invitrogen           1ml 
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50X B27- Invitrogen           2ml 
5µg/ml Heparin- Sigma           100µl 
10ng/ml bFGF (basic Fibroblast Growth Factor)-Gibco       100µl 
20ng/ml EGF (Epidermal Growth Factor)- Gibco           100µl 
Neural Stem Cell Differentiation Media                                         100ml 
DMEM (Dulbecoo’s Modified Eagle Medium)  47.5ml 
Ham’s Nutrient F12            47.5ml 
200mM L- Glutamine            1ml 
100X N2           1ml 
50X B27           2ml 
10X electrophoresis buffer:                                                              1 litre 
Tris                                                                                      30.3gm 
Glycine                                                                                                144gm 
SDS                                                                                                      10gm 
Distilled water                                                                                    1 litre 
Prepared and kept at room temperature 
Transfer buffer:                                                                                 10 litres 
Tris                                                                                                     30.3gm 
Glycine                                                                                               144gm 
Methanol                                                                                           2 litres 
DH2O                                                                                                 8 litres 
Prepared and kept at 4° C 
 213 
 
TBST:                                                                                                 10 litres 
Tris                                                                                                    30.3gm 
NaCl                                                                                                  73.12gm 
DH2O                                                                                                1 litre  
The pH should be adjusted to 7.6 by using Hcl. Then 9 litres and10 ml tween 
were added to the final solution. Prepared and kept at room temperature 
Lysis Buffer:                                                                                     500ml 
Tris                                                                                                   12.1gm 
EGTA                                                                                                1.9gm 
Sucrose                                                                                            51.7gm 
Triton X100                                                                                     500µl 
NaF                                                                                                  0.021gm 
Betaglycerophosphate                                                                   1.08gm 
DH2O                                                                                              500ml 
Prepared and kept in fridge at 4°C 
100µl of protease inhibitor was added to 10ml of lysis buffer to be used within 2 
weeks 
6X Solubilisation Buffer                                                                10ml 
SDS                                                                                                  2.4gm 
Glycerol                                                                                          3.0ml 
Betamercaptoethanol                                                                    3ml 
BPB                                                                                                 240µl 
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Tris Hcl                                                                                           2.5ml of 1.5M 
Prepared and kept in freezer at -20°C 
Lowry A Solution                                                                         500ml 
NaoH                                                                                              2gm 
SDS                                                                                                1gm 
NaCO3                                                                                          10gm 
DH2O                                                                                            500ml 
Prepared and kept at room temperature 
Lowry B Solution 
CuSO4                                                    1.0% 100µl in 20ml DH2O 
NaK Tartrate                                                      2.0% 100µL in 20ml DH2O 
Prepared and kept in fridge at 4°C  
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Appendix 2: Materials 
Plastic and Glass Wares: 
100 mm round Petri dishes Sterilin, UK 
24 well plates Nunc, UK 
48 well plate                                                                Nunc, Uk 
96 well plate (ultra-low attachment)        Corning 
96 well plates Costar and Nunc, UK 
Bijou tubes Sterilin, UK 
Eppendorf tubes Sterilin, UK 
Serological Pipette Gilson, France 
25 cm
2
 Tissue Culture Flasks (untreated) SPL Life Sciences- Korea 
75 cm
2 
Tissue Culture Flasks (untreated) SPL Life Science- Korea                                        
Universal tubes, 20 and 50 ml Sterilin, UK 
Conical centrifugation tubes, 15 ml BD Falcon, USA 
Filter 0.22 Sartorius Stedim, Germany 
Equipments: 
FLUORStar Galaxy BMG Cambridge, UK 
ASYS HITEC EXPERT 96 SLS, UK 
Balance A &D Intsrument, UK 
Centrifuge (Centaur 2) Fisons and Sigma, UK 
Class 1 laminar flow hood Faster, Italy 
Class 2 Laminar flow hood Heraeus Instrument, UK       
CO2 Incubator Sanyo, Japan and Heraeus, UK                                          
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Cooled Incubator Gallenkamp, UK 
Egg Incubator ChickTec, UK 
Haemocytometer Hawksley, UK 
Inverted phase microscope Zeiss, Germany and Olympus, Japan 
Plate shaker Luckham Ltd, UK  
Microtome Leica, Germany 
Automatic processor Leica, Germany 
Florescent microscope Leica, Germany 
Cell culture reagents: 
100% Ethanol Sigma-Aldrich, UK  
DMEM (Dulbecco’s Modified Eagle Medium)         Sigma-Aldrich, UK 
Ham’s Nutrient F12 Sigma-Aldrich, UK     
0.05% Trypsin -0.02% EDTA Sigma-Aldrich, UK 
B27 supplement Invitrogen, UK                                                                                      
N2 supplement Invitrogen, UK 
bFGF (Basic Fibroblast Growth Factor)    Gibco by Life technology, UK 
EGF (Epidermal Growth Factor)           Gibco by Life technology, UK 
Heparin Sigma-Aldrich, UK 
Foetal Calf Serum (heat Inactivated) Sigma-Aldrich, UK 
Hank’s Balanced Salt Solution (HBSS) Sigma- Aldrich, UK 
Dimethylsulfoxide (DSMO) Sigma- Aldrich, UK 
Horse Serum Sigma-Aldrich, UK 
L- Glutamine Sigma- Aldrich, UK   
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Penicillin-Streptomycin Sigma- Aldrich, UK 
Accutase                                                                     Sigma-Aldrich,UK 
Phosphate Buffer Saline tablet (PBS) Sigma- Aldrich, UK 
Paraformaldehyde PFA Sigma, UK 
Trigene Medichem International 
Poly D Lysine                                                              Sigma- Aldrich, UK 
Poly L Lysine                                                              Sigma- Aldrich, UK 
Collagen I rat tail                                                        Sigma- Aldrich, UK 
Laminin                                                                       Sigma- Aldrich, UK 
Drugs: 
Methyl mercury                                                           Sigma- Aldrich, UK 
Lead acetate                                                                 Sigma- Aldrich, UK 
Sodium Valproate Sigma- Aldrich, UK 
Phenytoin                                                                     Sigma- Aldrich, UK 
Phenobarbitone                                                            Sigma- Aldrich, UK 
Carbamazepine                                                            Sigma- Aldrich, UK 
Lithium Carbonate Fischer Scientific, UK 
Diazepam                                                                     Sigma- Aldrich, UK   
Amitriptyline                                                               Sigma- Aldrich, UK 
Folic acid                                                                     Sigma- Aldrich, UK 
Melatonin                                                                     Sigma- Aldrich, UK 
Chemicals for Cell Viability Assay:  
Resazurin Sigma- Aldrich, UK 
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Resorufin 95% dye colour Sigma- Aldrich, UK 
Chemicals for protein detection assay:  
Bovine Serum Albumin Sigma- Aldrich, UK 
Ethanol Sigma- Aldrich, UK 
Glacial Acetic acid Fischer Scientific, UK 
Kenacid Blue dye Sigma- Aldrich, UK 
Potassium Acetate Fischer Scientific, UK 
Western Blot Analysis: 
Precast gel                                                                   Biorad 
Tris                                                                              Invitrogen 
Glycine                                                                       Fisher Scientific 
SDS                                                                            Acros Organics 
Methanol                                                                    Sigma 
Nacl                                                                            Fisher Chemicals 
EGTA                                                                         Sigma 
Sucrose                                                                       Fisher Scientific 
Triton X100                                                                Sigma 
NaF                                                                             Sigma 
Betaglycerophosphate                                                Sigma 
Glycerol                                                                      Fisher Scientific 
Betamercaptoethanol                                                  Fisher scientific 
Bromophenolblue                                                       BDH 
NaOH                                                                         Fisher Scientific 
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NaCO3                                                                       Fisher Chemicals 
CuSO4                                                                       Fisher Scientific 
NaK Tartrate                                                              Fisher Scientific 
Software: 
Endnote X6                                                               Thomas Reuters, USA      
Prism statistical software version 6.0           Graph pad, USA 
Volocity version 6.3.1                                               PerkinElmer, USA 
Odyssey                                                                Li-Cor BioSciences, UK                                 
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Appendix 3: The Antibodies 
1. Primary and secondary antibodies in Western blot: 
 Primary Antibodies M.W Dilution Sources Cat. no 
1 Mouse monoclonal Anti-Tubulin 
III antibody 
50Kda 1:2000 Abcam ab78078 
2 Rabbit polyclonal Anti-GFAP 
antibody 
55Kda & 
48Kda 
1:20000 Abcam ab7260 
3 Mouse monoclonal Anti-GAPDH 
antibody 
37Kda 1:5000 Sigma G8795 
 
 Secondary Antibodies Dilution Sources Cat. no 
1 Goat Anti-mouse 1:30000 Li-Cor Odyssey 926-32211 
2 Goat Anti-rabbit 1:30000 Li-Cor Odyssey 926-68020 
 
2. Primary and secondary antibodies in Immunocytochemistry and 
Immunohistochemistry: 
 Primary Antibodies Dilution Sources Cat. no 
1 Mouse monoclonal Anti-Tubulin III 
antibody 
1:500 Abcam ab7751 
2 Rabbit polyclonal Anti-GFAP antibody 1:800 Abcam ab7260 
3 Rabbit polyclonal Anti-SOX2 antibody 1:2000 Abcam ab97959 
4 Mouse monoclonal Anti-Nestin 
Antibody 
1:1000 BD 
Biosciences  
611658 
 
 Secondary Antibodies Dilution Sources Cat. no 
1 Goat polyclonal secondary antibody to 
mouse IgG, Alexa  Fluor 488 
1:500 Abcam ab150113 
2 Goat polyclonal secondary antibody to 
rabbit IgG, Alexa  Fluor 555 
1:500 Abcam ab150098 
 
